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Abstract 
  
Inherited neuropathies are a clinically and genetically heterogeneous group of diseases affecting 
the peripheral nervous system (PNS). More than 70 causative genes have been recognised, 
however, there are still patients whose disease-causing genes have not been identified, 
particularly those presenting with complex phenotypes which also involve the central nervous 
system (CNS) and other organs. The main objective of my PhD was to establish the genetic 
diagnosis in these patients through an integrated approach combining conventional Sanger 
sequencing and the next generation sequencing (NGS) technologies which include whole exome 
sequencing (WES) and targeted resequencing.  
 
Based on this integrated approach, mutations in several genes for inherited neuropathies and 
related disorders have been identified. My thesis focuses on: (1) screening studies in large 
cohorts of patients conducted by Sanger sequencing to define  the frequency of the mutations  in 
the NEFL gene in Charcot-Marie-Tooth disease (CMT), in the SPTLC2 gene  in hereditary 
sensory neuropathy type I and in the PDYN gene in autosomal dominant cerebellar ataxia 
(ADCA) in British population; (2) WES studies to identify mutations in patients with inherited 
neuropathies or autosomal recessive cerebellar ataxia (ARCA), including a novel ADCK3 
mutation in ARCA and two novel genes causing  CMT, MARS and C12orf65; (3) the 
development of  two targeted resequencing panels for CMT and hereditary spastic paraplegia 
(HSP) with axonal neuropathy to identify disease-causing mutations in two cohorts; (4) the 
broadening of the phenotypic spectrum of KIF5A in patients with HSP  and CMT type 2. 
 
In this thesis functional studies for some of the identified mutations were also performed such as 
the impairment of the mitochondrial respiratory enzymes in the lymphoblasts of patients with 
the C12orf65 mutation and in fibroblasts of patients with the ADCK3 mutation.  
 
The challenges faced by the use of NGS in genetic diagnosis and how to address these 
challenges in the future are discussed.  
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Chapter 1 
 
Introduction  
 
Inherited neuropathies are a clinically and genetically heterogeneous group of diseases affecting 
the PNS. More than 70 causative genes have been recognised, however, there are still patients 
whose disease-causing genes have not been identified, particularly those presenting with 
complex and atypical phenotypes involving the CNS and even other organs. The objective of 
this thesis was to investigate the genetics and pathogenesis of inherited neuropathies via the 
approach of NGS in combination with conventional methods. The research projects undertaken 
were divided into the following parts: (1) screening of disease-causing mutations in newly-
identified genes or in rare genes responsible for inherited neuropathies, (2) screening of disease-
causing mutations in genes responsible for other inherited neurological disorders associated 
with peripheral neuropathies, (3) WES in patients in which genetic diagnosis has not been 
reached by conventional methods, (4) applications of targeted resequencing in cohorts of 
patients with inherited neuropathies and related disorders. Functional studies for some of the 
mutations identified were also performed.   
 
This chapter provides an overview of the neurological diseases studied in this thesis which 
include inherited neuropathies, hereditary cerebellar ataxia and hereditary spastic paraplegia 
(HSP). A brief introduction on NGS and its applications on genetic diagnosis is also outlined.  
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1.1 Overview of inherited neuropathies 
 
The commonest type of inherited neuropathies are Charcot-Marie-Tooth disease (CMT), 
hereditary sensory neuropathies (HSN) and the distal hereditary motor neuropathies 
(dHMN).(Reilly et al. 2009; Saporta et al. 2013; Siskind et al. 2013).  These three disorders 
represent a continuum from pure motor neuropathies (dHMN), involvement of both motor and 
sensory nerves (CMT) to sensory-predominant neuropathies (HSN). In the past two decades a 
great advancement has been achieved in the genetic diagnosis of inherited neuropathies with the 
identification of mutations in more than 70 causative genes.(Rossor et al. 2013) Interestingly, 
increasing overlaps in clinical phenotypes and genetic aetiologies between these disorders have 
been recognised.   
 
1.1.1 Charcot-Marie-Tooth disease (CMT) 
CMT was named after the three clinicians: Jean-Marie Charcot, Pierre Marie and Howard Henry 
Tooth who first described the familial neurological syndrome “peroneal muscular atrophy” in 
1886. CMT has now been recognised as the commonest inherited neuromuscular disorder 
affecting approximately 1 in 2,500 individuals.(Azzedine et al. 2012; Skre 1974) Also termed as 
hereditary motor sensory neuropathy (HMSN), CMT is a heterogeneous group of sensorimotor 
peripheral neuropathies characterised by distal muscle weakness and atrophy, distal sensory loss, 
decreased or absent tendon reflexes. The weakness results in foot drop and steppage gait. Foot 
deformities occur frequently. The onset is usually in the first two decades. Patients may have 
autosomal dominant (AD), autosomal recessive (AR) or X-linked inheritance; however, de novo 
dominant cases are not rare and thus some patients do not have a family history. In the north 
European and United States (US) populations, AD and X-linked are the commonest inheritance 
pattern accounting for near 90% of all cases of CMT. ARCMT cases are less common, although 
in countries with a higher rate of consanguineous marriages it can account for up to 40% of all 
CMT cases.(Dubourg et al. 2006a)  
 
CMT was first classified in demyelinating CMT1 [median motor nerve conduction velocity 
(MNCV) <38 m/s] and CMT2 (median MNCV >38 m/s) on the base of neurophysiological 
parameters.(Harding et al.1980) This classification remains the cornerstone of modern diagnosis. 
In all populations, CMT1 is consistently reported as the commonest form, accounting 50~75% 
of all affected patients, followed by CMT2 (30~50 %). A small group of patients (2~15%) have 
median MNCV ranging between 25~45 m/s and have been classified as the intermediate CMT 
(I-CMT).(Braathen et al. 2011; Nicolaou et al. 2010)  Congenital hypomyelinating neuropathies 
(CHN) or Dejerine Sottas neuropathy (DSN) is used to indicate severe forms of CMT with onset 
during infancy. CMT4 is currently used to characterise ARCMT1.(Reilly et al. 2009)   
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The identification of PMP22 as the first causative gene for CMT in 1991 was the breakthrough 
point in the understanding of CMT.(Lupski et al. 1991) Since then  there have been rapid 
advances in the molecular genetics of the disease with the identification of more than 70 
causative genes.(Reilly et al. 2011; Rossor et al. 2013) The classification of CMT is in 
continuous evolution due to the rapid development of molecular genetics. Current classification 
is based on clinical, electrophysiological, genetic and pathological criteria. Clinical features and 
causative genes are summarised in table 1-1 (p22). 
 
Autosomal dominant CMT1 (ADCMT1) is the largest subgroup of CMT. The majority of 
ADCMT1 are caused by mutations or rearrangement in the following five genes: PMP22, MPZ, 
LITAF, EGR2 and NEFL.(Azzedine et al. 2012; Murphy et al. 2012) CMT1A caused by the 
chromosome 17 duplication containing PMP22 gene is the commonest form and accounts for 
70% of all CMT1 cases in European/North American populations.(Saporta et al. 2011) A 
deletion in the same segment of DNA is associated with Hereditary Neuropathy with Liability 
to Pressure Palsies (HNPP), an autosomal dominant condition characterised by recurrent nerve 
palsies at points vulnerable to pressure. Point mutations in the same PMP22 gene are associated 
with variable phenotypes including classical CMT1A, more severe CMT1 and HNPP.(Relly et 
al. 2009, Russo et al. 2011) CMT1B caused by MPZ mutations accounts for approximately 10% 
of ADCMT1 cases. CMT1B patients are more likely to have an early-onset neuropathy and a 
more severe disease course (Shy et al. 2004), however late-onset CMT2, I-CMT and recessive 
CMT have all been described with MPZ mutations.(Azzedine et al. 2012) ADCMT1 caused by 
mutations of the other genes (LITAF, EGR2 and NEFL) are rare (<1% each),(Street et al. 2003; 
Sevilla et al. 2004; Warner et al. 1998) 
 
CMT2, the axonal form of CMT, is clinically heterogeneous and it can present as the classical 
CMT phenotype or as predominant sensory neuropathy or as predominant motor 
neuropathy.(Bienfait et al. 2011; Reilly et al. 2011) For ADCMT2, mutations in at least 22 genes 
have been reported and genetic testing is mainly guided by patient’s phenotype. CMT2A 
secondary to MFN2 mutations is the commonest form, representing approximately 20% of all 
patients with ADCMT2.(Murphy et al. 2012; Relly et al. 2009; Zuchner et al. 2004) In CMT2 
with predominant sensory impairment  the following genes should be considered as the priority: 
RAB7 (the causative gene for CMT2B), SPTLC1 and SPTLC2.(Auer-Grumbach et al. 2003; 
Rotthier et al. 2010; Verhoeven et al. 2003) SPTLC1 and SPTLC2 are  the causative gene of 
HSN but patients usually have significant motor involvement and hence the overlap with 
CMT2.(Bejaoui et al. 2001) 
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CMT2 with predominant motor involvement is usually associated with mutations in four genes: 
GARS, HSP27/HSPB1, HSP22/HSPB8 and TRPV4.(Reilly et al. 2009) Predominant upper limb 
involvement is commonly described in patients carrying GARS mutations (Antonellis et al. 2003) 
Mutations in HSPB1 and HSPB8 are otherwise more commonly identified  in patients with 
predominant lower limb involvement.(Murphy et al. 2012) Mutations in TRPV4 are associated 
with variable phenotypes. Dominant mutations were originally described causing skeletal 
dysplasia, brachyolmia type 3. Subsequently mutations were identified in patients with CMT2C, 
scapuloperoneal muscular atrophy and congenital distal spinal muscle atrophy (SMA).(Rossor 
et al. 2012)  
 
Table 1-1. Classification of Charcot-Marie-Tooth disease (CMT) 
Subtype Gene/Locus Phenotype  
CMT1 (ADCMT1) 
CMT1A 17p dup PMP22 (pm) CMT1/DSN/CHN 
CMT1B MPZ CMT1/DSD/CHN/rarely CMT2 
CMT1C LITAF CMT1 
CMT1D EGR2 CMT1/DSN/CHN/rarely recessive  
CMT1F NEFL CMT2/rarely CMT1/rarely I-CMT/rarely recessive 
Other FBLN5 CMT1/d-HMN with macular degeneration & hyperelastic skin 
 SOX10 CMT1/CHN with hypopigmentation & enteric aganglionosis 
 GJB3 Demyelinating polyneuropathy & hearing loss 
CMT2 (ADCMT2) 
CMT2A2 MFN2 CMT2/progressive/optic atrophy/pyramidal signs/rarely recessive 
CMT2A1 KIF1B CMT2/usually severe/optic atrophy 
CMT2B RAB7 CMT2B or HSN 1, predominant sensory involvement and sensory complications 
CMT2C TRPV4 
CMT2/dHMN(Congenital SMA)/Scapuloperoneal SMA with 
respiratory involvement/ arthrogryposis, laryngomalacia and vocal 
cord paresis 
CMT2D GARS CMT2/dHMN-V with predominant hand wasting 
CMT2E NEFL CMT2/rarely CMT1/rarely I-CMT/rarely recessive 
CMT2F HSPB1 CMT2, motor predominant/dHMN-II/rarely recessive 
CMT2I MPZ Late-onset CMT2 
CMT2J MPZ CMT2 with hearing loss and pupillary abnormalities 
CMT2K GDAP1 CMT1, severe and early-onset /ARCMT2C/RI-CMT with vocal cord and diaphragm paralysis 
CMT2L HSPB8 CMT2, motor predominant/dHMN-II 
CMT2M DNM2 Intermediate CMT (DI-CMTB)/CMT2 with cataracts, ophthalmoplegia, ptosis  
CMT2N YARS CMT2/d-HMN 
CMT2O DYNC1H1 CMT2 with learning difficulties/SMA-LED 
CMT2P LRSAM1 CMT2 
CMT2Q DHTKD1 CMT2 
Other TFG CMT2 with proximal involvement 
 MARS Late-onset CMT2 
 HARS CMT2 
 KIF5A  CMT2 with pyramidal signs/SPG10 
 MT-ATP6 CMT2 with pyramidal signs 
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Table 1-1. (cont) 
Subtype Gene/Locus Phenotype & additional feature 
CMT4 (ARCMT1) 
CMT4A GDAP1 CMT1, severe and early-onset /ARCMT2C/RI-CMT with vocal cord and diaphragm paralysis 
CMT4B1 MTMR2 severe CMT1with facial weakness, bulbar palsy and focally folded myelin 
CMT4B2 MTMR13 severe CMT1with glaucoma and focally folded myelin 
CMT4B3 SBF1 CMT1 and focally folded myelin 
CMT4C SH3TC2 severe CMT1with scoliosis 
CMT4D NDRG1 severe CMT1 with deafness and tongue atrophy, gypsy 
CMT4E EGR2 CMT1/DSN/CHN 
CMT4F PRX CMT1, predominant sensory, and focally folded myelin 
CMT4G    
(HMSN- 
Russe) 
HK1 severe and early-onset CMT1, Russe type 
CMT4H FGD4 CMT1 
CMT4J FIG4 CMT1, predominant motor, progressive 
CCFDN CTDP1 CMT1/gypsy/cataracts/dysmorphic features 
Other SURF1 severe and early-onset demyelinating neuropathy with lactic 
acidosis and cerebellar ataxia 
 EGR2  
 NEFL  
ARCMT2   
ARCMT2A LMNA CMT2 with proximal involvement, rapid progression/muscular dystrophy/cardiomyopathy/lipodystrophy 
ARCMT2B MED25 CMT2 
ARCMT2C GDAP1 CMT1, severe and early-onset /ARCMT2C/CMT-RIA with vocal cord and diaphragm paralysis 
Other NEFL  
 MFN2  
 TRIM2 very early onset CMT2  
 HINT1 CMT and neuromyotonia 
CMT X   
CMTX1 GJB1 (Cx32) CMT1/CMT2/I-CMT, male MCVs < female MCVs 
CMTX4 AIFM1 Cowchock sydnrome 
CMTX5 PRPS1 severe CMT2 with deafness and optic atrophy 
CMTX6 PDK3 CMT2 
Dominant intermediate CMT (DI-CMT) 
CMT-DIB DNM2 I-CMT/CMT2; with cataracts, ophthalmoplegia; ptosis 
CMT-DIC YARS I-CMT/CMT2 
CMT-DID MPZ I-CMT/CMT2 
CMT-DIE INF2 I-CMT with glomerulonephritis 
CMT-DIF GNB4 I-CMT 
Other NEFL CMT2/rarely CMT1/rarely I-CMT/rarely recessive 
Recessive intermediate CMT (RI-CMT) 
CMT-RIA GDAP1 CMT1, severe and early-onset /ARCMT2C/CMT-RIA with vocal cord and diaphragm paralysis
CMT-RIB KARS I-CMT with learning difficulty, vestibular schwannoma 
CMT-RIC PLEKHG5 I-CMT/SMA 
CCFDN: congenital cataracts, facial dysmorphism, and neuropathy; CHN: congenital hypomyelinating 
neuropathy; DSN: Dejerine Sottas neuropathy; dup: duplication; pm: point mutation; SMA: spinal 
muscular atrophy; SMA-LED: spinal muscular atrophy with lower limb predominance; SPG10: spastic 
paraplegia type 10.  
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Autosomal recessive CMT (ARCMT) includes both demyelinating (CMT4) and axonal forms 
(ARCMT2) and more than 20 causative genes have been identified so far.(Rossor et al. 2013; 
Tazir et al. 2013) These are rarer forms and account for approximately 30-50% of CMT in 
Mediterranean or Middle East countries. These patients generally have an early onset and a 
more severe course of disease than patients with typical ADCMT1. Patients can have delayed 
motor milestones and weakness often progresses to involve proximal muscle and may result in 
early loss of ambulation. GDAP1 is the first gene identified for ARCMT and its mutations can 
cause either demyelinating or axonal neuropathy. Vocal cord paralysis is a frequent associated 
feature. Recent reports suggest that CMT4C due to mutations of SH3TC2 is emerging as the 
commonest form in many populations and severe and early scoliosis is a characteristic clinical 
feature.(Houlden et al. 2009b; Murphy et al. 2012) Another subtype in which the mutation has 
been identified in the British/Irish population is CMT4H secondary to FGD4 mutations. The 
patients had very slowly progressive demyelinating neuropathy.(Houlden et al. 2009a) Recently, 
CMT4J secondary to FIG4 mutations were described in  patients with rapidly progressive 
asymmetrical demyelinating neuropathy, resembling an acquired inflammatory 
neuropathy.(Cottenie et al. 2013) Autosomal recessive CMT2 (ARCMT2) is a very rare 
condition. It can be associated with LMNA mutations (ARCMT2A) and patients usually presents 
with a severe neuropathy involving proximal muscles. LMNA mutations are also associated with 
Emery-Dreifuss muscular dystrophy and Dunnigan-type familial partial lipodystrophy.(Agarwal 
et al. 2003; De Sandre-Giovannoli et al. 2002) ARCMT2B is a milder subtype caused by 
MED25 mutations.(Leal et al. 2009) Very rarely, recessive mutations in GDAP1, NEFL and 
HSPB1 have been also reported.(Houlden et al. 2008; Reilly et al. 2011; Yum et al. 2009) 
 
CMTX1 caused by GJB1 mutations is the commonest form of X-linked CMT and also the 
second most frequent subtype of CMT. CMTX1 is an X-linked dominant disorder in which 
males are usually more severely affected than females. NCVs are usually slow in the 
demyelinating range in males while in females are usually in the axonal range, but for both it is 
common to have NCVs in the intermediate range as mentioned above. Patchy or asymmetric 
distribution is frequently observed.(Reilly et al. 2011) GJB1 mutations (52.8%) are responsible 
for the majority of intermediate CMT (MNCV ranging between 35 and 45 m/s).(Miller et al. 
2011; Nicholson et al. 1993). Therefore patients with intermediate conduction velocities, a 
classical phenotype in the absence of male-to-male transmission, should be first tested for GJB1 
mutations (CMT1X). If this testing is negative, testing should proceed to MPZ mutations (CMT-
DID/CMT1B). Alternatively, if there is male-to-male transmission, testing for MPZ mutations 
should occur first.(Miller et al. 2011; Nicholson et al. 2006) 
 
The group with intermediate MNCV but negative for GJB1 mutations is then subdivided into 
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dominant intermediate (DI-CMT) and recessive intermediate CMT (RI-CMT).(Kim et al. 2013; 
Nicholson et al. 2006) Some rare genes causing DI-CMT include DNM2 (CMT-DIB) and YARS 
(CMT-DIC) mutations. Recently, a few new genes have been identified for DI-CMT, like INF2 
(CMT-DIE) and GNB4 (CMT-DIF).(Soong et al. 2013; Toyota et al. 2013) RI-CMT is very rare 
and the responsible genes may cause other atypical manifestations, for example, vestibular 
Schwannoma and developmental delay caused by KARS (CMT-RIA) and elevated serum 
creatine kinase levels with PLEKHG5 (CMT-RIC) mutations.(Kim et al. 2013; McLaughlin et al. 
2010) 
 
1.1.2 Hereditary sensory neuropathies (HSN) 
Hereditary sensory neuropathies (HSN) are a group of diseases caused by degeneration of 
peripheral sensory neurons. The hallmark feature is prominent distal sensory loss with 
insensitivity to pain in some patients. The sensory loss frequently leads to chronic ulcerations 
and osteomyelitis resulting in amputations of toes and fingers. HSN was also termed hereditary 
sensory and autonomic neuropathies (HSAN) due to the  autonomic involvement occurring in 
these neuropathies.(Dyck et al. 1993)  Autonomic dysfunction observed in some patients 
includes anhidrosis, fever, blood pressure fluctuations and gastro-intestinal disturbances. 
Neurophysiology usually shows changes consistent with a sensory axonal neuropathy.(Auer-
Grumbach et al. 2003; Dyck et al. 1993; Rotthier et al. 2009; Rotthier et al. 2012) At least 14 
genes have been identified as causative genes of HSN (table 1-2, p26). Nevertheless, a genetic 
diagnosis can currently be reached in approximately 19% of patients, suggesting that further 
genes associated with HSN are waiting to be identified.(Davidson et al. 2012) In a study which 
included 140 HSN British patients, mutations in six genes were identified: SPTLC1, RAB7, 
WNK1/HSN2, FAM134B, NTRK1 and NGFB. The SPTLC1 Cys133Trp (C133W) mutation was 
the most frequently identified mutation.(Davidson et al. 2012)  
 
The current classification of HSN includes at least eight clinical subtypes and can be divided in 
two groups by the inheritance pattern. Patients with AD-HSN typically show a juvenile or adult 
onset sensory neuropathy with minimal autonomic disturbances and frequent motor 
involvement, whereas typical manifestations of AR-HSN are congenital or early onset, 
pronounced autonomic symptoms and minimal motor involvement.  
 
Five genes have been identified as the causative genes for AD-HSN: SPTLC1, SPTLC2, ATL1, 
DNMT1 and PRNP. Patients with mutations in SPTLC1 or SPTLC2 are almost phenotypically 
indistinguishable. They sometimes have significant motor involvement and hence the clinical  
overlap with CMT2.(Auer-Grumbach 2008; Rotthier et al. 2010) ATL1 is originally known as 
the causative gene for SPG3A, a dominant form of HSP, but its mutation have been identified in  
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Table 1-2. Classification of hereditary sensory neuropathies (HSN) 
Subtype Inheritance   Gene    Phenotype 
HSN-IA    AD SPTLC1 pan-sensory loss/lancinating pain /variable distal motor involvement/amputations/adolescence onset 
HSN-IC    AD SPTLC2 pan-sensory loss/lancinating pain /variable distal motor involvement/amputations/adolescence or adulthood onset 
CMT2B AD RAB7 predominant sensory involvement and sensory complications 
HSN-ID AD ATL1 severe distal sensory loss and amyotrophy in lower limbs/  skin and nail changes/acromutilation/adult onset 
HSN-IE AD DNMT1 pan-sensory loss /sensorineuronal hearing loss/dementia/early adult onset 
HSN with 
chronic diarrhea AD PRNP Dementia/ autonomic dysfunction/ sensory loss/diarrhoea
HSN-IIA AR HSN2 (WNK1) 
severe mutilations in hands and feet/acropathy/congenital 
or early childhood onset 
HSN-IIB AR FAM134B impaired nociception /childhood onset 
HSN-IIC AR KIF1A 
impaired propioception and vibration sense/minor distal 
weakness/ 
childhood to adolescence onset/SPG30 
HSN-III AR IKBKAP 
Riley-Day syndrome/prominent autonomic involvement 
with vasomotor instability and hyperhidrosis/absence of 
lingual fungiform papillae/congenital  
HSN-IV AR NTRK1 
Congenital insensitivity to pain with anhydrosis (CIPA) /
episodic fever/ mental retardation/unmyelinated fibers 
mainly affected  
HSN-V AR NGFB 
Congenital insensitivity to pain/severe loss of deep pain 
perception/ minimal autonomic/no mental retardation 
unmyelinated fibers affected 
HSN with spastic 
paraplegia AR CCT5 
loss of all sensory modalities/acromutilation/spastic 
paraplegia 
Channelopathy 
associated 
insensitive to 
pain 
AR SCN9A Congenital insensitivity to pain/Erythromelagia 
 
patients with AD-HSN.(Guelly et al. 2011) DNMT1 mutations cause hereditary sensory 
neuropathy with dementia and hearing loss (HSN/HSAN-IE), a neurodegenerative disorder 
characterised by dementia, sensorineural hearing loss and sensory neuropathy. Affected patients 
usually present with sensory impairment and hearing loss at the age of 20-35 and subsequently 
develop dementia in the third or fourth decade.(Klein 2012; Klein et al. 2011)  
 
Several causative genes have been identified in AR-HSN. Mutations in WNK1/HSN2, FAM134B 
and KIF1A (HSN II) are typically associated with early-onset sensory neuropathy. HSN-III 
caused by IKBKAP mutations, also called familial dysautonomia or Riley–Day syndrome, 
manifests at birth with prominent and progressive autonomic disturbances and small-fiber 
sensory dysfunction which reduce life expectancy in affected patients. The disease occurs 
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almost solely in the eastern European Jewish population.(Slaugenhaupt et al. 2001) HSN-IV 
caused by NTRK1 mutations, also known as congenital insensitivity to pain with anhidrosis 
(CIPA), typically presents with a combination of absence of normal responses to painful stimuli, 
markedly decreased or absent sweating associated with recurrent episodes of fever and variable 
mental retardation with self-mutilating behaviour.(Langer et al. 1981; Nolano et al. 2000) HSN-
V is caused by mutations in NGFB. Patients with HSN-V show hypohidrosis rather than 
anhidrosis and do not have mental retardation.(Dyck et al. 1983) However, the distinction 
between HSN-IV and HSN-V is not always clear, as one patient with NGFB mutation 
presenting with a HSN-IV phenotype (Carvalho et al. 2011) and another patient with HSN-V 
was identified with a homozygous NTRK1 mutation.(Houlden et al. 2001)   
 
1.1.3 Distal hereditary motor neuropathies (dHMN) 
Distal hereditary motor neuropathy (dHMN), also known as distal spinal muscular atrophy 
(SMA) or the spinal form of CMT, it is a clinically and genetically heterogeneous condition 
characterised by the selective involvement of motor neurons.(Dierick et al. 2008) The cardinal 
feature is an almost exclusive motor involvement with distal wasting and weakness of upper and 
lower limbs though minor sensory abnormalities may be observed. dHMNs are quite often 
associated with additional features, including vocal cord paralysis and pyramidal signs.(Irobi et 
al. 2006) To date, at least 17 causative genes have been identified for the dHMNs. However, in 
only 20% of patients can a definite genetic diagnosis can be achieved.(Dierick et al. 2008; Irobi 
et al. 2006; Rossor et al. 2012) The classification of dHMN is based on the system proposed by 
Harding (Harding 1993b) but has been expanded to include the currently known genes (table 1-
3, p28).  
 
Patients with dHMN can be divided into two main groups according to the inheritance pattern. 
Among AD-dHMN, affected patients typically present with  length-dependent neuropathy with 
weakness starting in the lower limbs.(Houlden et al. 2008) They can be caused by mutations in 
several genes, however, HSPB1 and HSPB8  are the two genes in which most of the mutations 
have been identified so far.(Irobi et al. 2006) Interestingly, a recessive HSPB1 mutation has 
been identified in a family with neuropathy.(Houlden et al. 2008) There is often an overlap 
between AD-dHMN with mild sensory abnormalities and CMT2 with predominant motor 
involvement. At least five genes have been identified causing both CMT2 and dHMNs: TRPV4, 
GARS, HSPB1, HSPB8 and DYNC1H1.( Dubourg et al. 2006b; Reilly et al. 2011; Rossor et al. 
2012; Sivakumar et al. 2005) Both phenotypes have been observed within a family with the 
same HSBP1 mutation.(Solla et al. 2010) 
 
AD-HMNs caused by mutations in other genes are rare.(Rossor et al. 2012) Patients presenting 
with predominant hand involvement usually carry mutations in BSCL2 or GARS genes.(Reilly et 
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al. 2011) Patients with BSCL2 mutations have a variable phenotype ranging from typical dHMN 
to spastic paraplegia with hand amyotrophy (Silver Syndrome). Recently mutations in two 
genes related to dynein, DYNC1H1 and BICD2, were documented to be the cause of spinal 
muscular atrophy with lower limb predominance (SMA-LED), a form of AD-SMA overlapping 
with dHMN. SMA-LED is clinically  characterised by early onset, predominant lower limb 
involvement and very slow disease progression.(Harms et al. 2012; Peeters et al. 2013; 
Tsurusaki et al. 2012; Weedon et al. 2011) The identification of these two new genes 
highlights the importance of dynein-mediated motility in motor neuron function in humans.  
 
Table 1-3. Classification of distal hereditary motor neuropathies (dHMN) 
Subtype Inheritance Gene Phenotype 
dHMN2A AD HSPB8 Adult onset typical dHMN/CMT2L 
dHMN2B AD HSPB1 Adult onset typical dHMN/CMT2F 
dHMN2C AD HSPB3 Adult onset typical dHMN 
dHMN5A AD 
GARS Upper limb onset/CMT2D 
BSCL2 Upper limb onset, frequent spasticity in lower limbs/ Silver syndrome (SPG17) 
dHMN5B AD REEP1 Predominant hand wasting /SPG31 
dHMN6 AR IGHMBP2 SMARD1/infantile onset, respiratory distress 
dSMA5 AR DNAJB2 early adult onset, predominantly in lower limbs
SPSMA AD TRPV4 Adult onset/vocal cord paralysis 
dHMN7A AD SLC5A7 Vocal cord palsy 
dHMN7B AD DCTN1 Adult onset/vocal cord paralysis/facial weakness 
dHMN and  
pyramidal features AD SETX HMN/ALS4/early onset/pyramidal signs 
dHMN/SMA AD TRPV4 vocal cord paralysis, distal weakness, congenital SMA/CMT2/arthrogryposis 
SMAX3      X-linked ATP7A distal-onset wasting and weakness 
dHMN AD AARS Typical HMN 
SMA-LED AD 
BICD2 Congenital, contractures, lower-limb predominant, pyramidal signs  
DYNC1H1 
Congenital, contractures, lower-limb 
predominant, pyramidal signs,  learning 
difficulties
PNMHH AD MYH14 distal myopathy, hoarseness, hearing loss 
ALS: amyotrophic lateral sclerosis, PNMHH: peripheral neuropathy, myopathy, hoarseness, 
and hearing loss, SMARD1: spinal muscle atrophy with respiratory distress type 1. 
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AR-dHMN is very rare. dHMN-6 caused by mutations in IGHMBP2, also termed spinal 
muscular atrophy with respiratory distress type 1 (SMARD1), is characterised by severe distal 
weakness and diaphragmatic palsy occurring in early infancy . This is one of the most severe 
forms of dHMN and it is associated with poor prognosis. Patients usually die from respiratory 
complications before the age of 20.(Pitt et al. 2003) Only one X-linked form of dHMN has been 
so far described. This condition is caused by mutations in the ATP7A gene which was firstly 
described as the gene responsible for Menke’s disease, a severe developmental disorder due to 
abnormal copper metabolism with onset during infancy. The two mutations associated with 
dHMN have not been reported in Menke’s disease and the affected individuals had normal 
serum copper concentrations.(Kennerson et al. 2010) 
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1.2 Peripheral neuropathies associated with other related disorders 
 
There is increasing evidence of overlap between inherited neuropathies and other neurological 
syndromes. In many conditions, inherited neuropathy is part of a multisystem disorder affecting 
also the CNS or other non-neurological systems. Cerebellar ataxias and spasticity are two 
additional features frequently observed in patients with inherited neuropathies. Conversely, 
peripheral neuropathy can be part of the clinical picture of hereditary cerebellar ataxias or 
hereditary spastic paraplegia (HSP).  
 
1.2.1 Peripheral neuropathies and hereditary spastic paraplegia 
HSP is a group of clinically and genetically heterogeneous disorders characterised by spasticity 
in the limbs, gait abnormalities, urinary disturbances  with over 60 loci or genes 
recognised.(Behan et al. 1974; Bruyn 1992; Schule et al. 2012) HSPs are classified into pure 
HSPs (pHSP) which have isolated pyramidal system involvement and complex HSPs (cHSP) in 
which the pyramidal signs are associated with variable combinations of additional neurological 
or extra-neurological involvement.(Harding 1983) Clinically, peripheral neuropathy has been 
recognised as the most frequent associated feature in cHSP, including mutations in one of  the 
commonest genes: ATL1(SPG3A) and SPAST (SPG4).(Al-Maawali et al. 2011; Kumar et al. 
2012) Nerve conduction studies (NCS) are now routinely included in the evaluation of patients 
with spastic paraplegia. SPG6 was previously considered a form of pHSP until the identification 
of a heterozygous missense NIPA1 mutation in a family with peripheral neuropathy and spastic 
paraplegia.(Du et al. 2011) REEP1(SPG31) mutations can be associated with amyotrophy, 
peripheral nerve involvement and bulbar palsy.(Hewamadduma et al. 2009) Up to two thirds of 
SPG10 patients with KIF5A mutations have peripheral neuropathy.(Crimella et al. 2012; Goizet 
et al. 2009) As mentioned earlier, mutations in genes for HSP can occasionally cause isolated 
neuropathy, such as ATL1(SPG3A) in AD-HSN and BSCL2 (SPG17) in dHMN.(Guelly et al. 
2011; Windpassinger et al. 2004)  
 
Conversely, mutations in genes causing primarily inherited neuropathies have been identified in 
patients with HSP. For example, mutations of KIF1A, the gene for HSN-IIC, have been found in 
patients with SPG30.(Erlich et al. 2011; Klebe et al. 2012) Another example is CCT5 in which 
the mutations result in autosomal recessive mutilating sensory neuropathy with spastic 
paraplegia.(Bouhouche et al. 2006) CNS involvement is well recognized in CMT2A patients 
due to MFN2 mutations.(Chung et al. 2006). SOX10 mutations cause a rare form of 
demyelinating CMT associated with spastic quadriplegia and sensorineural deafness.(Inoue et al. 
1999) The group of inherited neuropathies with  significant upper motor neuron (UMN) 
component is continuously expanding. The coexistence of peripheral neuropathies and 
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pyramidal signs highlights common pathophysiological pathways in these disorders.   
 
1.2.2 Peripheral neuropathies and hereditary cerebellar ataxia 
Hereditary cerebellar ataxias are a clinically and genetically heterogeneous group of disorders 
characterised by slowly progressive cerebellar ataxia associated with dysarthria and abnormal 
eye movements.(Anheim 2011; Harding 1993a) The clinical phenotype is often complicated by 
involvement of other neurological or non-neurological systems. Peripheral neuropathy is 
frequently present. Therefore neurophysiological assessment is often included in the evaluation 
of patients with hereditary cerebellar ataxia.(Anheim et al. 2011) 
 
In autosomal dominant cerebellar ataxias (ADCA) / spinocerebellar ataxia (SCA), the 
commonest type of neuropathy is sensory motor axonal neuropathy (SMAN) which has been  
frequently observed in patients of SCA1, 2, 3, 4, 6, 8, 12, 18, 22, 25, 27 and DRPLA 
(Dentatorubro-pallidoluysian atrophy) and is particularly prevalent in patients with SCA2 (up to 
68%).(Manto et al.2009; Durr 2010) 
 
SMAN is also associated with many forms of autosomal recessive cerebellar ataxias (ARCA) 
which include cerebrotendinous xanthomatosis, ataxia telangiectasia (AT) and AT-like disorder, 
oculomotor apraxia type 1 (AOA1), oculomotor apraxia type 2 (AOA2) and ataxia with 
coenzyme Q10 deficiency.(Anheim 2011; Embirucu et al. 2009; Manto et al.2009) Another 
well-known example is spinocerebellar ataxia with axonal neuropathy (SCAN1) secondary to 
TDP1 mutations. Patients are characterised by areflexia, steppage gait and pes 
cavus.(Takashima et al. 2002). 
 
In addition to SMAN, other types of neuropathies have been described in ARCA. For example 
patients with  autosomal recessive Charlevoix-Saguenay-spastic ataxia (ARSACS) secondary to 
SACS mutations have usually sensory motor demyelinating neuropathy.(Vermeer et al. 2008) 
DNMT1 mutations can lead to either HSN-IE or autosomal dominant cerebellar ataxia, deafness 
and narcolepsy (ADCA-DN).(Winkelmann et al. 2012) In both phenotypes, affected patients 
may have co-existing sensory axonal neuropathy and cerebellar ataxia.  Sensory axonal 
neuropathy is also a prominent feature in Friedreich ataxia, abetalipoproteinemia, ataxia with 
vitamin E deficiency, and ataxia with POLG mutation. Otherwise, sensory demyelinating 
neuropathy frequently presents in Refsum disease.(Embirucu et al. 2009; Milone et al. 2008; 
Van Goethem et al. 2004; Weiss et al. 2010)  
 
Peripheral neuropathy is also observed in X-linked ataxia. Variable degrees of peripheral and 
autonomic nerve involvement can be found in patients with fragile-X tremor ataxia syndrome 
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(FXTAS).(Leehey et al. 2012; Verkerk et al. 1991)  
 
Cerebellar ataxia with neuropathy and bilateral vestibular areflexia syndrome (CANVAS) is a 
distinct syndrome with cerebellar ataxia, non-length-dependent sensory neuropathy and absent 
visually enhanced vestibulo-ocular reflex. The majority of patients had evidence of cerebellar 
atrophy involving anterior and dorsal vermis on brain magnetic resonance image (MRI) and 
absent sensory nerve action potential (SAP). Nevertheless, the disease-causing gene has not 
been identified yet.(Szmulewicz et al. 2011)  
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1. 3 Applications of next generation sequencing in genetic diagnosis 
 
An accurate diagnosis of inherited neuropathy requires detailed information of the phenotype 
(type of neuropathy, mode of inheritance, associated clinical features) and the updated 
knowledge of genetic subtypes including their frequencies in different populations. Current 
diagnostic strategy is based on a sequential genetic screening strategy guided by the 
phenotype.(Murphy et al. 2012a; Saporta et al. 2011) as illustrated in figure 1-1.   
 
 
Figure 1-1. Current diagnostic strategy for CMT 
Molecular diagnosis of CMT starts with classification of the phenotypes according to the 
patient’s neurophysiological features: CMT1, CMT2 or I-CMT. For CMT1 and CMT2, the 
arrows indicate a sequential genetic screening strategy. MM: male to male inheritance  
 
Although a genetic diagnosis is currently achieved in approximately 60~70% of CMT patients 
via conventional approach, pursuing a definite diagnosis in the rest patients remains a great 
challenge.(Braathen et al. 2011; Miller et al. 2011; Reilly et al. 2011) The major reason is the 
constantly growing number of genes that have to be screened due to increasing overlap in 
phenotypes and genotypes. Sanger sequencing, the current main method of genetic diagnosis, 
can only get the maximal read length at around 800 bps and screens usually one exon in a single 
round. Thus the identification of the disease-causing mutations is often a time-consuming and 
expensive process.  
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For patients in which a genetic diagnosis has not been achieved the traditional approach 
employs linkage analysis as the core method to define the candidate region, followed by 
positional cloning to narrow the candidate region until the gene and its mutations are found. 
Nevertheless, there are several factors which may prevent a successful outcome: small families 
with a limited number of affected individuals, sporadic cases, reduced penetrance, locus 
heterogeneity, and alleles that impair reproductive fitness.  
 
Since the commercial launch of the first platform in 2005, next-generation sequencing (NGS) 
has revolutionised the process of identifying novel genes and markedly accelerated multiple 
areas of genomics research. NGS, also known as high-throughput sequencing, allows massively 
parallel sequencing of deoxyribonucleic acid (DNA) molecules so that hundreds of megabases 
to gigabases of nucleotide-sequence can be generated in a single instrument run.(Hirschhorn 
2009)  The most widely used NGS technologies for genetic diagnosis is exome sequencing 
(exome capture) with the concept of using a complex pool of biotinylated RNA probes to 
hybridize and then to capture the exons for sequencing (figure 1-2).(Choi et al. 2009; Gnirke et 
al. 2009) Exome sequencing can be applied in two ways:  (1) whole exome sequencing (WES) 
to capture all the known coding exons and exon/intron boundaries of the genome  (2) targeted 
resequencing capture only genomic specific regions of  interest instead of whole exome, for 
example, exons of specific genes.(Voelkerding et al. 2009) 
 
 
Figure 1-2. Overview of exome 
sequencing using the hybrid selection 
method.  
The steps involved in the preparation of a 
complex pool of capture probes (“bait”; 
top left), genome fragment input library 
(“pond”; top right) and hybrid-selected 
enriched output library (“catch”; bottom) 
are illustrated. Two sequencing targets 
and their respective baits are shown in 
red and blue. Thin and thick lines 
represent single and double strands, 
respectively. Universal adapter sequences 
are grey. The excess of single-stranded 
non-self-complementary RNA (wavy 
lines) drives the hybridization. (modified 
from Gnirke et al. 2009)  
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1.3.1 Whole exome sequencing (WES)  
The “exome” represents all the exons in the human genome and accounts for about 180,000 
exons and for around 1% of the human genome which translates to about 30 Mb in length. It is 
estimated that about 85% of disease-causing mutations lie within the protein-coding regions of 
the human genome. Because most mutations causing monogenic disorders are exomic, whole 
exome sequencing has been introduced as an efficient strategy to identify novel genes 
associated with rare mendelian disorders.(Choi et al. 2009; Ng et al. 2009; Singleton et al.)  
 
Inherited neuropathy is an attractive model in which WES could be employed as a diagnostic 
tool because of the genetically heterogeneity of the disease. WES was first successfully used in 
the identification of a novel GJB1 mutation in a CMT family.(Montenegro et al. 2011) Several 
studies subsequently documented WES as a powerful tool in the identification of novel CMT 
genes (figure 1-3).(Pandra et al. 2012; Rossor et al. 2013)  
 
Figure 1-3. A timeline of discovery of genes involved in Charcot–Marie–Tooth disease and 
related disorders.  
WES: whole-exome sequencing. (cited from Rossor et al. 2013) 
 
WES is also helpful in unraveling new pathogenic variants and genotype-phenotype 
associations. Genes can be found to cause a phenotype which was previously unexpected. For 
example, ATL1 was known to cause SPG3A but it was subsequently detected by WES causing 
HSN.(Guelly et al. 2011) WES has also identified new types of mutations in many known genes 
thus broadening the  phenotypic spectrum of the diseases due to these genes. Heterozygous 
mutations in the ATPase family gene 3-like 2 gene (AFG3L2) can cause SCA28, a type of 
ADCA frequently associated with pyramidal signs and ophthalmoplegia.(Koppen et al. 2007) 
By WES, a homozygous AFG3L2 mutation was identified in a recessive family with a spastic-
ataxia-neuropathy syndrome, a phenotype very close to recessive SPG7 caused by SPG7 
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mutations (figure1-4).(Pierson et al. 2011). Interestingly, AFG3L2 and SPG7 are paralogous 
genes and both of them carry the AAA (ATPases associated with various cellular activities) 
metalloprotease domain and proteolytic domain in their coding proteins. The genetic finding 
suggests that a common pathway is involved in the pathogenesis of peripheral neuropathy, 
spasticity and cerebellar ataxia.   
Figure 1-4. A homozygous AFG3L2 mutation causes recessive spastic ataxia-neuropathy, a 
phenotype overlapping between SCA28 and SPG7. 
Top. The genomic organization of AFG3L2 and the domain structure of the coding protein. All 
published mutations are marked in red. Bottom. The genomic organization of SPG7 and the 
domain structure of the coding protein. Other published mutations are marked in blue. 
Homozygous Y616C mutation in the proteolytic domain was identified in a recessive family 
with spastic paraplegia, peripheral neuropathy, and cerebellar ataxia.(the picture has been 
published in Pandraud et al. 2012) 
 
1.3.2 Targeted resequencing 
Targeted resequencing is a NGS technique which is able to sequence only those exons of the 
human genome of interest for a particular disease.  The aim is therefore to reduce the amount of 
false positive signals and to enhance the efficiency of the analysis as compared to WES. 
Furthermore, the overall time and cost of a sequencing experiment can be reduced. Targeted 
resequencing allows high throughput and massive parallel sequencing of multiple genes with 
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various NGS sequencing platforms and different target enrichment strategies, including 
microarray-based capture, in-solution capture and PCR-based amplification.(Albert et al. 2007; 
Gnirke et al. 2009; Hodges et al. 2009; Hodges et al. 2007; Okou et al. 2007) By customization 
of the targeted coordinates, targeted resequencing is more flexible to fit for the specific aim and 
sample size of the research project and capable of supporting a wider range of genomic 
applications more quickly and efficiently than WES. Resequencing panels have been applied in 
different research projects, such as sequencing of a single gene with numerous exons for 
multiple samples, to establish molecular diagnosis of particular disorders, or to screen multiple 
genes which are known to cause overlapping phenotypes.(Denning et al. 2007; Dufke et al. 
2012; Kothiyal et al. 2010; Nemeth et al. 2013; Schlipf et al. 2011; Waldmuller et al. 2008)  
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1.4. Objectives  
 
1.4.1 Investigating genetic aetiologies in patients with inherited neuropathies and 
associated disorders  
The aim of my research was to establish the genetic diagnosis in several cohorts of patients 
affected by CMT, HSN, or peripheral neuropathy in complex syndromes. The phenotypic-
genotypic correlations of identified mutated genes were investigated.  To achieve the above 
objectives, an integrated approach combining conventional Sanger sequencing and NGS 
technology was taken. My research projects were divided into the following parts: 
 
(1) Screening of disease-causing mutations in newly-identified genes or rare genes for inherited 
neuropathies in large cohorts of patients. The investigated genes included: 
(a) NEFL gene and the five prime untranslated region (5’UTR) of PMP22 in CMT patients  
(b) Two novel genes, MARS and C12orf65, in CMT patients 
(c) SPTLC2 gene in HSN patients 
 
(2) Screening of disease-causing mutations in genes responsible for other disorders which may 
be also associated with peripheral neuropathies in cohorts of patients. The studied genes 
included: 
(a) KIF5A (SPG10) in patients with cHSP with axonal neuropathy and CMT2 with spasticity 
(b)PDYN (SCA23), AFG3L2 (SCA28) and KCND3 (SCA19/SCA22) in patients with 
    cerebellar ataxia 
 
(3) WES of selected families or sporadic patients in which a genetic diagnosis has not been 
reached by conventional methods.  The phenotypes of the investigated patients included: 
(a) HSN with cerebellar ataxia. 
(b) X-linked HSN 
(c) ARCMT2 
(d) ARCA or ARCA-plus syndromes 
 
(4) Targeted resequencing in patients with inherited neuropathies and related disorders. The 
development of an effective screening panel included design of the probe library, recruitment 
of patients, execution of the library preparation and validation of the panel using positive and 
negative controls. Two panels using different technology were developed to explore the 
potentiality for targeted resequencing as a tool in genetic diagnosis,:  
(a) ARCMT1 panel using the Truseq system (Illumina) 
(b) HSP with axonal neuropathy panel using the HaloPlex system (Agilent) 
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1.4.2 Investigating the pathogenesis of inherited neuropathies and associated disorders 
Functional studies were also performed for two identified mutations/variations:  
(1) Gene expression and the pathogenic effects of a novel C12orf65 mutation were studied in 
lymphoblasts of CMT patients  
(2) The pathogenic effect of a novel ADCK3 mutation was studied in fibroblasts of patients with 
ARCA.  
 
The scope of this thesis was summarised in figure 1-5. 
 
 
Figure 1-5. Scope of this thesis 
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Chapter 2 
 
Methods 
 
2.1 Patients  
All studies in the thesis were approved by the joint ethics committee of UCL Institute of 
Neurology and The National Hospital for Neurology and Neurosurgery (NHNN). Clinical 
evaluation, blood or other biological samples were obtained after written or oral informed 
consents from the affected patients and family members according to the regulations of NHNN 
or other institutes and then sent to our laboratories. When mutations were identified patients 
were assessed and had detailed clinical and neurophysiological examinations if necessary. NCS 
was performed using standard technique. 
 
2.2 Mutation nomenclature 
 
The mutation and polymorphisms identified were labelled based on the published 
complementary deoxyribonucleic acid (cDNA) sequence (http://www.ncbi.nlm.nih.giv). The 
nomenclature system followed the recommendation of the Human Genome Variation 
Society.(den Dunnen et al.2003) Gene cDNA sequence was prefixed c. for cDNA nucleotide and 
numbering +1 refers to the first nucleotide of the ATG translation initiation codon. The amino 
acid numbering was taken from the published cDNA sequence.  
 
2.3 Sanger sequencing 
 
2.3.1 DNA extraction from blood  
Genomic DNA (gDNA) was extracted from 4~5 ml of whole blood using Promega Wizard DNA 
extraction kit or using the Qiagen Gentra Puregene Blood Kit, following manufacturer’s 
instructions. DNA extracted from blood was stored at -80˚C freezer. 
 
2.3.2 DNA quantification 
The amount of gDNA was measured by the NanoDrop Spectrophotometer equipped with the 
interactive software ND-1000 V2.3.2 (NanoDrop Technologies). The NanoDrop 
spectrophotometer was loaded with 1~2 µl of solution and the gDNA concentration was 
expressed in ng/µl. DNA absorbed at 260 nm and contributed to the total absorbance. For 
quality control, the ratios of absorbance at 260/280 nm and 260/230 nm were used to assess the 
purity of DNA. Ratios of 260/280 around 1.8 and 260/230 around 2.0~2.2 denoted pure DNA. If 
in both cases the ratio was appreciably lower than expected, it might indicate the presence of 
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contaminants which absorbed at 280 and/or 230 nm.  
 
2.3.3 Polymerase chain reaction (PCR)  
DNA was prepared at a concentration of 10~30 ng/µl for the polymerase chain reaction (PCR). 
PCR was performed using Roche Faststart PCR Master (400 RXN/10 ml), primers at a dilution 
of 10 pmol/µl and DNA at a concentration of 10~30 ng/µl. Reagents were added in a total 
volume of 25 µl as following: Roche Master 12.5 µl, forwarded and reverse primers 0.75µl for 
each, autoclave water 10 µl and DNA 1 µl in a single run of reaction. With difficult PCR’s, 
usually due to GC rich regions, DMSO was added at 10% of PCR total volume.  
 
2.3.4 Agarose gel electrophoresis 
Agarose gel electrophoresis was used to verify the quality and size of PCR amplification 
product. The 1.0~1.5% gel was prepared using Ultrapure Agarose (Invitrogen) and TBE 1X 
buffer (VWR). Samples and the DNA ladder (1 Kb) (Novagen) were loaded on the gels and a 
run at 50~70 mV was performed for 30~45 minutes. DNA fragments were visualized and 
photographed using UV transluminator. 
 
2.3.5 PCR product purification  
PCR product was filtered using the 96 wells PCR filter plates (Millipore). 80 µl of autoclave 
water was then added for each sample to filter the PCR product on the manifold. Then the filter 
plate was seated onto the vacuum platform (Eppendorf) with the vacuum on and the lid off for 5 
minutes. Subsequently PCR product was re-suspended in 50 µl of autoclave water and shaken 
on the thermoshaker (Eppendorf) at room temperature (RT, 15~25°C) at 300 rpm for 5~30 
minutes. The ~50 µl resuspended, purified PCR product was transferred to a labelled blue 
skirted plate (Eppendorf). It was used for sequencing reaction. The rest of the purified PCR 
product was stored at -20˚C freezer. 
 
2.3.6 Sequencing reaction  
Reagents were added in a total volume of 10 µl as following : 0.5 µl of BigDye Terminator 
(V3.1 or V3.3), 2 µl of 5X Sequencing Buffer (Applied Biosystems), 0.5µl of forward or 
reverse primers at the concentration 3.2 pmol/µl, 3.5 µl of purified PCR product and 6.5 µl of 
autoclave water. Sequencing reaction was performed using the settings as following: 
a. 24 cycles of: 
  96°C for 10 seconds 
  55°C for 5 seconds 
  60°C for 4 minutes  
b. 4°C forever 
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2.3.7 Dye removal of sequencing product 
The purpose of this step is to remove excess fluorescently labelled 2',3' dideoxynucleotides 
(ddNTPs), primers and salts from the sequencing reactions. Two methods were used depending 
availability of reagents and consumables.  
 
(1) Millipore plate clean up 
Sequencing product was filtered using the 96 wells PCR filter plates (Millipore). 80 µl of 
autoclave water was then added for each sample to filter the PCR product on the manifold. Then 
the filter plate was seated onto the vacuum platform with the vacuum on and the lid off for 5 
minutes. Subsequently sequencing product was re-suspended in 20 µl of autoclave water and 
shaken on the thermoshaker (Eppendorf) at RT at 300 rpm for 5~30 minutes. The ~20 µl 
purified sequencing product was transferred to a 96-well reaction plate and run in the 3730 
Genetic Analyser (Applied Biosystems).   
 
(2) Dye terminator removal plate clean up 
A dye terminator removal plate (ABgene) containing a gel separation matrix of spheres with 
pores in them was used. The matrix retained the smaller ddNTPs and allowed the DNA 
fragments to pass through into the filtrate. Dye removal was performed in the following steps:  
1. The dye removal plate was removed from its silver foil. The bottom cover was removed from 
the plate and placed over one of the plates with the rounded wells. 
2. The top cover was removed and the plate was spun in the centrifuge at 2150 rpm for 3 
minutes.  
3. The dye removal plate was sit over a fresh, labelled PCR plate. 
4. 10 µl of autoclave water was added to each sequencing reaction (well). 
5. All 20 µl of diluted sequencing reaction agents were pipetted gently into the centre of the 
filters in the dye removal plate wells. 
6. The dye removal plate and PCR plate were spun at 2150 rpm for 3 minutes 
7. After spinning, the PCR plate should contain ~20 µl of filtrate in each well. The PCR plate 
was placed into a black, plastic holder and then submitted to the 3730 Genetic Analyser for 
sequence analysis.  
 
2.3.8 Sequence analysis 
The 3730 Genetic Analyser was used for gene sequencing. The resulting sequences were aligned 
and analysed with Sequencher software (Gene Codes Corporation). Sequence variants were 
confirmed by repeat sequencing. 
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2.4 PCR based messenger ribonucleic acid (mRNA) expression studies 
 
2.4.1 RNA isolation  
Ribonucleic acid (RNA) was extracted from lymphoblasts of patient and healthy controls in 
C12orf65 gene expression study (Section 3.1). The RNA had to be pure and intact and free of 
contaminants such as DNA and other potential inhibitors, for example, RNAses. Therefore, a 
sterile technique was employed at all times when handling reagents and equipment used for 
RNA isolation.  
 
Purification of total RNA was performed with the RNeasy Mini Kit (Qiagen) which 
combines phenol/guanidine-based lysis of samples and silica-membrane–based purification of 
total RNA. RNA isolation was performed as the following procedures:  
1. 700 µl QIAzol Lysis Reagent was added and mixed evenly to loosen the cell pellet 
thoroughly by vortex. 
2. The tube containing the homogenate was placed at RT for 5 minutes. 
3. 140 µl chloroform was added to the tube which contained the homogenate and capped it 
securely. The tube was shook vigorously for 15 seconds. 
4. The tube containing the homogenate was placed at RT for 2~3 minutes. 
5. The tube containing the homogenate was then centrifuged for 15 minutes at 12,000 x g at 4°C. 
After centrifugation, the sample separated into 3 phases: an upper, colorless, aqueous phase 
containing RNA; a white interphase; and a lower, red, organic phase. The volume of the 
aqueous phase was approximately 350 µl. 
6. The upper aqueous phase was transferred to a new collection tube. 1.5 volumes (usually 525 
µl) of 100% ethanol were added and mix thoroughly by pipetting up and down several times. 
Continue without delay with step 7. 
7. 7Up to 00 µl of the sample, including any precipitate that may have formed, was pipetted into 
an RNeasy Mini spin column in a 2 ml collection tube. The lid was closed gently. The tube 
was centrifuged at ≥8000 x g (≥10,000 rpm) for 15 seconds at RT. The flow-through was 
discarded. The collection tube would be reused in step 8. 
8. Step 7 was repeated using the remainder of the sample. The flow-through was discarded. The 
collection tube would be reused in step 9. 
9. 700 µl Buffer RWT was added to the RNeasy Mini spin column. The lid was closed gently 
and the tube was centrifuged for 15 s at ≥8000 x g (≥10,000 rpm) to wash the column. The 
flow-through was discarded.  
10. 500 µl Buffer RPE was pipetted onto the RNeasy Mini spin column. The lid was closed 
gently and the tube was centrifuged for 15 s at ≥8000 x g (≥10,000 rpm) to wash the column. 
The flow-through was discarded. The collection tube would be reused in step 11. 
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2.4.2 cDNA synthesis  
RNA was reverse transcribed form cDNA using the First-Strand cDNA synthesis Superscript II 
RT kit (Invitrogen). The reaction constituted 2µg of total RNA, 1 µl of random primers, 1 µl of 
dNTP mix (10mM) and 8 µl of RNAase-free water. The mixture was heated to 65°C for 5 
minutes, followed by a quick chill on ice. The contents were then centrifuged and the remaining 
cDNA synthesis mixture was added which included 4 µl of 5X First-Strand Buffer, 2 µl of 0.1 
M dithiothreitol (DTT), followed by 1 µl of RNAse OUT (40 units/µl). RNaseOUT is optional 
and required when the starting RNA is less than 50ng. The contents were then mixed gently and 
incubated 25°C for 2 minutes. 1 µl (200 units) of SuperScript II RT was added by pipetting 
gently up and down. The mixture was incubated at 42°C for 50 minutes, followed by 70°C for 
15 minutes to inactivate the reaction. The synthetic cDNA can be stored at -20°C. 
11. Another 500 µl Buffer RPE was added to the 
RNeasy Mini spin column. The lid was closed 
gently and the column was centrifuged for 2 
minutes at ≥8000 x g (≥10,000 rpm) to dry the 
RNeasy Mini spin column membrane. The 
long centrifugation dried the spin column 
membrane, ensuring that no ethanol was 
carried over during RNA elution.  
12.The RNeasy Mini spin column was 
transferred to a new 1.5 ml collection tube. 
30~50 µl RNase-free water was pipetted 
directly onto the RNeasy Mini spin column 
membrane. The lid was closed gently and the 
column was centrifuged for 1 min at ≥8000 x 
g (≥10,000 rpm) to elute the RNA. 
13. The RNA concentration was measured and 
assessed the quality with spectrophotometer 
by evaluating the 260/280 nm and 260/230 
nm ratio. 
 
The procedures were summarised in figure 2-1. 
 
 
     
Figure 2-1. The miRNeasy Mini procedures
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2.4.3 Quantitative Real Time PCR (qRT-PCR)  
A multiplex quantitative real-time PCR assay for the levels of C12orf65 and RPL13A were 
performed using SYBR Green PCR Master Mix kit (Applied Biosystems) with a Corbett Rotor-
Gene real-time quantitative thermal cycler (Corbett Research/Qiagen). The 25µl reaction 
required 5µl of cDNA (50ng/µl), 12.5µl SYBR-green, 2.25µl primers (900nM) and 3µl ddH2O. 
Thermal cycling consisted of 10 minutes at 94°C for initial denaturation and DNA polymerase 
activation, followed by 40 cycles of denaturation at 94°C for 15 seconds and 
annealing/extension at 60°C for 1 minute. Each assay contained template negative controls and 
a quantitative standard curve dilution run in duplicate. All reactions were performed in triplicate 
in a final volume of 10 μl. Dissociation curves were run to detect nonspecific amplification, and 
single amplified product was confirmed in each reaction. Standard curves showed that all 
duplexed assays had equal efficiencies (99.9%), satisfying criteria for the comparative Ct 
method of quantification. The quantities of each test gene and internal controls were then 
determined from the standard curve using the Rotor-Gene 6000 series software 1.7 (Corbett 
Research/Quiagen). Relative quantity of each C12orf65 level normalized by the RPL13A level 
was then calculated. The results were expressed as percentage of control.  
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2.5 Targered resequencing  
 
2.5.1 Design of the probe library in targeted resequencing  
(1) TruSeq Custom Amplicon project  
The library of probes for the ARCMT1 panel was designed though TruSeq Custom Amplicon 
(TSCA) system (Illumina).(Section 6.1) Custom oligonucleotide probes were first designed in 
web-based DesignStudio (https://icom.illumina.com/). Each panel was designed for a project, 
referring to a group of diseases, e.g. ARCMT1. A project contained several target regions of 
interest. A target region comprised a pair of coordinates that define a continuous sequence in the 
genome, usually CCDS (Consensus coding DNA sequence) of the target gene. Each target 
region then was divided into several targets. Targets were the actual coordinates used for 
designing probes to make each amplicon ~250 bps in length. The TSCA kit allowed the 
procession of up to 384 amplicons per sample and integrated indexes to support up to 96 
samples per run. The reference genome was based on UCSC iGenomes (hg19) (Homo sapiens) 
(http://genome.ucsc.edu). Figure 2-2 illustrated the online DesignStudio. 
 
 
Figure 2-2. Design of custom oligonucleotide probes in web-based DesignStudio. 
Target probes could be designed across the entire target region (full region), or these targets 
could be discontinuous if the probes were designed for just the exons (exon only). Padding per 
exon was to add from 0 to 25 bases upstream and downstream of each exon.
 
(2) Halo Design Wizard  
The target sequencing panel of the HSP-neuropathy panel was designed with the web-based 
Agilent Halo Design Wizard (http://www.halogenomics.com/haloplex/custom-reagent-kits) 
(Section 6.2). The design procedure was started to input a list of target genes or a set of genomic 
coordinates. Then regions of interest for each gene were defined as required, for example, 
CCDS only or the whole genomic gene. After reviewing the target regions on Halo design 
servers, the project was assigned the name and then submitted to the server.  
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(3) Report of the design 
By selection of the way to design probes and adjustment of the settings, the amplicons were 
optimized with the attempt to get a full coverage of the target regions. After the design was 
completed, a report containing the location and coverage of the custom amplicons was 
generated. In table 2-1 amplicons of FGD4 are provided as an example.  
 
Table 2-1. Report of the design of FGD4 custom amplicons 
Target Chr Start Stop Length (bp) Amplicon Avoid SNP Coverage Score
FGD4 ex3 12 32729242 32729383 142 1 Yes 100 95 
FGD4 ex4 12 32734894 32735401 508 4 Yes 100 85 
FGD4 ex5 12 32751431 32751520 90 1 Yes 100 95 
FGD4 ex6 12 32754212 32754357 146 1 Yes 100 95 
Amplicon Chr Start Stop Target Length (bp) Strand 
Avoid 
SNP Score
Amplicon 
(3081506) 12 32729100 32729327 Exon_2193735 228 R Yes 95 
Amplicon 
(3081507) 12 32729276 32729513 Exon_2193735 238 F Yes 87 
Amplicon 
(3081512) 12 32734742 32734974 Exon_2196253 233 R Yes 74 
Amplicon 
(3081513) 12 32734920 32735150 Exon_2196253 231 F Yes 95 
Chr= chromosome, Avoid SNP = indicating whether SNPs are being avoided for the target 
region and/or amplicon, Coverage = the total number of non-overlapping base covered by the 
attempted amplicons divided by the total number of bases in design, Score= an Illumina 
estimate of the percentage of attempted probes that will successfully enrich the targeted 
sequences. This prediction is based on GC content and probe uniformity. Actual assay 
performance and resultant sequencing depth may vary across targeted regions due to a variety of 
factors including library quality and probe hybridization efficiency. Only part of the targets and 
amplicons are listed in the table. 
 
The following figure 2-3 (p57) illustrated how designed amplicons covered the targeted regions.  
All the short-fragmented custom amplicons for FGD4 (black tracks) are inspected on the 
genome browser to check if they together could cover CCDS (green tracks) without any gaps.  
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Figure 2-3. Designed custom amplicons can cover CCDS of FGD4 without gaps 
 
2.5.2 Sample assessment and preparation 
Next generation sequencers require stringent control of sample preparation. To obtain an 
accurate quantification of the DNA library, the sample gDNA used in targeted resequencing and 
WES were assessed by the Qubit Fluorometry system with dsDNA BR Assay (Invitrogen) and 
the Qubit ® 2.0 Fluorometer (Invitrogen) using 2 µl of each gDNA sample with 198 µl of the 
Qubit working solution for sample quantification. Once high quality DNA had been extracted, 
the library was prepared using the TruSeq DNA Sample Prep Kit (Illumina) following 
manufacturer’s instructions, which provided an indexed adapter sequence for each DNA sample, 
enabling multi-sample pooling in a single enrichment reaction.  
 
2.5.3 Library enrichment- TruSeq Enrichment System 
Library enrichment of WSE and the targeted resequencing ARCMT1 panel with reactions of a 
total of 96 samples were completed by using the TruSeq Custom Enrichment System, but 
different oligonucleotide reagents were used for WSE and targeted resequencing during the 
hybridization procedures. The workflow is summarised in figure 2-4 (p58). 
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Figure 2-4. TruSeq enrichment system workflow 
 
(1) Sample preparation 
Prior to library enrichment, the human DNA library was prepared using the TruSeq DNA 
Sample Preparation kit as mentioned in Section 2.5.2 
 
(2) First Hybridization 
In this process, the DNA library was mixed with capture probes of targeted regions.  
1. The Capture Target Buffer 1 tube (CTB1) was put on the vortex for 5 seconds to make sure 
no crystal structures were present. 
2. The reaction mix was prepared in a total volume 100 µl per sample in each well of the new  
96-well PCR plate labelled CTP1 in the following order: diluted DNA library 40 µl, CTB1 
50 µl, Custom Selected Oligos10 µl. The entire volume was pipetted gently up and down 
10~20 times to mix thoroughly.  
3. The CTP1 plate was sealed with an adhesive seal tightly to prevent potential evaporation.  
4. The CTP1 plate was centrifuged to 280 xg for 1 minute. 
5. The sealed CTP1 plate was placed on the pre-programmed thermal cycler with the lid closed 
and incubated using the settings: 
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a. Pre-heated lid set to 100°C 
b. 95°C for 10 minutes 
c. 18 cycles of 1 minute incubations, starting at 93°C, then decreasing 2°C per cycle 
d. 58°C for 16~20 hours 
 
(3) First Wash 
In this process, streptavidin beads were used to capture probes containing the targeted regions of 
interest. Three wash steps were performed to remove non-specific binding from the beads. The 
enriched library was then eluted from the beads and prepared for a second hybridization. 
 
1. The CTP1 plate was removed from the thermal cycler. 
2. The CTP1 plate was centrifuged to 280 xg for 1 minute. 
3. The CTP1 plate was placed on a 96-well rack and the adhesive seal was removed from the 
plate.  
4. The entire contents of each well was transferred from the CTP1 plate to the corresponding 
well of the new 96-well plate labelled WTP1. 
5. The Streptavidin Magnetic Beads tube was put on the vortex until the beads are well 
dispersed, then 250 µl of well-mixed Streptavidin Magnetic Beads was added to the wells of 
the WTP1 plate. The entire volume was pipetted gently up and down 10 times to mix 
thoroughly. 
6. The WTP1 plate was sealed with an adhesive seal. 
7. The WTP1 plate was placed at RT for 30 minutes. 
8. The WTP1 plate was centrifuged to 280 xg for 1 minute. 
9. The adhesive seal was removed from the WTP1 plate. 
10. The WTP1 plate was placed on the magnetic stand for 2 minutes at RT until the liquid 
appearing clearly. 
11. All of the supernatant was removed and discarded from each well. 
12. The WTP1 plate was removed from the magnetic stand. 
13. The Wash Solution 1 tube was put on the vertex for 5 seconds to make sure that no crystal 
structures were present. 
14. 200 µl Wash Solution 1 was added to each well of the WTP1 plate. The entire volume was 
pipetted gently up and down 10~20 times to make sure the beads were fully resuspended. 
15. The WTP1 plate was placed on the magnetic stand for 2 minutes at RT until the liquid 
appearing clearly. 
16. All of the supernatant was removed and discarded from each well. 
17. The WTP1 plate was removed from the magnetic stand. 
18. The Wash Solution 2 tube was put on the vertex or 5 seconds to make sure that the Wash 
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Solution 2 was mixed thoroughly. 
19. 200 µl Wash Solution 2 was added to each well of the WTP1 plate. The entire volume was 
pipetted gently up and down 10~20 times to mix thoroughly and avoid excessive bubbling 
or foaming. The beads had to be fully resuspended. 
20. The WTP1 plate was placed on the magnetic stand for 2 minutes at RT until the liquid 
appearing clearly. 
21. All of the supernatant was removed and discarded from each well. 
22. The WTP1 plate was removed from the magnetic stand. 
23. 200 µl Wash Solution 2 was added to each well of the WTP1 plate. The entire volume was 
pipetted up and down 10~20 times to mix thoroughly and avoid excessive bubbling or 
foaming. The beads had to be fully resuspended. 
24. The entire contents of each well was transferred of the WTP1 plate to the corresponding 
well of the new 96-well PCR plate labelled IWP1. 
25. The IWP1 plate was sealed with an adhesive seal.  
26. The IWP1 plate was incubated on the thermal cycler at 42°C for 30 minutes with a heated 
lid set to 100°C. 
27. The magnetic stand was placed next to the thermal cycler for immediate access. 
28. The IWP1 plate was removed from the thermal cycler and immediately placed on the 
magnetic stand for 2 minutes until the liquid appearing clearly. 
29. The adhesive seal was removed from the IWP1 plate. 
30. All of the supernatant was immediately removed and discarded from each well.  
31. The IWP1 plate was removed from the magnetic stand. 
32. 200 µl Wash Solution 2 was added to each sample well of the IWP1 plate. The entire 
volume was pipetted gently up and down 10~20 times to mix thoroughly and avoid 
excessive bubbling or foaming. The beads had to be fully resuspended. 
33. Steps 25~30 were repeated once. 
34. The IWP1 plate was removed from the magnetic stand. 
35. 200 µl Wash Solution 3 was added to each well of the IWP1 plate. The entire volume was 
pipetted gently up and down 10~20 times to mix thoroughly. 
36. The IWP1 plate was placed on the magnetic stand for 2 minutes at RT until the liquid 
appearing clearly. 
37. All of the supernatant was removed and discarded from each well. 
38. Steps 34~37 were repeated once. 
39. To remove any residual Wash Solution 3, the IWP1 plate was sealed with an adhesive seal.  
40. The IWP1 plate was centrifuged briefly to collect any residual Wash Solution 3. 
41. The IWP1 plate was placed on the magnetic stand for 2 minutes at RT until the liquid 
appearing clearly. 
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42. The adhesive seal was removed carefully from the IWP1 plate. 
43. Any residual supernatant was removed and discarded from each well. 
44. The elution pre-mix was prepared in a total volume per sample 30 µl in in a separate PCR 
tube in the following order: Elute Target Buffer 1 (ETB1) 28.5 µl, 2N NaOH 1.5 µl. 
45. The IWP1 plate was removed from the magnetic stand. 
46. 30 µl of the elution pre-mix was added to each well of the IWP1 plate. The entire volume of 
each well was pipetted gently up and down 10~20 times to mix thoroughly. 
47. The IWP1 plate was sealed with an adhesive seal tightly.  
48. The IWP1 plate was placed at RT for 5 minutes. 
49. The IWP1 plate was centrifuged to 280 xg for 1 minute. 
50. The IWP1 plate was placed on the magnetic stand for 2 minutes until the liquid appearing 
clearly. 
51. The adhesive seal was carefully removed from the IWP1 plate.  
52. 29 µl of supernatant was transferred from each well of the IWP1 plate to the corresponding 
well of the new 96-well PCR plate labelled TTP1. 
53. 5 µl Elute Target Buffer 2 (ETB2) was added to each well of the TTP1 plate containing 
samples to neutralize the elution. The entire volume was gently pipetted up and down 
10~20 times to mix thoroughly. 
54. The TTP1 plate was sealed with an adhesive seal tightly. 
55. 2 µl of the first elution was diluted in 98 µl PCR grade water (1:50 dilution) in a new PCR 
tube labelled “First Elution for qPCR”. Each tube was capped and stored at -15° to -25°C. 
 
(4) Second Hybridization 
In this process, the first elution of the DNA library was mixed with the capture probes of target 
regions. The second hybridization made sure that the targeted regions were further enriched. 
 
Reagents were prepared as following: 
1. The Custom Selected Oligos tube was removed from -15°to -25°C storage and thawed on ice. 
2. The Capture Target Buffer 1 tube was thawed at RT. 
3. The TTP1 plate was thawed at RT. The thawed TTP1 plate was centrifuged to 280 xg for 
1 minute. The adhesive seal was removed from the thawed TTP1 plate. 
 
1. The Capture Target Buffer 1 tube was put on the vortex for 5 seconds to make sure that no 
crystal structures were present. 
2. The reagents were prepared to a total volume per sample100 µl in the order listed to each well 
of the new 300 µl 96-well PCR plate labelled CTP2: Capture Target Buffer 1 50 µl, Custom 
Selected Oligos 10 µl, PCR Grade Water 10 µl and First Elution from TTP1 Plate 30 µl. The 
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entire volume was gently pipetted up and down 10~20 times to mix thoroughly. The tip had 
to be changed after each sample. 
3. The CTP2 plate was sealed with an adhesive seal tightly.  
4. The CTP2 plate was centrifuged to 280 xg for 1 minute. 
5. The sealed CTP2 plate was placed on the pre-programmed thermal cycler with the lid closed 
and incubated using the pre-programmed settings: 
a. Pre-heated lid set to 100°C 
b. 95°C for 10 minutes 
c. 18 cycles of 1 minute incubations, starting at 93°C, then decreasing 2°C per cycle 
d. 58°C for 16–20 hours 
 
(5) Second Wash 
In this process, streptavidin beads were used to capture probes containing the targeted regions of 
interest. Three wash steps were performed to remove non-specific binding from the beads. The 
enriched library was then eluted from the beads and prepared for sequencing. 
1. The CTP2 plate was removed from the thermal cycler. 
2. The room temperature CTP2 plate was centrifuged to 280 xg for 1 minute. 
3. The CTP2 plate was placed on a 96-well rack and the adhesive seal was removed from the 
plate.  
4. The entire contents from each well of the CTP2 plate was transferred to the corresponding 
well of the new 96-well plate labelled WTP2. 
5. The Streptavidin Magnetic Beads tube was put on the vortex until the beads were well 
dispersed, then 250 µl of well-mixed Streptavidin Magnetic Beads was added to the wells of 
the WTP2 plate. The entire volume was gently pipetted up and down 10 times to mix 
thoroughly. 
6. The WTP2 plate was sealed with an adhesive seal. 
7. The WTP2 plate was placed at RT for 30 minutes. 
8. The WTP2 plate was centrifuged to 280 xg for 1 minute. 
9. The adhesive seal was removed from the WTP2 plate. 
10. The WTP2 plate was placed on the magnetic stand for 2 minutes at RT until the liquid 
appears clear. 
11. All of the supernatant was removed and discarded from each well. 
12. The WTP2 plate was removed from the magnetic stand. 
13. The Wash Solution 1 tube was put on the vortex for 5 seconds to make sure that no crystal 
structures were present. 
14. 200 µl Wash Solution 1 was added to each well of the WTP2 plate. The entire volume was 
gently pipetted up and down 10~20 times to make sure the beads were fully resuspended. 
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15. The WTP2 plate was placed on the magnetic stand for 2 minutes at RT until the liquid 
appearing clear. 
16. All of the supernatant was removed and discarded from each well. 
17. The WTP2 plate was removed from the magnetic stand. 
18. The Wash Solution 2 tube was put on the vortex for 5 seconds to make sure that the Wash 
Solution 2 was mixed thoroughly. 
19. 200 µl Wash Solution 2 was added to each well of the WTP2 plate. The entire volume was 
gently pipetted up and down 10~20 times to mix thoroughly and avoid excessive bubbling 
or foaming. The beads had to be fully resuspended. 
20. The WTP2 plate was placed on the magnetic stand for 2 minutes at RT until the liquid 
appearing clear. 
21. All of the supernatant was removed and discarded from each well. 
22. The WTP2 plate was removed from the magnetic stand. 
23. 200 µl Wash Solution 2 was added to each well of the WTP2 plate. The entire volume was 
gently pipetted up and down 10~20 times to mix thoroughly and avoid excessive bubbling 
or foaming. The beads had to be fully resuspended. 
24. The entire contents of each well of the WTP2 plate was transferred to the corresponding 
well of the new 96-well PCR plate labelled IWP2. 
25. The IWP2 plate was sealed with an adhesive seal tightly. 
26. The IWP2 plate was incubated on the thermal cycler at 42°C for 30 minutes with a heated 
lid set to 100°C. 
27. The magnetic stand was placed next to the thermal cycler for immediate access. 
28. The IWP2 plate was removed from the thermal cycler and immediately placed on the 
magnetic stand for 2 minutes until the liquid appearing clear. 
29. The adhesive seal was removed from the IWP2 plate. 
30. All of the supernatant was removed and discarded from each well immediately. 
31. The IWP2 plate was removed from the magnetic stand. 
32. 200 µl Wash Solution 2 was added to each sample well of the IWP2 plate. The entire 
volume was gently pipetted up and down 10~20 times to mix thoroughly and avoid 
excessive bubbling or foaming. The beads had to be fully resuspended. 
33. Steps 25~30 were repeated once. 
34. The IWP2 plate was removed from the magnetic stand. 
35. 200 µl Wash Solution 3 was added to each well of the IWP2 plate. The entire volume was 
gently pipetted up and down 10~20 times to mix thoroughly. 
36. The IWP2 plate was placed on the magnetic stand for 2 minutes at RT until the liquid 
appearing clear. 
37. All of the supernatant was removed and discarded from each well. 
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38. Steps 34~37 were repeated once. 
39. To remove any residual Wash Solution 3, the IWP2 plate was sealed with an adhesive seal.  
40. The IWP2 plate was briefly centrifuged to collect any residual Wash Solution 3. 
41. The IWP2 plate was placed on the magnetic stand for 2 minutes at RT until the liquid 
appearing clear. 
42. The adhesive seal was carefully removed from the IWP2. 
43. Any residual supernatant was removed and discarded from each well. 
44. The elution pre-mix was prepared in a total volume per sample 30 µl in in a separate PCR 
tube in the following order: ETB1 28.5 µl and 2N NaOH 1.5 µl. 
45. The IWP2 plate was removed from magnetic stand 
46. 30 µl of the elution pre-mix was added to each well of the IWP2 plate. The entire volume 
was gently pipetted up and down 10~20 times to mix thoroughly. 
47. The IWP2 plate was sealed with an adhesive seal tightly.  
48. The IWP2 plate was placed at RT for 5 minutes. 
49. The IWP2 plate was centrifuged to 280 xg for 1 minute. 
50. The IWP2 plate was placed on the magnetic stand for 2 minutes until the liquid appearing 
clearly. 
51. The adhesive seal was carefully removed from the IWP2 plate. 
52. 29 µl of supernatant from each well of the IWP2 plate was transferred to the corresponding 
well of the new 96-well PCR plate labelled TTP. 
53. 5 µl ETB2 was added to each well of the TTP2 plate containing samples to neutralize the 
elution. The entire volume was gently pipetted up and down 10~20 times to mix thoroughly. 
 
(6) PCR Amplification 
In this process, PCR was performed to amplify the enriched DNA library for sequencing with 
the same PCR primer cocktail used in TruSeq DNA Sample Preparation. 
 
Reagents were prepared as following: 
1. One tube of PCR Master Mix and PCR Primer Cocktail were removed from -15° to -25°C 
storage to thaw, then the tubes were placed on ice. 
2. The thawed PCR Primer Cocktail and PCR Master Mix tubes were briefly centrifuged for 
5 seconds. 
3. The AMPure XP beads were removed from storage and placed at RT for at least 30 minutes. 
 
1. The following reagents were added in a total volume per sample 50 µl to each well of the new 
96-well PCR plate labelled TAP1: Second Elution from TTP2 plate 20 µl, PCR Master Mix 
25 µl and PCR Primer Cocktail 5 µl. Gently pipette the entire volume up and down 10 times 
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to mix thoroughly. 
2. The TAP1 plate was sealed with an adhesive seal.  
3. The TAP1 plate was centrifuged to 280 xg for 1 minute. 
4. The sealed TAP1 plate was placed on the pre-programmed thermal cycler with the lid closed 
and incubated using the pre-programmed settings: 
a. Pre-heated lid set to 100°C 
b. 98°C for 30 seconds 
c. 10 cycles of : 
  98°C for 10 seconds 
  60°C for 30 seconds 
  72°C for 30 seconds 
d. 72°C for 5 minutes 
e. Hold at 10°C 
5. The adhesive seal was removed from the TAP1 plate. 
6. The AMPure XP Beads were put on the vortex until the beads are well dispersed, then 90 µl 
of the mixed AMPure XP Beads was added to each well of the TAP1 plate containing 50 µl 
of the PCR amplified library. The entire volume was gently pipetted up and down 10~20 
times to mix thoroughly. 
7. The TAP1 plate was incubated at RT for 15 minutes. 
8. The TAP1 plate was placed on the magnetic stand at RT for 5 minutes or until the liquid 
appearing clearly. 
9. Using a 200 µl single or multichannel pipette, 140 µl of the supernatant was removed and 
discarded from each well of the TAP1 plate. 
10. With the TAP1 plate remaining on the magnetic stand, 200 µl of freshly prepared 80% EtOH 
was added to each well without disturbing the beads. 
11. The TAP1 plate was incubated for at least 30 seconds at RT, then the supernatant was 
removed and discarded from each well. 
12. Steps 10~11 were repeated once for a total of two 80% EtOH washes. 
13. The TAP1 plate was kept on the magnetic stand and placed at RT for 15 minutes to dry, then 
the plate was removed from the magnetic stand. 
14. The dried pellet in each well was resuspended with 30 µl Resuspension Buffer. The entire 
volume was gently pipetted up and down 10 times to mix thoroughly. 
15. The TAP1 plate was incubated at RT for 2 minutes. 
16. The TAP1 plate was placed on the magnetic stand at RT until the liquid appearing clearly. 
17. 30 µl of the clear supernatant from each well of the TAP1 plate was transferred to the 
corresponding well of the new 96-well PCR plate labelled CAP.  
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(7) Enriched library validation 
Performing procedures for quality control analysis on sample library and quantification of the 
DNA library templates were crucial for a successful run. Data were assessed by the use of 
TruSeq Enrichment scripts after alignment with Illumina Consensus Assessment of Sequence 
and Variation (CASAVA) software programmes. CASAVA converted raw image data into 
intensity scores, base calls, quality scored alignments, and additional formats for downstream 
analysis, transforming data into biologically relevant information.  
 
2.5.4 Library enrichment- HaloPlex Custom Enrichment System 
The HSP-neuropathy panel was performed by the application of the HaloPlex Target 
Enrichment System. Reactions of a total of 72 samples were completed through seven runs of 
12 samples each. The overall workflow of the HaloPlex Target Enrichment System is 
summarised in figure 2-5.  
 
Figure 2-5. HaloPlex custom enrichment workflow 
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(1) Digest genomic DNA with restriction enzymes 
1. The Qubit dsDNA BR Assay was used to determine the concentration of gDNA samples.  
2. For 12-reaction runs, 11 gDNA samples and one Enrichment Control DNA sample (ECD) 
were prepared and stored on ice. 
a. In separate 0.2-mL PCR tubes, 225 ng of each gDNA sample was diluted in 45 µl 
nuclease-free water to reach a final DNA concentration of 5 ng/µl. 
b. In a separate 0.2-mL PCR tube, 45 µl of the supplied ECD was dispensed.  
3. Eight separate restriction enzyme master mixes were prepared by combining two enzymes 
(from Enzyme Strips 1 and 2, each 0.5 µl for one reaction), restriction buffer (34 µl for one 
reaction), and BSA (0.85 µl for one reaction) in each well of an 8-well strip tube as shown in 
figure2-6 (A). 
4. Using a multichannel pipette, 5 µl of each RE master mix was carefully distributed row-wise 
into each well of the restriction digest reaction plate (RD plate) as shown in figure  
     2-6 (B). 
5. DNA samples (5 µl per well) were aliquot along the horizontal side of the RD plate as shown 
in figure 2-6 (C). 
 
 
Figure 2-6. Preparation and distribution of the Restriction Enzyme Master Mix Strip for a 
12-sample run   
RE= restriction enzyme, Rx=reaction. 
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6. The plate was carefully vortexed to mix the digestion reactions. 
7. The RD plate was briefly spun in a plate centrifuge. 
8. The RD plate was placed in a thermal cycler with a heated lid and run the programme as 37°C 
for 30 min then hold at 8°C. 
9. The restriction digestion reaction was validated by electrophoretic analysis of the ECD 
reactions. The RD plate was kept on ice during validation. 
  a. 4 µl of each ECD digestion reaction was transferred from wells of the digestion reaction  
      plate to fresh 0.2-ml PCR tubes. 
  b. The removed 4 µl samples were incubated at 80°C for 5 minutes to inactivate the 
      restriction enzymes. 
  c. An undigested DNA gel control was prepared by combining 2 µl of the ECD stock solution 
and 2 µl of nuclease-free water in a separate tube. 
  d. A HS DNA Kit was used to analyze the prepared samples using microfluidic electrophoresis 
on the 2100 Bioanalyzer. Each of the eight digested ECD samples should have a smear of 
gDNA restriction fragments between 100 and 2500 bp, overlaid with three predominant 
bands at approximately 125, 225 and 450 bp. These three bands corresponded to the 800-bp 
PCR product-derived restriction fragments, and precise sizes were differ after digestion in 
each of the eight RE master mixes (figure 2-7). 
 
Figure 2-7. Validation of restriction digestion by 2100 Bioanalyzer analysis.  
Lane 1: 50-bp DNA ladder, Lane 2: Undigested Enrichment Control DNA, Lanes 3~10: ECD 
digestion reactions A~H. (cited from HaloPlex Target Enrichment System Protocol Version C, 
June 2012) 
 
(2) Hybridize digested DNA to HaloPlex probes for target  
In this step, HaloPlex probes were hybridized selectively to fragments originating from target 
69 
 
regions of the genome and to direct circularization of the targeted DNA fragments. During the 
hybridization process, Illumina sequencing motifs including index sequences were incorporated 
into the targeted fragments. 
1. A Hybridization Master Mix was prepared by combining Hybridization Solution (50 µl per 
reaction) and HaloPlex Probe (20 µl per reaction). 
2. 70 µl of the Hybridization Master Mix was distributed to each of 12 tubes. 
3. 10 µl of the appropriate Indexing Primer Cassette was added to each tube containing 
Hybridization Master Mix. 
4. Digested DNA samples were transferred from the RD Plate directly into hybridization 
reaction tubes. All eight digestion reactions that correspond to one DNA sample were 
transferred into the appropriate hybridization reaction tube. The digestion samples would not 
pooled before adding to the hybridization reaction mixture as restriction enzymes were still 
active and might catalyze inappropriate cleavage events. After pooling, each hybridization 
reaction contained 70 µl Hybridization Master Mix, 10 µl Indexing Primer Cassette and 
approximately 80 µl pooled digested DNA samples. 
5. The mixtures were put on the vortex and spun briefly. The hybridization reaction tubes were 
placed in a thermal cycler to run the programme: 
a. Pre-heated lid set to 100°C 
b. 95°C for 10 minutes 
c. 46°C for 3 hours 
d. Hold at 8°C 
  
(3) Capture the target DNA 
In this step, the circularized target DNA-HaloPlex probe hybrids, containing biotin, were 
captured on streptavidin beads.  
1. The following reagents were placed at RT: the Capture Solution, Wash Solution, Ligation 
Solution , SSC Buffer, the HaloPlex Magnetic Beads and fresh 50 mM NaOH (25 µl per 
sample). 
2. The provided HaloPlex Magnetic Beads were vigorously resuspended on a vortex mixer.  
3. 40 µl (1 Volume) of HaloPlex Magnetic Beads per hybridization sample were prepared for the 
capture reaction: 
  a. The appropriate volume of bead suspension was transferred to a 1.5-ml tube.  
  b. The tube was put into a 1.5 ml tube-compatible magnetic rack for 5 minutes. 
  c. After verifying that the solution has cleared, the supernatant was carefully removed and 
discarded using a pipette. 
  d. An equivalent volume of Capture Solution was added to the beads and resuspended by 
pipetting up and down. 
70 
 
4. 40 µl of the prepared bead suspension was added to each 160-µl hybridization reaction. 
5. After adding the magnetic beads, the capture reactions were mixed thoroughly by pipetting up 
and down 15 times using a 100-µl pipette set to 80 µl. 
6. The capture reactions were incubated at RT for 15 minutes. 
7. The tubes were briefly spun in a desktop centrifuge and then transferred to the Agencourt 
SPRIPlate Super Magnet magnetic plate. 
8. After the solution being clear (about 30 seconds), the supernatant was then removed and 
discarded using a pipette set to 200 µl. 
10. Wash the bead-bound samples: 
  a. The capture reaction tubes were removed from the magnetic plate and 100 µl of Wash 
Solution was added to each tube. 
  b The beads were resuspended thoroughly by pipetting up and down 10 times using a 100-µl 
multichannel pipette set to 80 µl. 
  c. The tubes were incubated in a thermal cycler at 46°C for 10 minutes, using a heated lid.  
  d. The tubes were briefly spun in a desktop centrifuge and then transferred to the magnetic 
plate. 
  e. After the solution being clear (about 30 seconds), the supernatant was then removed and 
discarded using a pipette set to 120 µl.  
 
(4) Ligate the captured, circularized fragments 
In this step, DNA ligase was added to the capture reaction to close nicks in the circularized 
HaloPlex probe-target DNA hybrids.  
1. A DNA ligation master mix was prepared by combining the reagents in the following table. 
The components were mixed thoroughly by gently vortexing and spinning the tube briefly. 
2. 50 µl of the DNA ligation master mix was added to the beads in each DNA capture reaction 
tube. 
3. The beads were resuspended thoroughly by pipetting up and down 15 times using a 100-µl 
multichannel pipette set to 40 µl. 
4. The tubes were incubated in a thermal cycler at 55°C for 10 minutes, using a heated lid. 
 
(5) Prepare the PCR Master Mix 
In this step, a PCR master mix was prepared for the captured target DNA amplification step  
1. The PCR master mix was prepared by combining the reagents in table 2-2 (p71): 
2. The master mix components was mixed by gently vortexing, then 30-µl aliquots were 
distributed to fresh 0.2-ml reaction tubes. 
3. The tubes were stored on ice until they were used in PCR amplification of the captured target 
libraries. 
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Table 2-2. Preparation of PCR master mix 
 
(6) Elute captured DNA with NaOH 
When the 10-minute ligation reaction period was complete, the following steps were proceeded 
to elute the captured DNA libraries. 
1. The ligation reaction tubes were briefly spun in a desktop centrifuge and then transferred to 
the magnetic plate. 
2. After the solution being clear (about 30 seconds), the supernatant was then removed and 
discarded using a pipette set to 50 µl.  
3. The tubes were removed from the magnetic plate and 100 µl of the SSC Buffer was added to 
each tube. 
4. The beads were resuspended thoroughly by pipetting up and down 10 times using a 100-µl 
multichannel pipette set to 80 µl. 
5. The tubes were briefly spun and then put back to the magnetic plate. 
6. After the solution being clear (about 30 seconds), the SSC Buffer was then carefully removed 
and discarded using a pipette set to 120 µl.  
7. 25 µl of 50 mM NaOH was added to each tube. 
8. The beads were resuspended thoroughly by pipetting up and down 10 times using a 100-µl 
multichannel pipette set to 15 µl. 
9. Samples were incubated for 1 minute at RT to allow elution of the captured DNA.  
10. The tubes were briefly spun and then transferred to the magnetic plate. PCR amplification 
had to be proceeded immediately the following section. 
 
(7) PCR amplify the captured target libraries 
1. The amplification reactions were prepared by transferring 20 µl of cleared supernatant from 
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each tube on the magnetic plate to a PCR Master Mix tube held on ice. 
2. The liquid was mixed by gentle vortexing and then spun briefly. 
3. The amplification reaction tubes were run in a thermal cycler with the programme: 
a. Pre-heated lid set to 100°C 
b. 98°C for 2 minutes 
c. 21 cycles of: 
    98°C for 30 seconds 
    60°C for 30 seconds 
    72°C for 1 minute 
d. 72°C for 10 minutes 
e. Hold at 8°C 
 
(8) Purify the amplified target libraries 
In this step, the amplified target DNA was purified using AMPure XP beads. 
1. The AMPure XP beads were placed at RT for at least 30 minutes.  
2. 400 µl of 70% ethanol per sample were prepared. 
3. 40 µl of each PCR reaction sample was transferred to a fresh 0.2-ml tube. The remaining 
volume of each sample was stored at –20°C for troubleshooting. 
4. The AMPure XP bead suspension was resuspended well, until the suspension appeared 
homogeneous and consistent in color. 
5. 60 µl (1.5 Volumes) of homogenous AMPure XP beads were added to each 40-µl amplified 
library sample and then vortexed thoroughly. 
6. Samples were incubated for 5 minutes at RT.  
7. The liquid was spun briefly to collect, then the tubes were placed in the magnetic plate until 
the solution being clear (approximately 2 minutes).  
8. The tubes were kept in the magnetic plate. The cleared solution was carefully removed and 
discarded from each tube using a 100-µl pipette set to 100 µl. The beads could not be 
touched while removing the solution. 
9. The tubes were kept in the magnetic plate while 200 µl of 70% ethanol was added into the 
tubes. Fresh 70% ethanol was used for optimal results. 
10. After disturbed beads being settled (approximately 30 seconds), the ethanol was removed 
using a 200-µl pipette set to 200 µl. 
11. Step 9 and step 10 were repeated once for a total of two washes. 
12. Residual ethanol was removed with a 20-µl volume pipette. 
13. The tubes were air-dried with open lids at RT until the residual ethanol completely 
evaporated. 
14. The tubes were removed from the magnetic plate and 40 µl of 10 mM Tris-acetate or Tris-
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HCl buffer (pH 8.0) was added to each sample. Room-temperature Tris-acetate or Tris-HCl 
buffer was used for elution at this step. 
15. The liquid was mixed thoroughly by pipetting up and down 15 times using a 100-µl pipette 
set to 30 µl. 
16. The samples were incubated for 2 minutes at RT to allow elution of DNA. 
17. The tube in the magnetic plate was left for 2 minutes or until the solution was clear.  
18. The cleared supernatant (approximately 40 µl) was removed to a fresh tube.  
 
(9) Validate enrichment and quantify enriched target DNA 
Each amplicon contained one target insert surrounded by sequence motifs required for 
multiplexed sequencing using the Illumina platform. Amplicons include 50 to 500 bp of target 
DNA insert and 125 bp of sequencing motifs, as shown in figure 2-8. The amplicons should 
range from 175 to 625 bp in length, with the majority of products sized 225 to 525 bp.  
 
Figure 2-8. Content of HaloPlex-enriched target amplicons 
Each amplicon contains one target insert (blue) surrounded by the Illumina paired-end 
sequencing elements (black), the sample index (red) and the library bridge PCR primers 
(yellow). (cited from HaloPlex Target Enrichment System Protocol Version C, June 2012) 
 
Prior to sample pooling and sequencing sample preparation, the 2100 Bioanalyzer was used to 
validate enrichment and quantify the enriched target DNA in each library sample. The 
electropherogram for each sample was analyzed. The concentration of enriched target DNA in 
the sample was determined by integration under the peak between 175 and 625 bp. Any 
spurious DNA products outside of this size range in any sample were excluded from the target 
DNA quantitation results. See figure 2-9 for an example.   
 
Figure 2-9. Validation of HaloPlex enrichment by 2100 Bioanalyzer analysis 
(cited from HaloPlex Target Enrichment System Protocol Version C, June 2012) 
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(10) Sample pooling and sequencing platform 
Samples with different indexes were pooled with equimolar amounts of each sample to optimize 
the use of sequencing capacity. The final HaloPlex enrichment pool was ready for 150 + 150 bp 
paired-end sequencing using standard Illumina primers and chemistry on the Illumina MiSeq. 
Sequence alignment and variant calling were performed against the reference human genome 
(UCSC hg19). Before aligning reads to the reference genome, the reads from Illumina adaptor 
sequences were trimmed with NextGene software (Softgenetics). 
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2.6 Whole exome sequencing 
 
2.6.1 Sample assessment and preparation 
The sample gDNA used in WES were assessed by the Qubit Fluorometry system with dsDNA 
BR Assay (Invitrogen) and the Qubit ® 2.0 Fluorometer (Invitrogen) with the same method 
described in Section 2.5.2. Once high quality DNA had been extracted, the Covaris E210 
acoustic disruptor (LGC Genomics) was used to shear gDNA to be at 150 bp target size. The 
sheared gDNA was then purified and assessed using a High Sensitivity DNA Kit (p/n 5067-
4626) and the 2100 Bioanalyzer system with 2100 Expert Software (version B.02.07) (Agilent).  
 
After DNA fragmentation, the library was prepared using the TruSeq DNA Sample Preparation 
Kit (Illumina) following manufacturer’s instructions, which provided an index for each DNA 
sample, enabling multi-sample pooling in a single enrichment reaction. For samples passing 
quality control, the 3' ends of the fragmented DNA was repaired using an End Repair Mix and 
then purified. The 3' to 5' exonuclease activity of this mix removed the 3' overhangs and the 
polymerase activity filled in the 5' overhangs. After purification, a single ‘A’ nucleotide was 
added to the 3’ ends of the blunt fragments to prevent them from ligating to one another during 
the adapter ligation reaction. A corresponding single ‘T’ nucleotide on the 3’ end of the adapter 
provided a complementary overhang for ligating the adapter to the fragment. This was to ensure 
a low rate of chimera (concatenated template) formation. The DNA was purified again. At this 
point the paired end adapters were ligated to the DNA sample. An additional purification step 
and assessment on the 2100 Bioanalyzer system were performed again. The adapter-ligated 
library was then amplified using 6 rounds of PCR, purified and assessed on a 2100 Bioanalyzer 
looking for peak enrichment at 200 bp. At this point enrichment of the DNA library for exome 
fragments could proceed.  
 
2.6.2 Library enrichment 
Library enrichment of WSE was completed by using the TruSeq Custom Enrichment System. 
The workflow was the same as which in targeted sequencing (Section 2.5.3) except for different 
oligonucleotide reagents were used for WSE. 
 
2.6.3 Bioinformatics pipeline of data procession 
A substantial amount of data is produced from next generation sequencing. After the genome 
analyser generated the raw sequencing images (image analysis), several steps were involved in 
the read conversion to variant calling. 
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(1) UCL Genetics Institute (UGI) pipeline 
For the exomes which were annotated by Dr. Vincent Plagnol at UGI, the bioinformatics 
pipeline was described as following: FASTQ files were aligned to the hg19 reference sequence 
using Novoalign version 2.07.19, including hard and soft clipping, quality calibration and 
adapter trimming. Duplicate reads were excluded using the PICARD tool MarkDuplicates 
(http://picard.sourceforge.net/). Calling was performed using SAMtools v0.18 (http://samtools. 
sourceforge.net/) and single sample calling. The resulting calls were annotated with the software 
ANNOVAR. Candidate variants were typically filtered based on function: frameshift, premature 
stop, non-synonymous or potential splice altering variants (defined as being with 5 bp of the 
actual splice site) and frequency (< 0.5%in the 1,000 Genomes and NHLBI for homozygous and 
compound heterozygous variants, and absent from both of these databases for heterozygous 
variants). Variant Call Format (VCF) tools were used to annotate gene information for the 
remaining novel variants. The Integrative Genomics Viewer (IGV) was used to inspect variants. 
  
Homozygosity mapping was performed based on the exome sequence data. An in-house R script 
that implemented a hidden Markov model with two hidden states was used. In the 
"homozygosity stretch" state, the proportion of heterozygous SNPs was set to 1%. In the 
"normal" state, the frequency of heterozygous SNPs was set to its exome-wide average. The 
most likely hidden chain of homozygosity states was reconstructed using a maximum likelihood 
Viterbi algorithm. 
 
(2) UCL Institute of Neurology (ION) pipeline 
For the exomes which were processed at ION, there were several steps involved in the read 
conversion to variant calling as following: 1) Initial base-calling with quality score generation 
was performed using the Illumina pipeline, 2) conversion of reads into Sanger format and 3) 
read trimming based on per lane quality score. Sequence was aligned against the human genome 
and converted into SAM files using BWA (http://bio-bwa.sourceforge.net/) and SAMTools. 
Building, indexing and sorting SAM files, recalibrating per base quality scores, removal of PCR 
duplicates, lane merging were performed when necessary by the use of BWA, SAMTools, 
Genomic Analysis Toolkit (GATK) (https://www.broadinstitute.org/gsa/wiki/index.php/ 
TheGenomeAnalysisToolkit) and PICARD tool.  Subsequently on target and per base coverage 
read statistics were generated based on NCBI consensus coding sequence project CCDS defined 
exom (http://www.ncbi.nlm.nih.gov/projects/CCDS/CcdsBrowse.cgi). Calling raw variants was 
performed using GATK and SAMTools, calling single nucleotide variants and short indels. IGV 
was used to inspect variants to check the sequencing depth and coverage. Variants were filtered 
based on quality control criteria and a genotype file was produced. Annotation and prediction of 
consequence (amino-acid change, predicted damage of variant) was conducted using the 
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package SIFT (Sorting Intolerant From Tolerant; http://sift.jcvi.org/) and PolyPhen2 
(Polymorphism Phenotyping v2) prediction of functional effects of human nsSNPs; 
http://genetics.bwh.harvard.edu/pph2/). 
  
2.6.4 Selecting and prioritizing variants 
To distinguish genetic variations from true disease-causing mutations, a number of filtering 
strategies to prioritize variants were used as following:  
 
(1) After total variants were generated, benign variants were filtered out by the following 
criteria: synonymous variants and any variant present at a global minor allele frequency 
(MAF) ≥ 1% in a range of publically available databases of sequence variation: dbSNP 
(www.ncbi.nlm.nih.gov/projects/SNP), 1000 Genomes Project (www.1000genomes.org), the 
National Heart, Lung, and Blood Institute Exome Sequencing Variant (ESV) database and 
the Genome Variant Database for Neuromuscular Diseases (NMD) 
(http://hihg.med.miami.edu/gvd-nmd/). 
 
(2) Heterozygous or homozygous variants were selected according to the inheritance mode. If 
the inheritance is uncertain, all types of variants were included. 
 
(3) Variants which were present in the genes located in known linkage and shared haplotype 
intervals from the literature were selected.  
 
(4) Variants which were present in all patients of the same family (segregating with disease) or 
were present in multiple families and were absent in matched controls were selected.  
 
(5) Variants in genes already known for related phenotypes were first considered. The gene list 
was based on PubMed (http://www.ncbi.nlm.nih.gov/pubmed), Washington University 
Neuromuscular Disease Center (WUNDC) Database (http://neuromuscular.wustl.edu/) and 
Inherited Peripheral Neuropathies Mutation (IPNMD) Database 
(http://www.molgen.ua.ac.be/cmtmutations/Mutations). 
 
(6) If there was no candidate variants in the known genes, variants were prioritized by gene 
function and expression, mutation type, evidence from animal and cellular models. Variants 
which were highly expressed or had evidence of unique alternative splicing in the central or 
peripheral nerve system were selected. Variants which were present in genes causing 
associated phenotypes from known network pathways and known interactors were also 
picked. The following public genomic variant and in-house databases were used as reference: 
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Online Mendelian Inheritance in Man (OMIM) (www.omim.org/), (Search Tool for the 
Retrieval of Interacting Genes/Proteins (STRING) (http://string-db.org/), ESV, NMD, 
Tissue-specific Gene Expression and Regulation (TiGER) 
(http://bioinfo.wilmer.jhu.edu/tiger/) and HEX (hex.ion.ucl.ac.uk). 
 
(7) The variants were expected to cluster in candidate genes and pathways and to overlap 
between cases with similar phenotypes. For cases with similar phenotype but without 
probable variants in the known genes, sequences were pooled together to look for any 
common mutated gene shared by more than one family. 
 
(8) When variants in a candidate gene were identified, Sanger sequencing using the method 
described above was performed to confirm them. Variants would need to be confirmed with 
Sanger sequencing.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
79 
 
References: 
Choi M, Scholl UI, Ji W, Liu T, Tikhonova IR, Zumbo P, Nayir A, Bakkaloglu A, Ozen S, Sanjad S, 
Nelson-Williams C, Farhi A, Mane S, Lifton RP (2009) Genetic diagnosis by whole exome 
capture and massively parallel DNA sequencing. Proc Natl Acad Sci U S A 106: 19096-101 
den Dunnen JT, Antonarakis SE (2003) Mutation nomenclature. Curr Protoc Hum Genet Chapter 7: Unit 
7.13. Review. 
 
 
 
80 
Chapter 3 
 
Results: Genetic and functional studies in novel 
forms of inherited neuropathies and other 
inherited disorders    
 
This chapter describes genetic and functional studies of four novel forms of inherited 
neuropathies and other inherited neurological disorders: 1) axonal neuropathy and optic atrophy 
due to a homozygous C12orf65 mutation; 2) late-onset CMT2 due to the newly-identified 
MARS mutation; 3) hereditary sensory neuropathy type 1 due to a novel SPTLC2 mutation; 4) 
juvenile complex autosomal cerebellar ataxia due to a novel ADCK3 mutation. Genetic 
screening in various cohorts of patients was performed to investigate the mutation frequencies 
of these genes. Functional studies were also performed with the aim of providing further 
understanding of the pathogenesis of each mutation.  
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3.1 A novel C12orf65 mutation in patients with axonal neuropathy and optic atrophy 
 
3.1.1 Introduction 
The association between CMT and optic atrophy, also known as CMT6 (OMIM_601152), has 
been reported in families with different modes of inheritance, comprising over 50 
cases.(Chalmers et al. 1996; Chalmers et al. 1997; Ippel et al. 1995) Clinical features of CMT6 
are distal weakness, wasting and sensory loss in the lower limbs associated with optic atrophy. 
MFN2 mutations have been already described causing dominant forms of CMT6 (Zuchner et al. 
2006) and PRPS1 mutations have been linked to X-linked form of CMT6 (Kim et al. 2007), but 
homozygous mutations causing recessive form of the disease have never been identified. In this 
study a novel homozygous mutation c.346delG; p.Val116X [V116X]) in the chromosome 12 
open reading frame 65 gene (C12orf65) was identified in a large consanguineous Gujerati 
family by the combination of WES and homozygosity mapping.(Tucci et al. 2014) Affected 
family members presented with axonal neuropathy, optic atrophy, mental retardation and 
pyramidal signs. The family was previously reported by MacDermot et al.1987 but the disease-
causing gene was not identified at the time of publication.  
 
C12orf65 encodes a 166-amino-acid mitochondrial matrix protein which is involved in the 
translation and assembly of the mitochondrial oxidative phosphorylation system 
(OXPHOS).(Antonicka et al. 2010) Before this study, three pathogenic C12orf65 mutations 
have been documented causing defects in the translation and assembly of the mitochondrial 
OXPHOS, which was defined as combined oxidative phosphorylation deﬁciency 7 (COXPD7) 
(MIM_613559). Patients carrying these mutations presented with a wide range of phenotypes: 
from a severe early onset encephalomyopathy with respiratory failure to a slowly progressive 
spastic paraplegia with mild neuropathy and reduced vision (SPG55).(Antonicka et al. 2010; 
Shimazaki et al. 2012) The novel V116X mutation is associated with recessive axonal 
neuropathy associated with optic atrophy, a phenotype not previously reported in patients with 
C12orf65 mutations.  Segregation analysis and C12orf65 screening in additional cohorts with a 
similar phenotype were performed to support the pathogenic role of this novel mutation. Levels 
of gene expression were measured to investigate whether the nonsense mutation resulted in 
mRNA decay. Mitochondrial function assays were performed to study functional impacts of this 
mutation. 
 
3.1.2 Patients and methods 
(1) C12orf65 sequencing 
DNAs from both parents of the index patient were sequenced for the coding exons of C12orf65 
(NM_001143905). Two series of patients were also screened for C12orf65 mutation. The first 
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series included DNA extracted from blood of 93 patients who had axonal neuropathy with one 
of the following features: optic atrophy, retinitis pigmentosa, psychomotor retardation, 
cerebellar ataxia, or pyramidal sign (the neuropathy series). All these patients had been 
previously resulted negative for mutations in the PMP22, GJB1, MFN2, MPZ, GDAP1, BSCL2, 
TRPV4, NEFL, HSPB1, HSPB8 and GARS genes. The second series was a collection of DNA 
extracted from muscles of 90 patients who presented a decreased activity of mitochondrial 
respiratory chain (MRC) complex V or combined oxidative phosphorylation enzymes 
deficiency in the blue native polyacrylamide gel electrophoresis (BN-PAGE) (the mitochondrial 
dysfunction series, kindly provided by the Neurometabolic Unit at the NHNN). Clinical 
presentations of patients in the second cohort included Leigh-like phenotype, neuropathy, 
cerebellar ataxia and/or optic atrophy.  
 
(2) RNA purification and cDNA synthesis 
Purification of total RNA from lymphoblasts of the index patient, her parents and two healthy 
controls was performed with the Qiagen miRNeasy Mini Kit (Hilden, Germany) according to 
the manufacturer’s instructions. RNA concentration was then measured with spectrophotometer 
and quality was assessed evaluating 260/280 nm and 260/230 nm ratio. cDNA was synthesized  
from RNA by the use of Qiagen Omniscript RT Kit (Hilden, Germany). (The details of 
experiment method were described in Section 2.4) 
 
(3) Reverse transcription and quantitative real-time PCR (RT-qPCR). 
Multiplex quantitative real-time PCR assays for the cDNA / mRNA levels of C12orf65 and the 
house-keeping gene RPL13A were performed using SYBR Green PCR Master Mix kit (Applied 
Biosystems) with a Corbett Rotor-Gene real-time quantitative thermal cycler (Corbett 
Research/Qiagen). Thermal cycling consisted of 10 minutes at 94°C for initial denaturation and 
DNA polymerase activation, followed by 40 cycles of denaturation at 94°C for 15 seconds and 
annealing/extension at 60°C for 1 minute. All reactions were performed in triplicate in a final 
volume of 10 μl. Relative quantity of C12orf65 level normalized by RPL13A level was then 
calculated. (The details of experiment method were described in Section 2.4) 
 
(4) Lymphoblast cell cultures 
Lymphoblast cells were obtained from Case 1 and two unaffected relative carriers. 
Lymphoblastoid cell lines were established by Epstein–Barr virus transformation of 
lymphocytes isolated from peripheral blood. Cell lines were stored at the European Collection 
of Cell Cultures. Informed consent was obtained for all samples. Patient and control 
lymphoblasts were thawed and maintained in culture in modiﬁed RPMI-1640 medium  
containing 300 mg/L L-Glutamine and HEPES (Invitrogen) supplemented with 10% heat-
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inactivated Fetal Bovine Serum (FBS) (Invitrogen) at 37°C and 5% CO2 . Fresh medium was 
added every 3 days and cultures were expanded accordingly. 
 
(5) Blue native in-gel complex V assay 
The mitochondrial fraction was obtained from the lymphoblastoid cell pellets (7.5×10 5 cells) 
using two low-speed centrifugation steps (600 g×10 min) at 4°C, separated by a homogenization 
step. Then, the mitochondrial membranes were solubilised with a 750 mM amino hexanoic 
acid/50 mM Bis Tris buffer + 4% n-dodecyl β-D maltoside detergent. Samples were left on ice 
for 30 min and a further high spin (14000 g×10 min) was used to pellet insoluble material.  An 
equal quantity of mitochondrial protein was loaded from each sample. Blue Native (BN) gel 
was run using a 3~12% Bis–Tris gel (Invitrogen) to ensure discrete separation of complex V. 
Complex V activity was measured in a reverse direction. Complex V assay was performed by 
incubating the gel overnight in stain containing 34 mM Tris, 270 mM glycine, 14 mM 
magnesium chloride, 6 mM lead (II) nitrate and 8 mM ATP. 
 
(6) O2 consumption 
To measure mitochondrial respiration rate in intact cells, approximately 1×10
7
 cells were 
suspended in respiration medium (HBSS with 10 mM D-glucose) in a Clark-type oxygen 
electrode thermostatically maintained at 37°C. The oxygen electrode was calibrated with air-
saturated water, assuming 406 nmol O2 atoms/mL at 37°C. Oxygen consumption was measured 
over 10 min with addition of oligomycin (ﬁnal concentration 2 μg/mL) and 
trifluorocarbonylcyanide phenylhydrazone (FCCP) (0.5 μM). All data were obtained using an 
Oxygraph Plus System (Hansatech Instruments, UK) with chart recording software. For 
measurements of mitochondrial membrane potential (Δψm), cells were loaded with 25 nM  
tetramethylrhodaminemethylester (TMRM) for 30 min at room temperature in HBSS (156 mM 
NaCl, 3 mM KCl, 2 mM MgSO4 , 1.25 mM KH2PO4, 2 mM CaCl2 , 10 mM glucose and 10 mM 
HEPES, pH adjusted to 7.35),  and  the  dye was present during the experiment. TMRM was 
used in the redistribution mode and therefore a reduction in TMRM ﬂuorescence represents 
Δψm depolarisation. Z-stack images were obtained for accurate analysis. The values for wild-
type (WT) were set to 100% and the other genotypes were expressed relative to WT. Confocal 
images were obtained using a Zeiss 710 LSM with a 40X oil immersion objective. TMRM was 
excited using the 560 nm laser and ﬂuorescence was measured at 580 nm. 
 
3.1.3 Results 
(1) Clinical features 
The pedigree of the family is shown in figure 3-1 (p84). Two brothers (Case 1 and 2) and their 
maternal cousin (Case 3) had axonal neuropathy, optic atrophy, mental retardation and 
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pyramidal signs with onset in the first 3 years of life.(MacDermot et al. 1987)  The symptoms 
progressed very slowly and all patients were still able to walk in their 20s. Two other maternal 
cousins had isolated retinitis pigmentosa.  
 
 
Figure 3-1.  Pedigree of the family with C12orf65 V116X mutation 
Affected individuals of axonal neuropathy and optic atrophy are filled in black,  = affected by 
retinitis pigmentosa, number in  or  = number of unaffected siblings. __= examined family 
member. (modified from MacDermot et al, 1987) 
 
WES was performed in Case 2 and Case 3 in order to establish the genetic diagnosis and 
detected  a novel homozygous mutation c.346delG; p.Val116X [V116X]) in the C12orf65 gene.  
Details of their clinical features are listed in table 3-1. 
 
Table 3-1. Clinical features of patients with C12orf65 V116X mutation 
Patient 
AAO/ 
ALE 
Presenting 
symptom 
Neuropathy Eyes Reflexes 
Additional 
symptoms 
Case2 
(M) 
3/30 
delayed  
walking  
wasting and 
weakness 
started in  LL, 
and involving 
later  UL 
Bilateral optic 
atrophy with 
macular 
colloid bodies 
Generalized 
brisk reflexes 
except absent  
ankle reflexes 
Mental 
retardation, 
primary 
position and 
gaze induced 
nystagmus 
Case 3 
(F) 
1/22 
delayed   
walking  
wasting and 
weakness 
started in  LL, 
and involving  
later UL 
Bilateral optic 
atrophy with 
macular 
colloid bodies 
Normal  UL, 
brisk knee and 
abductor 
reflexes, 
reduced  ankle 
jerks 
Mental 
retardation 
AAO= age at onset; ALE= age of last exam; F= female; LL = lower limbs; M=male; UL = 
upper limbs. 
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Neurophysiology of the affected members showed reduced sensory action potentials (SAPs) in 
the lower limbs with preserved nerve conduction velocities (NCV), compatible with an axonal 
neuropathy (table 3-2). 
 
Table 3-2. Nerve conduction studies of the patient with C12orf65 V116X mutation 
  
Case 1 Case 2 Case 3 V-1 IV-II 
CMAP (uV):      
         Ulnar NA 40 NA NA NA 
SAP amplitude (uV): 
 
    
 
Median  10 NA 15 40 NA 
 
Ulnar  6 NA 12 20 16 
 
Sural  2 NA 5 NA NA 
MCV (m/s): 
     
 
Ulnar 41 46 51 54 60 
CMAP = compound muscle action potentials; NA=not available; MCV=  motor conduction 
velocity, recorded over abductor digiti minimi (Case 1, V-1 and IV-II) and flexor carpi ulnaris 
(Cases 2 and 3); SAP=sensory action potentials, median and ulnar SAPs were recorded from 
second and fifth fingers to wrist. (modified from Tucci et al.2014) 
 
Sural nerve biopsy from Case 1 showed a marked reduction of large myelinated fibres and 
numerous small myelinated fibres, the majority of which were associated with regeneration 
clusters, consistent with axonal degeneration (figure 3-2, p86). The neuropathological findings  
were similar to previously described patients with documented MFN2 mutation, another subtype 
of axonal CMT. 
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Figure 3-2. Sural nerve biopsy of the patient with C12orf65 V116X mutation 
Semi-thin resin sections stained with toluidine blue show marked reduced numbers of large 
myelinated fibres in the sural nerve from Case 1 with the C12orf65 V116X mutation (A). 
Numerous regeneration clusters of unmyelinated axons (red arrows) were also revealed and 
further highlighted by ultrastructure assessment (C). These above histological features were 
similar to those in a CMT2 patient with proved MFN2 mutation (B and D).  
 
(2) Mutation validation 
Sanger sequencing validated that Case 2 and Case 3 shared a common homozygous 1bp 
deletion causing premature translational termination at the Val 116 codon of C12orf65 
(c.345delG; V116X). Both parents of Case 3 were heterozygous carriers of this mutation 
confirming segregation of the mutation within family (figure 3-3, p87). 
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Figure 3-3. Segregation of C12orf65 V116X mutation within the family 
 
 
 
Figure 3-4. Genomic structure of C12orf65 and the locations of its mutations 
A. Both 210delA and 238delT cause stop gain at the same amino acid Leu84. They were 
identified from patients with a severe early encephalopathy.(Antonicka et al. 2010) 
B. 345delG; V116X in exon 3 is associated with AR-CMT6 (this study, Tucci et al. 2014). 
C. The missense mutation C394T leads to translational termination at the R132 codon and was 
associated with SPG55.(Shimazaki et al. 2012) 
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As shown in figure 3-4 (p87), V116X, similarly to three other previously reported C12orf65 
mutations, is a nonsense mutation. It is localized in the RF-1 domain, a highly conserved motif 
with peptidyl-tRNA hydrolase activity.(Song et al. 2000). 
 
(3) Screening in additional cohorts 
A total of 183 patients were screened for C120rf65 mutations but no additional mutations were 
found except for one heterozygous synonymous mutation and two known SNPs which were 
identified in three patients (table 3-3).  
 
Table 3-3. C12orf65 variations identified in patients of the neuropathy series 
cDNA Codon Variation type SNP ID 
c.G952A Q103 Heterozygous synonymous coding . 
c.C917T I91 Heterozygous synonymous coding rs2280424 
c.G688A R15Q Heterozygous non-synonymous coding rs78651634 
 
(4) Gene expression study 
The mRNA level of C12orf65 in lymphoblasts from Case 3 was measured by multiplex qRT-
PCR assays. There was no significant difference between the C12orf65 mRNA levels of the 
patient, his parents and the control (figure 3-5). This documented that the nonsense mutation 
V116X did not induce mRNA nonsense-mediated decay.  
 
Figure 3-5. C12orf65 mRNA levels in lymphoblasts 
The bar graphs represented the relative C12orf65 mRNA levels which were normalized to 
RPL13A levels and were shown as the percentage of the average in the control. There was no 
significant difference in C12orf65 mRNA levels between all samples. Data are shown as means 
of 3 experiments, with error bars representing SDs. SDs were calculated using 1-way analysis of 
variance with Bonferroni multiple correction. Cont= control. 
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(4) MRC complex assembly 
BN-PAGE was used to study the assembly pattern of MRC protein complexes and their in-gel 
activity of lymphoblasts.  A significant decrease in the activity as well as an assembly defect in 
complex V were observed in cells from Case 3 when compared to cells from the control and the 
parents (figure 3-6,  A, p90). 
 
(5) Oxygen consumption 
The rates of oxygen consumption in lymphoblasts were measured to investigate the effect of this 
mutation on mitochondrial respiration (figure 3-6, B).  The rate basal oxygen consumption in 
cells from Case 3 was significantly reduced up to 49% compared with control cells (p<0.001). 
When Oligomycin (an inhibitor of MRC complex V) was added to inhibit the respiration 
coupled to oxidative phosphorylation, respiration was inhibited but to a significantly lesser 
extent in patient’s cells compared with control cells (p<0.001).  These findings provided 
evidence of profound mitochondrial uncoupling and confirmed decreased complex V activity in 
Case 3 cells. FCCP could uncouple the electron transport system from the oxidative 
phosphorylation system and accelerate respiration to maximal levels in control lymphocytes but 
to a significantly lesser degree in Case 3 cells, suggesting that the activity of respiratory chain 
enzymes in the patient’s cells were limited. 
 
(6) Mitochondrial membrane potential (Δψm)  
Δψm is a major indicator of mitochondrial function.  Δψm in Case 3 and control lymphoblasts 
were assessed by the fluorescent indicator TMRM. Mutant cells were associated with a 
significant reduction in the TMRM signal (and hence in Δψm) to 77.5±3.9% compared with 
controls (p<0.001) (figure 3-6, C).  
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3.1.4 Discussion 
This study describes for the first time a novel homozygous mutation in C12orf65 gene in 
patients with recessive CMT6. Functional studies confirm that the nonsense mutation V116X 
could cause mitochondrial dysfunction. The multi-systemic involvement of PNS, CNS and non-
neurological organs in the affected patients reflect the critical impacts of mitochondrial 
dysfunction which is caused by mutant C12orf65.  
 
 
Figure 3-6. Mitochondrial function 
assays in lymphoblasts with C12orf65 
V116 mutation   
 
A. Blue native polyacrylamide gel 
electrophoresis (in gel activity)  
Reduced complex V activity in Case 3 is 
demonstrated by reduced band density. 
Complex V = complex V holoenzyme; F1 
= catalytic site of complex V only. 
 
B. Oxygen consumption rate (OCR)  
Data are represented as mean ± SEM. The 
basal OCR in Case 3: 0.42±0.02 
nmol/O2/min/106cells; n=4 experiments; 
the average OCR of Con1 and Con2: 
0.85±0.03 nmol O2/min/106 cells; n=5 
experiments (p<0.001). OCR in Case 3 
was less inhibited by oligomycin 
(inhibitor of complex V; 2μg/m) and less 
accelerated by the FCCP (uncoupler of 
MRC; 1μM) as compared to controls 
(p<0.001).  
 
C. Mitochondrial membrane potential 
(Δψm)  
Δψm in lymphoblasts from control, 
parents and Case3 were determined by 
TMRM fluorescence. The TMRM signal 
representing Δψm in mutant cells was 
77.5±3.9% of controls (p<0.001). n=3 
experiments. Con= control; Par= parent; * 
= p<0.05; ** = p<0.001.  
 
All the above experiments were 
performed double blindly. (The figure is 
modified from Tucci et al. 2014) 
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V116X in our family, similarly to other three pathogenic C12orf65 mutations, leads to a 
premature translational termination in the RF-1 domain. Interestingly, these mutations were 
associated with various phenotypes. Both two homozygous mutations, c.248delT and c.210delA,  
caused  premature termination at Leu84 and were associated with infantile subacute necrotizing 
encephalomyelopathy, also called Leigh syndrome,  presenting with generalized psychomotor 
retardation, peripheral neuropathy and ventilator-dependent respiratory failure.(Antonicka et al. 
2010) Another nonsense mutation (c.394C>T, p.R132X) was identified in patients with SPG55, 
a newly-defined recessive cHSP presenting with predominant spastic paraplegia in association 
with optic atrophy and axonal neuropathy.(Shimazaki et al. 2012) There seemed to be an inverse 
correlation between the severity of phenotype and the length of intact protein: the longer the 
preserved segment, the milder the phenotype (figure 3-4, p87).   
 
C12orf65 mutations have been associated with different patterns of assembly defects in the 
subunit of mitochondrial OXPHOS. Whereas V116X mutation in this study caused defects in 
the MRC complex V only, other mutations resulted in multiple MRC complexes defects: 
complex I~IV in fibroblasts with L84X mutation and complexes I and IV in R132X mutant 
cells.(Antonicka et al. 2010; Shimazaki et al. 2012)  We have documented that V116X did not 
cause disease through mRNA nonsense mediated decay, indicating that different segment of the 
protein may have distinct functions and variable impact on the stability of MRC complexes.  
 
Several genes in which the mutations result in defects of the mitochondrial OXPHOS subunits 
or in mitochondrial dysfunction have been identified in peripheral neuropathy, suggesting a 
common pathway of  nerve  degeneration.(Diaz 2010) For example, MFN2, the major cause of 
AD-CMT2, is a mitochondrial membrane protein involved in mitochondrial fusion, the 
regulation of mitochondrial membrane potential and the OXPHOS.(Pich et al. 2005)  Mutations 
in GDAP1, which encodes a mitochondrial membrane protein, can cause both dominant and 
recessive CMT2. Recently, mutations in the mitochondrial DNA encoded ATP synthase 6 gene 
(MT-ATP6, MIM_516060), encoding the ATP6 subunit of the mitochondrial OXPHOS complex 
V, were recognized to cause axonal type of CMT.(Pitceathly et al. 2012) The identification of 
C12orf65 and MT-ATP6 mutations suggested that complex V defects may have a key role in 
axonal degeneration of peripheral nerves though the detail is still not clear. In addition by 
confirming C12orf65 as a new gene in AR-CMT6 and revealing its effects on the MRC complex, 
our results provided new insights on the pathogenesis of axonal neuropathy. 
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3.2 A significant variant in MARS may cause late-onset CMT2 
 
3.2.1. Introduction 
Despite the high number of genes identified in various forms of CMT2, many families are still 
genetically undiagnosed. During the past few years, WES has helped identifying several new 
genes causing CMT2.(Weedon et al. 2011; Weterman et al. 2012) For example using WES we 
identified a novel missense mutation [c.852C<T; p.Arg618Cys (R618C)] in the methionyl-
tRNA synthetase gene (MARS) in a family with late onset CMT2 and incomplete penetrance. 
Following the identification of MARS as a possible new gene for CMT2, the screening of MARS 
in additional CMT2 patients was performed. Also, functional studies were conducted to 
investigate the pathogenicity of the identified mutation.  
 
3.2.2 Patients and methods 
(1) Mutation screening in the additional cohorts 
Direct sequencing for all coding exons (exon 1-21) of MARS (NM_004990) was performed in 
48 patients with a clinical diagnosis of AD-CMT2. Because of the incomplete penetrance of the 
identified mutation, exon 15 (where the mutation was localized) was also screened in further 
140 patients with sporadic CMT2. In view of the frequent presence of pyramidal signs in 
patients carrying previously identified mutations in another aminoacyl-tRNA synthetase gene 
(GARS), exon 15 was also sequenced in 140 patients with axonal neuropathy and pyramidal 
signs. Mutations of GJB1, MFN2, MPZ, GDAP1, BSCL2, TRPV4, NEFL, HSPB1 and HSPB8 
genes had been excluded in these patients. 
 
(2) Structural model of human MetRS 
Structural model of human MARS encoding protein (MetRS) was generated by homology 
modeling based on the crystal structure of MetRS from archaea Pyrococcus abyssi (pdb 1RGG) 
using the Phyre2 server (www.sbg.bio.ic.ac.uk/phyre2/). Out of the total 900 residues of human 
MetRS, 576 residues that contain the catalytic domain (Residue 251-658) and the anticodon 
binding domain (Residue 659-806) were modeled. The N-terminal GST domain and the C-
terminal WHEP domain are eukaryotic specific extensions and were omitted from the structural 
modeling.The model was verified manually by comparison with available crystal structures of 
MetRS from different species (pdb 1PG2, 2FMT and 1PFU).  
 
(3) Cloning and mutagenesis 
DNA constructs were generated using Gateway cloning technology (Invitrogen, Carlsbad, CA). 
The Saccharomyces cerevisiae MES1 locus (including the open reading frame and 783 base 
pairs of proximal promoter sequence and 321 base pairs of distal termination sequence) were 
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PCR amplified using Saccharomyces cerevisiae genomic DNA. The cloning primer was 
designed to include flanking Gateway attB1 (forward) and attB2 (reverse) sequences. 
Subsequently, purified MES1 PCR products were recombined into the pDONR221 vector and 
sequenced to yield appropriate entry clones. Mutagenesis of MES1 was performed using the 
QuikChange II XL Site-Directed Mutagenesis Kit (Agilent Technologies, Santa Clara, CA) and 
appropriate mutation-bearing oligonucleotides. Subsequently, plasmid DNA purified from each 
entry clone was subcloned into a gateway-compatible pRS315 or pRS316 destination vector 
according to the manufacturer’s instructions. Each resulting expression construct was analyzed 
by restriction enzyme digestion with BsrGI (New England Biosystems, Ipswich, MA) to 
confirm the presence of an appropriately-sized insert.  
  
(4) Yeast viability assays  
To assess the functional consequences of MARS R618C variant in vivo, the variant was 
introduced in the yeast ortholog MES1. The ability to rescue deletion of endogenous MES1 was 
determined in wild-type MES1, an insert-free pRS315 construct, R618C MES1 and R727Q 
MES1 (a common variation, dbSNP rs113808165). Two independently generated mutant-
bearing constructs were analysed. Cultures of each yeast strain were inoculated and grown on 
solid growth medium containing 5-FOA (Fluoroorotic Acid Monohydrate, Teknova, Hollister, 
CA). A commercially-available diploid heterozygous mes1Δ yeast strain (MATa/α, 
his3Δ1/his3Δ1, leu2Δ0/leu2Δ0, LYS2/lys2Δ0, met15Δ0/MET15, ura3Δ0/ura3Δ0; Open 
Biosystems, Huntsville, AL) was transformed with a URA3-bearing pRS316 vector containing 
wild-type MES1. Lithium acetate transformations were performed at 30°C using 200 ng of 
plasmid DNA. Subsequently, sporulation and tetrad dissections were performed to yield a 
haploid mes1Δ strain that also contains the wild-type MES1 pRS316 maintenance vector. Two 
resulting haploid mes1Δ strains bearing a wild-type MES1 pRS316 maintenance vector were 
then transformed with LEU2-containing pRS315 constructs containing wild-type or mutant 
MES1 (described above). For each transformation, three colonies were selected for analysis on 
0.1%5-FOA. Because 5-FOA is toxic to yeast cells bearing a functional URA3 allele, only cells 
that lost the URA3 maintenance plasmid and for which the LEU2 test plasmid could 
complement the chromosomal mes1Δ allele were expected to grow. 
 
3.2.3 Results 
(1) Clinical feature  
The index case (ﬁgure 3-7, III.1, p94) had progressive sensory loss and weakness in the distal 
upper and lower limbs since the age of 50. He had also pain in his feet. Examination revealed 
bilateral foot drop, distal wasting in the upper and lower limbs, mild distal weakness in the 
upper limbs to Medical Research Council (MRC) scale grade 4. In the lower limbs he had equal 
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distal and proximal weakness with both hip flexion and ankle dorsiflexion and plantar flexion 
being grade 4. All sensory modalities were affected with impairment of pinprick and vibration 
sensation up to knees bilaterally.  His maternal uncles had an axonal neuropathy with onset at 
age 67. His mother was clinically unaffected and had normal examination and neurophysiology 
at age 85. For the index patient, causes of acquired peripheral neuropathy were excluded and 
screening for mutations in the MFN2, MPZ, PMP22, CX32, GDAP1, HSPB8, HSPB1, TRPV4 
and NEFL genes were all negative.  
 
(2) Genetic analysis 
WES identified a variant R618 in MARS gene. The variant was a highly conserved amino acid 
residue in multiple species alignment (figure 3-7, B). The variant showed high conservation 
scores in other prediction softwares (GERP = 5.04, PhastCons =1) The strict conservation of the 
amino acid residue supported the pathogenic role of this variant. No further nucleotide 
variations in MARS were identified in 48 patients with AD-CMT2 or in the other two cohorts of 
patients (280 patients in total).  
 
 
Figure 3-7. Pedigree of the family with MARS R618C mutation and conservation of the 
R618 codon  
A. Pedigree of the dominant CMT2 family displaying segregation but incomplete segregation of 
R618C mutation. Two affected male individuals (III.1 and II.3) were analysed by WES ( in red 
circles). The mother of the index patient, II.2, was an obligate carrier although she was 
clinically unaffected. 
B. Sequence alignment of MetRS with multiple species showing that Arg618 is a strictly 
conserved residue.(modified from (Gonzalez et al. 2013) 
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(3) Structural change of mutant MetRS protein  
In silico modeling of the core domains of human MetRS showed that R618 is located at the 
interface of the catalytic domain (Figure 3-8, A). Interactions with both domains suggest that 
R618 plays an important role in stabilising the domain interface. The R618C variation is 
predicted to create a disulfide bond and cause a neomorphic structural opening in the protein. 
The hypothetic structural opening may affect the tRNA aminoacylation function of MARS, 
which is essential for the translation process.  
 
(4) Loss of function in mutant yeasts 
Both R618C MES1 and the insert-free construct failed to rescue the MES1 allele, whereas wild 
type and R727Q MES1 were able to fully complement MES1 (Figure 3-8, B). The results 
confirmed that MES1 is an essential gene and suggested a loss-of-function effect caused by 
R618C variant.  
 
 
Figure 3-8. Structural and functional impacts of MARS R618C mutation 
A. Structural model of human MetRS showed that Arg618 (R618) is localized at the interface of 
the catalytic domain (blue) and the anticodon-binding domain (yellow), with the guanidinium 
side chain forming a strong salt-bridge with the side chain of Asp292 from the catalytic domain, 
and extensive hydrogen-bonding interactions with the backbone carbonyl oxygens of Phe347 
and Asn348 from the catalytic domain and of Pro758 and Tyr759 from the anticodon-binding 
domain.  
B. Cultures of yeast strains previously transfected with a vector containing no insert (pRS315), 
wild-type MES1 (wt MES1) or the indicated variant form of MES1. Three representative 
cultures of each yeast strain were shown. Two independently generated mutant-bearing 
constructs were analysed (DNA Set 1 and DNA Set 2). (modified from Gonzalez et al. 2013) 
 
3.2.4 Discussion  
This study identified MARS R618C variation in a family with late-onset CMT2 and incomplete 
penetrance. Although this was the only family with CMT2 identified to carry MARS mutation, 
there are multiple lines of evidence supporting MARS as a novel rare CMT2 gene: (1) 
96 
 
segregation of this mutation with the phenotype in the family, (2) unusually strong conservation 
of the R618 codon across species, (3) a demonstrated loss-of-function effect of R618C variant, 
and (4) the negative screening results in a large cohort of CMT2 patients which ruled out the 
possibility that R618C is a rare ethnic polymorphism. The disease phenotype associated with 
MARS mutation is expanding. Following the identification of the CMT2 family in this study, 
compound heterozygous MARS mutations (F370L and I523T) in highly conserved regions were 
reported in a recessive family with infantile multi-organ complex including myopathy and 
seizure.(van Meel E et al. 2013) This report provides additional evidence that mutations in 
MARS can lead to a variety of clinical manifestations including the peripheral nervous system. 
 
MARS encodes a member of aminoacyl-tRNA synthetases (ARSs), a family of enzymes that 
covalently attach transfer RNA (tRNA) and amino acids. Before MARS, mutations in five genes 
in the ARS family have been described to cause axonal forms of CMT or documented to be 
neurotoxic: glycyl-tRNA synthetase (GARS), tyrosyl-tRNA synthetase (YARS), alanyl-tRNA 
synthetase (AARS), lysyl-tRNA synthetase (KARS) and histidyl-tRNA synthetase 
(HARS).(Antonellis et al. 2003; Jordanova et al. 2003; Jordanova et al. 2006; Latour et al. 2010; 
Stum et al. 2010; Vester et al. 2013) The loss-of-function effect of MARS R618C in our family is 
similar to many other CMT-associated mutations in these ARS genes.(Antonellis et al. 2006; 
Jordanova et al. 2006; McLaughlin et al. 2010; Vester et al. 2013) Recently, DARS mutations 
have been identified in recessive neurologic phenotypes presenting with brain stem and spinal 
cord involvement and leg spasticity.(Taft et al. 2013) Interestingly, while these ARSs are 
ubiquitously expressed, these diseases are characterized by neurodegeneration and neuropathy. 
The increasing numbers of neuropathy-related variants in aminoacyl-tRNA synthetases genes 
implies that they may have nerve-specific roles in addition to the well-known ubiquitously 
expressed function.  
 
In summary the genetic and functional studies for a late-onset CMT2 family suggest that MARS 
is a novel, yet very rare cause of the disease.  
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3.3 HSN type 1 caused by a novel SPTLC2 mutation  
 
3.3.1 Introduction 
HSN type I (HSN-I) is clinically and genetically heterogeneous and includes all autosomal 
dominant forms of HSN. Two of the HSN-I genes encode the subunits of the serine 
palmitoyltransferase (SPT), a heteromeric enzyme composed of three subunits (SPTLC1~3) 
localized in the outer membrane of the endoplasmic reticulum.(Hanada 2003; Hornemann et al. 
2006) SPTLC1 encodes the first subunit of SPT and its mutations are the commonest cause of 
HSN-I in the British population accounting for 12% of cases.(Bejaoui et al. 2001; Davidson et 
al. 2012; Dawkins et al. 2001) Mutations in the second subunit (SPTLC2) were subsequently 
found in patients with a very similar phenotype.(Rotthier et al. 2010)  
 
SPT catalyzes the first and rate limiting step in the de novo sphingolipid synthesis pathway: the 
condensation of L-serine and palmitoyl-CoA. Mutations in SPTLC1 and SPTLC2 can cause a 
shift in the substrate specificity of SPT leading to the alternative use of L-alanine and L-glycine 
over its canonical substrate L-serine.(Penno et al. 2010; Zitomer et al. 2009) This leads to the 
formation of probable neurotoxic 1-deoxysphingolipids (1-deoxySLs), which impedes the 
formation of complex sphingolipids but also their canonical degradation. Elevated 1-deoxySL 
levels have been found in the plasma and lymphoblasts of patients with HSN-I.(Penno et al. 
2010; Rotthier et al. 2010) 
 
In this study, SPTLC2 was sequenced in a cohort of HSN patients and a novel SPTLC2 mutation 
was identified in a family with ulceromutilating sensory-predominant neuropathy accompanied 
by early and severe motor involvement. The plasma level of 1-deoxySLs in patients and the 
biochemical properties of the mutant protein were also investigated.  
 
3.3.2 Materials and methods 
(1) Genetic sequencing 
Nucleotide variants in all 12 exons and flanking introns of SPTLC2 were screened in a cohort of 
107 genetically undetermined HSN-I patients. Diagnosis was based on clinical phenotype and 
neurophysiology. These patients presented with distal progressive sensory loss, with or without 
ulceromutilating complications or autonomic dysfunction. Patients who had motor involvement 
were still included when the sensory features were predominant. All patients were negative for 
mutations in SPTLC1 and the majority of patients were  also negative for mutations in RAB7, 
NGFB, FAM134B and NTRK1.  
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(2) Cloning 
The A182P was introduced into the SPTLC2 cDNA by site-directed mutagenesis. All constructs 
were verified by sequencing. HEK293 cells (ATCC, Manassas, VA) were stably transfected with 
the empty vector (control), SPTLC2 wild type (wt), or the A182P mutant. Expression of the 
constructs was confirmed by RT-PCR and immune blotting. 
 
(3) Metabolic labeling assay  
Transfected HEK293 cells were cultured in Dulbecco’s modified Eagle medium for 3 days 
before medium was changed to Dulbecco’s modified Eagle medium without L -serine 
(Genaxxon BioScience, Ulm, Germany). After 2 hours of preincubation, isotope-labeled (2,3,3-
d 3 , 15 N) L -serine (1 mM) and (2,3,3,3)-d 4–labeled L -alanine (5 mM) (Cambridge Isotope 
Laboratories, Inc., Andover, MA) were added to the cells. In some cases, cells were treated with 
Fumonisin B1 (FB1) (35 mM). Cells were harvested after 24 hours, counted (Z2 Coulter 
Counter; Beckman Coulter, Brea, CA), and pelleted (800g, 5 minutes at 4°C). Pellets were 
stored at 220°C.  
 
(4) SPT in vitro activity assay and lipid-base extraction 
SPT in vitro activity was measured as described previously.(Rütti et al.2009) In modification to 
the original protocol, 64 mM L -serine or 320 mM L –alanine (Sigma, St. Louis, MO) was used.  
 
(5) Acid-base extraction and analysis of sphingoid bases 
The plasma sphingoid base levels of patients and healthy controls were analyzed after acid-base 
extraction as described before.(Penno et al. 2010) MetOH 500 mL including 200 pmol internal 
standard (d7-sphinganine and d7-sphingosine; Avanti Polar Lipids, Alabaster, AL) were added 
to 100 mL of plasma or frozen cell pellets which were resuspended in 100 mL phosphate-
buffered saline. Lipid extraction was performed for 1 hour at 37°C with constant agitation at 
1,000 rpm (Thermomixer Comfort; Eppendorf, Hamburg, Germany). Precipitated protein was 
removed by centrifugation (5 minutes at 16,000g). After transferring the supernatant into a new 
tube, lipids were extracted and analyzed by liquid chromatography–mass spectrometry. 
 
3.3.3 Results 
(1) Genetic analysis 
In the selected cohort, a novel mutation c.544G>C, p.Ala182Pro (A182P) was found in one 
British patient belonging to a four-generation family. The family had autosomal dominant 
inheritance. Segregation analysis revealed the mutation in the affected daughter (pedigree 
shown in figure 3-9, p99). The mutation was not detected in 358 British control chromosomes 
and PolyPhen2 and SIFT both predicted damaging and intolerable effects of the mutation.  
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Figure 3-9. Pedigree of the family with SPTLC2 A182P mutation 
The chromatograms of affected patient and control are shown in the bottom. 
m/+: heterozygous  mutation; arrow: proband. (cited from (Murphy et al. 2013) 
 
 
(2) Clinical feature 
In both affected individuals, the presenting symptoms were reduced sensation in the feet during 
the first decade. Sensory complications including ulcers and accidental burns developed later. 
Patient III-2 had painful tingling in the hands whereas IV-2 had no history of pain. Furthermore, 
they had marked motor involvement soon after the onset of sensory impairment. On 
examination, both had a glove-and-stocking sensory loss with pinprick appreciation more 
severely affected than vibration perception. They also had severe distal wasting and weakness in 
all four limbs. They did not report hearing loss or autonomic dysfunction. The clinical features 
are summarised in table 3-4 (p100).  
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Table 3-4. Clinical features of patients with SPTLC2 A182P mutation  
Patient 
AAO/ 
ALE 
Symptom 
at onset 
Positive 
sensory 
symptoms 
Sensory Motor Reflexes CMTNS2 
III-2 (F) 10/63 Numb feet 
Painful 
tingling in 
hands 
Vib to knees, 
pin above 
wrists and 
above knees 
Severe distal 
UL and LL 
Brisk UL, 
absent at 
ankles 
25/36 
IV-2 (F) 5/29 Numb feet No 
Vib to ankle, 
pin above 
elbow and 
above knee 
Mild 
proximal and 
severe 
distal 
UL/severe 
distal LL 
Brisk UL, 
reduced at 
ankles 
27/36 
F= female; AAO= age at onset; ALE= age of last exam; Vib = vibration; Pin= pinprick; UL = 
upper limbs; LL = lower limbs; CMTNS2 = Charcot- Marie-Tooth Neuropathy Score version 2. 
(Murphy et al. 2011)  
 
Neurophysiology of the affected individuals is presented in table 3-5. Overall, NCS 
demonstrated a sensorimotor axonal neuropathy. SAPs were absent in the lower limbs and 
reduced or absent in the upper limbs. Motor responses were absent or reduced in the lower 
limbs and normal or reduced in the upper limbs. In patient III-2, mild slowing of MNCV with 
reasonable MAPs in the upper limbs were observed (<38 m/s). 
 
Table 3-5. Neurophysiology of patients with SPTLC2 A182P mutation  
DML = distal motor latency; CV = conduction velocity; CMAP = compound motor action 
potential; SAP = sensory action potential; ms = milliseconds; m/s = metres per second; mV = 
millivolts; uV = microvolts (modified from Murphy et al. 2013) 
 
(3) Plasma sphingoid and deoxysphingoid base levels  
Although total sphinganine (SA) or sphingosine (SO) levels showed no difference between 
SPTLC2-A182P patients and healthy controls (figure 3-10, A, p101), the 1-deoxySL levels were 
significantly elevated in the plasma of the two A182P carriers (figure 3-10, B). Also, the 1-
deoxySL plasma levels were higher in patient IV-2 who was more severely affected (figure 3-10, 
B). 
 
Patient Median Ulnar Common peroneal Sural 
 
DML 
ms 
CV 
m/s 
CMAP 
mV 
SAP 
uV 
DML 
ms 
CV 
m/s 
CMAP 
mV 
SAP  
uV 
DML 
ms 
CV 
m/s 
CMAP 
mV 
SAP 
 uV 
III-2 3.5 32 4.5 NR 3.9 33 3.1 NR NR NR NR NR 
IV-2 3.1 25 0.2 NR 3.1 29 0.3 NR 5.4 30 0.2 NR 
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Figure 3-10. Plasma sphingoid and deoxysphingoid base levels of patients with SPTLC2- 
A182P mutation 
A. There was no difference between the plasma levels of sphinganine (SA) or sphingosine (SO) 
of SPTLC2-A182P patients and healthy controls. 
B. Significantly elevated 1-deoxysphingolipid levels were found in the two patients carrying 
SPTLC2-A182P mutation. Higher 1-deoxySL plasma levels were found in the more severely 
affected patient IV-2.  
Data are represented as mean, with error bars representing SDs. SDs were calculated using 1-
way analysis of variance with Bonferroni multiple correction. n.s.= not significant; SA= 
sphinganine; SO = sphingosine. ***p , 0.001; ****p , 0.0001. (cited from Murphy et al. 2013) 
 
(4) Effect of the SPTLC2-A182P mutation on SPT activity 
Two metabolic labeling assays checking the accumulation of SA, a measure for cellular SPT 
activity, confirmed that the SPTLC2-A182P expressing HEK293 cells showed significantly 
reduced activity with L -serine and increased activity with L -alanine. The first in vitro assay 
showed that the SPTLC2 mutant had a 65% reduced activity with L-serine and a 3.5-fold 
increased activity with L-alanine in comparison with SPTLC2wt cells (figure 3-11, p102, A and 
B, p97). The second assay in which isotope-labelled (d3, 
15
N)L-serine (1 mM) and (d4)L-alanine 
(5 mM) would lead to the formation of isotope-labeled (M+3)SA and (M+3)de-oxySA 
separately also revealed the same phenomenon (figure 3-11, C, p100).(Ikushiro et al. 2008)  
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Figure 3-11. SPT activity of the SPTLC2 A183P mutant cell  
A. In vitro SPT activity with L-serine measured in 1 mg total protein lysate extracted from 
HEK293 cells. The A182P mutation leads to a significant decrease in keto-SA compared with 
the SPTLC2wt-expressing control (p<0.001).  
B. In vitro SPT activity with L-alanine measured in 1 mg total protein lysate extracted from 
HEK293 cells. The A182P mutation leads to a significant increase in keto-deoxySA compared 
with the SPTLC2wt-expressing control (p<0.0001).  
C. SPT activity measured in HEK293 cells. SPT activity in the SPTLC2wt is increased in the 
presence of FB1, whereas this increase is lost for the A182P mutant (p<0.0001). Without FB 1, 
SPT activity is not different between mutant and SPTLC2wt.  
D. Generation of deoxySLs in HEK293 cells. The A182P mutation leads to a significant 
increase in deoxySL formation compared with SPTLC2wt cells (p<0.0001). In the presence of 
FB1, deoxySLs are also generated by SPTLC2wt cells (p<0.001), but the formation was 
significantly higher in the A182P cells (p<0.0001).  
FB1 = Fumonisin B1; deoxy-SA = deoxysphinganine; deoxy-SO = deoxysphingosine; deoxySL 
= deoxysphingolipid; SA = sphinganine; SO = sphingosine; SPT = serine palmitoyltransferase; 
wt = wild-type. Data are shown as means, with error bars representing SDs. SDs were 
calculated using 1-way analysis of variance with Bonferroni multiple correction. n.s.= not 
significant; SA= sphinganine; SO = sphingosine. **p, 0.01; ***p, 0.001; ****p, 0.0001. (cited 
from Murphy et al. 2013) 
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The isotope-labelled assay was performed in the presence or absence of FB1, an inhibitor for 
ceramide synthase leading to the accumulation of SA, which is a measure for cellular SPT 
activity. In the absence of FB1, the sphingoid bases were mostly metabolized into (M+3) SO 
after acid hydrolysis (figure 3-11, C) whereas deoxySLs were predominantly present as (M+3) 
deoxySA (figure 3-11, D). In the presence of FB1, the SPTLC2wt cells showed a 2- to 3-fold 
higher accumulation of (M+3)SA and (M+3)deoxySA compared with controls (figure 3-11, C 
and D). In the A182P cells, the formation of (M+3)SA was reduced 2- to 3-fold (figure 3-11, C) 
whereas (M+3)deoxySA formation was 15-fold higher than in SPTLC2wt cells (figure 3-11, D). 
 
3.3.4 Discussion 
This study reports a novel A182P mutation in the SPTLC2 gene identified from a dominant 
family and provides functional data demonstrating its pathogenic role. The age of onset in the 
affected patients was in the first decade, younger than is typically seen in HSN-I patients. To 
date, only three SPTLC2 mutations have been described (V359M, G382V and I504F) and one of 
these has been also associated with onset in the first decade.(Rotthier et al. 2010) Patients 
developed significant motor involvement in the early stages of the disease, suggesting a wide 
phenotypic spectrum of SPTLC2 mutations. Slowing of motor conduction velocities suggestive 
of demyelinating changes was noted in one of the patients, a finding which has been previously 
observed in patients with SPTLC1 mutations.(Houlden et al. 2006) 
 
In both A182P carrier, elevated serum 1-deoxySL levels were described confirming the 
pathogenicity of the mutation, and a higher level was found in the more severely affected 
daughter.  The in vitro cell study and two metabolic labeling assays confirmed that the A182P 
mutant reduced significantly the SPT activity with L-serine and increased the activity with L-
alanine. The combined genetic, clinical and functional data confirmed the association of this 
novel SPTLC2 mutation with HSN-I.  The findings confirmed the observation that  other 
mutations in SPTLC1 and SPTLC2 genes  are  associated with reduced canonical activity and 
increased 1-deoxySL formation.(Bejaoui, Wu et al. 2001; Dawkins, Hulme et al. 2001; Houlden, 
King et al. 2006; Rotthier, Auer-Grumbach et al. 2010) 
 
This study also supported the pathogenic role of 1-deoxySLs in HSN-I, indicating that it may be 
a metabolic disorder and 1-deoxySLs can be considered relevant biomarkers in HSN-I. 
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3.4 Autosomal recessive cerebellar ataxia caused by a novel ADCK3 mutation  
 
3.4.1 Introduction 
Autosomal-recessive cerebellar ataxias (ARCAs) are a group of inherited neurodegenerative 
disorders characterised primarily by cerebellar ataxia, but are frequently associated with other 
neurological manifestations including spasticity, peripheral neuropathy, seizures and optic 
atrophy. ARCAs are genetically heterogeneous with more than 20 causative genes currently 
recognized.(Degardin et al. 2012; Jayadev et al.2013; Sailer et al.2012) Coenzyme Q10 (CoQ10) 
deficiency (MIM_607426) is one of the potentially treatable causes of ARCA as the symptoms 
in many patients improve with CoQ10 supplementation.(Emmanuele et al. 2013; Potgieter et al. 
2013) CoQ10 is a lipid-soluble component located in the inner mitochondrial membrane. It 
plays a pivotal role in the OXPHOS by shuttling electrons derived from MRC complexes I 
[Nicotinamide adenine dinucleotide (NADH) ubiquinone oxidoreductase] and II (succinate 
ubiquinone oxidoreductase) to complex III (ubiquinol cytochrome c oxidoreductase) and also 
participates in other cellular processes as a potent antioxidant and by influencing pyrimidine 
metabolism.(DiMauro et al. 2007; Quinzii et al. 2010) 
 
The AarF domain containing kinase 3 gene (ADCK3, MIM_606980) is one of the genes 
involved in the biosynthetic pathway of CoQ10 thus their mutations can cause CoQ10 
deficiency where most mutations are loss of function. ADCK3 is the homologue of the yeast 
Coq8 gene and encodes a mitochondrial protein which functions in an electron-transferring 
membrane protein complex in the MRC.(Lagier-Tourenne et al. 2008) Patients with ADCK3 
mutations usually have disease onset in infancy or early childhood and can present with pure 
cerebellar ataxia or a complex phenotype with additional features such as seizures, cognitive 
impairment, depression, peripheral neuropathy, strabismus or exercise intolerance.(Gerards et al. 
2010; Horvath et al. 2012; Lagier-Tourenne et al. 2008; Mollet et al. 2008)  
 
In this study, WES identified a homozygous frameshift mutation in ADCK3 in a patient affected 
by cerebellar ataxia, myoclonus and dysarthria. This is a read-though mutation resulting in the 
loss of the stop codon and extension of the protein by 81 amino acids. CoQ10 level and the 
MRC enzyme activities in the index patient’s fibroblasts were also investigated and CoQ10 
supplementation was given to her based on the genetic and functional results.  
 
3.4.2 Materials and methods 
(1) Patients 
The index patient and the affected siblings were examined and blood samples were obtained 
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after informed consent. A skin biopsy was also obtained from the index patient. 
 
(2) Genetic analysis 
WES was carried out on the index patient at the National Institutes of Health (NIH) (Bethesda, 
US). Nimblegen SeqCap EZ Exome kit (in solution capture) was used for the exome capture. 
Shotgun sequencing libraries were generated from 3 µg genomic DNA. Sequencing was 
performed on a Genome Analyzer IIx, according to the manufacturer's instruction. Sanger 
sequencing of exon 15 and the adjacent intronic junctions of the ADCK3 gene (NM_020247) 
was performed in the index patient and the affected sibling to validate the identified variant 
(DNAs of the parents were unavailable).   
 
(3) Cell culture  
Primary ﬁbroblasts were obtained from a skin biopsy from the index patient. The fibroblasts 
were cultured in Dulbecco’s modified Eagle’s medium (DMEM) GlutaMAX supplemented with 
10% (v/v) heat-inactivated foetal bovine serum (FBS) and 1% (v/v) penicillin-streptomycin and 
they were maintained at 37oC, humidified and 5% CO2 in air.      
 
(4) Quantification of CoQ10 levels 
CoQ10 levels were quantified using a tandem mass spectrometer with a 2975 HPLC (Waters, 
Manchester, UK) as previously described.(Duberley et al. 2013) A hexane: ethanol (5:2, v/v) 
extraction was initially performed and the upper hexane layer was retained for analysis. 
Samples were re-suspended in 50:50 HPLC grade ethanol and methanol. Separation was 
achieved using a 3M Hypersil Gold C4 (150mm x 3mm, 3µm) with a Gold C4 guard column 
(3mm, 10mm length, 3µm) operated at 40ºC at a flow rate of 0.4ml/min. The mobile phases 
consisted of methanol, 4mM ammonium acetate 0.1% formic acid and methanol:isopropanol: 
formic acid (45:55:0.5, v/v/v) containing 5mM methylamine as an ion pair reagent. Isocratic 
delivery of the mobile phase ensured elution of the CoQ10 methylammonium adduct at 
approximately 8 minutes. D6-CoQ10 was used as an internal standard. 
 
(5) MRC enzyme activities 
Activities of MRC complex I, complex II-III , complex IV (cytochrome c oxidase) and citrate 
synthase (CS) were determined in the fibroblast cells according to methods  previously 
described.(Hargreaves et al, 2006) Results were expressed as a ratio to CS activity and were 
normalized against protein. Protein quantification was determined using the Lowry method 
using bovine serum albumin as a standard.(Lowry et al.1951) 
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3.4.3 Results 
(1) Clinical features 
The proband was a 35-year-old lady who started experiencing myoclonus and jerky tremor in 
the head and limbs at the age of 10. In her second decade she developed slurred speech and 
unsteady gait. Symptoms did not respond to levodopa. By the age of 30, she became wheelchair 
dependent because of the ataxic myoclonic gait. She also had difficulty in writing and holding 
objects due to ataxia and involuntary movements. Her speech fatigued easily, was often 
tremulous and dysarthric and she also complained of muscle fatigue on exertion. One of the four 
siblings, had a similar presentation with myoclonus, tremor and unsteady gait with onset at age 
14. Their parents were first cousins and were originally from Pakistan (pedigree shown in figure 
3-12, B, p107).  
 
Examination of the index case at the age of 35 showed cerebellar dysarthria with a tremulous 
quality to her speech. Eye movements were full with jerky pursuit, marked coarse tremor of the 
hands and head, which was both jerky and dystonic in nature. There was upper limb myoclonus 
and both upper and lower limb movements were uncoordinated when performing the finger 
nose task and the heel-knee-shin test. Her gait was ataxic and interrupted by frequent myoclonic 
jerks and she was unable to tandem walk. Her cognition and visual acuity were normal. She had 
symmetrical normal reflexes, flexor plantars, normal sensory examination and full muscle 
power. Her affected brother also had myoclonic movements, ataxic gait and dysarthria when 
examined at age 32. 
 
Brain magnetic resonance imaging (MRI) of the index case at the age of 35 showed mild 
cerebellar atrophy which was consistent with previous reports of patients with ADCK3 
mutations.  NCS and needle electromyography were normal. In both affected siblings, acquired 
causes of ataxia were excluded as well as Friedreich’s ataxia, AOA1, AOA2, ataxia 
telangiectasia, early-onset primary dystonia (DYT1), Vitamin E-deficiency, Wilson’s disease 
and SCA type 1-3. 
 
(2) Genetic analysis 
The process of variant prioritization is summarised in figure 3-12, A. A total of 17,240 exonic 
variants were identified in the index patient. According to the Consensus Coding Sequences 
hg19 definition of the exome, 92% of exome capture baits had at least 10× depth and 85% at 
least 30× depth. After excluding synonymous variants and those with MAF >1%, 78 coding 
variants remained.  None of these variants were detected in genes known to be associated with 
ARCAs and related neurological disorders. A homozygous 1bp insertion in the ADCK3 
(NM_020247; c.1844_1845insG; p.Ser616Leufs*114) was identified (figure 3-12, C). The 
107 
 
variant was validated by Sanger sequencing. Genetic analysis of the affected brother 
documented the segregation of this variant within the family (figure 3-12, D). 
 
Figure 3-12. Genetic study and pedigree of the family with ADCK3 S616Lfs mutation 
(A) Filtering and prioritization of variants from WES in the index patient. The criteria of filters 
were described in Method (Secton 2.6.1)  
(B) Pedigree of the family. The index patient is labelled with a black star. Based on the 
consanguinity, only homozygous variants were selected. 
(C) A good sequence depth up to 122X and the homozygosity of the novel ADCK3 mutation as 
the insertion G was detected in 110 of the total 122 counts were shown when inspected with the 
Integrative Genomics Viewer (IGV). 
(D) Sanger sequencing validated the mutation and proved its segregation within the family. 
(Picture cited from Liu et al. 2014) 
 
The genomic structure of the human ADCK3 gene and mutations in this gene are illustrated in 
figure 3-13, A (p109). These mutations were classified by the patients’ age of onset. The family 
described in this chapter is the second kindred of ADCK3 mutation with a juvenile onset of 
disease (between 10 to 20 years) as only a single study has previously reported a family with 
compound heterozygous missense mutations in ADCK3: R271C and A304T.(Horvath et al. 2012) 
The novel frameshift mutation is localised to the C-terminal of ADCK3 resulting  in an 
alteration of several highly-conserved codons in the last coding exon. Furthermore, the 
frameshift is predicted to eliminate the original stop codon and allow translation to continue on 
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into the three prime untranslated region (3'UTR), extending the peptide by 81 amino acids 
(figure 3-13, B). 
 
(3) CoQ10 level and MRC enzyme activity 
The serum CoQ10 level of the patient was found to be within the normal range, however, the 
CoQ10 level in the patient’s fibroblasts was low:  35% of the average CoQ10 level of controls. 
The assay of MRC enzymes in fibroblasts obtained from a skin biopsy from the index patient 
also revealed that the activities of complex I and complex II-III were significantly reduced as 
compared with controls. A decrease in complex II-III activity is compatible with CoQ10 
deficiency, as the activity of this linked enzyme system is dependent upon endogenous 
CoQ10.(Rahman et al. 2001) Details of these analyses are shown in table 3-6. 
 
Table 3-6. CoQ10 levels and the mitochondrial respiratory chain enzyme activities in the 
patient with ADCK3 S616Lfs mutation 
 
Patient Control P/C ratio P value 
CoQ 10 levels (pmol/mg]     
  in serum 43.00 37~133
#
 /  
  in fibroblasts 31.29 89.3
§
 (n=50) 35.0% p<0.05 
MRC enzyme activity     
  CI/CS 0.15±0.167 0.82±0.18 (n=3) 18.3% p<0.05 
  CII+CIII/CS 0.046±0.03 0.122±0.02 (n=3) 37.7% p<0.05 
  CIV/S 0.017±0.0052 0.015±0.004 (n=3) 113.3% ns 
P/C ratio, the ratio of patient’s measurement to control value; CI, complex I (NADH 
ubiquinone oxidoreductase); CII, complex II (succinate ubiquinone oxidoreductase); CIII, 
complex III (ubiquinol cytochrome c oxidoreductase); CIV, complex IV (cytochrome c oxidase: 
EC 1.9.3.1); CS, citrate synthase; MRC enzyme activity, the mitochondrial respiratory chain 
enzyme activities assessed in patient’s fibroblasts. Abnormal values are shown in bold. When 
experiments were done more than once, values are given as means± standard error of the mean. 
#
 From the diagnostic laboratory at National Hospital of Neurology and Neurosurgery, Queen 
Square, London, UK. 
§
Reference range 57.0~121.6 pmol/mg, average 89.3 pmol/mg; Age: 
20.75±1.4 years (range, 0.03~55 years); ratio of males to females, 2:3.(Duberley et al. 2013) 
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(4) Treatment and outcome 
Following the identification of primary CoQ10 deficiency in the index patient, CoQ10 
replacement was initiated with a starting dose of 200mg bd. After 3 months of therapy, 
myoclonus dramatically improved whereby she was able to discontinue clonazepam which she 
had been taking for the previous 2 years to manage her frequent myoclonic jerking. The quality 
of her speech also improved and was less tremulous although she continued to have residual 
dysarthria. Self-reported symptoms of fatigue also improved. 
 
These improvements were sustained when she was reviewed 6 months after initiation of CoQ10 
replacement. There was subjective and objective improvement in her ataxia with a reduction in 
SARA (scale for the assessment and rating of ataxia) scores dropped from 17 to 13 (table 3-
7).(Schmitz-Hubsch et al. 2006) Her affected sibling has also shown improvement in speech and 
fatigue after  taking CoQ10 100mg twice daily for three months.  
 
Table 3-7. SARA scores of the patient with ADCK3 S616Lfs mutation before and after 6 
months of CoQ10 supplement  
SARA score Before treatment 
After 6 months of 
treatment 
(1) Gait 4 3 
(2) Stance 4 3 
(3) Sitting 1 1 
(4) Speech disturbance 1 1 
(5) Finger chase* 2 1 
(6) Nose-finger test* 2 1 
(7) Fast alternating hand movements* 1.5 1.5 
(8) Heel-shin slide* 1.5 1.5 
Total 17 13 
SARA (scale for the assessment and rating of ataxia) has eight items that yield a total score of 0 
(no ataxia) to 40 (most severe ataxia): (1) Gait (score 0 to 8), (2) Stance (score 0 to 6), (3) Sitting: 
(score 0 to 4), (4) Speech disturbance (score 0 to 6), (5) finger chase (score 0 to 4),  (6) nose-
finger test (score 0 to 4), (7) fast alternating hand movements (score 0 to 4), (8) Heel-shin slide 
(score 0 to 4). *Limb kinetic functions (items 5 to 8) are rated independently for both sides, and 
the arithmetic mean of both sides is included in the SARA total score.  
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3.4.4 Discussion 
In this study genetic and biochemical data were demonstrated in a family with a complex ataxia-
myoclonus phenotype CoQ10 deficiency and abnormal MRC enzyme activities due to  a novel 
frameshift mutation in the ADCK3 gene and. One of the unusual features of this family was the 
onset in the second decade, which is later than most of previously reported cases with ADCK3 
mutations. Also, this family was affected with marked myoclonic-dystonic movements but 
relatively mild cerebellar ataxia, suggesting a wide phenotypic spectrum of ADCK3 mutations.  
 
To date, autosomal recessive mutations in ADCK3 have only been identiﬁed in 22 patients from 
13 families, and these mutations have been associated with clinically heterogeneous 
diseases.(Horvath et al. 2012) Patients usually present with a complex neurological phenotype, 
with cerebellar ataxia as the predominant manifestation.(Gerards et al. 2010; Horvath et al. 2012; 
Lagier-Tourenne et al. 2008; Mollet et al. 2008) In this family, cerebellar symptoms were 
relatively mild compared to the disabling myoclonus and involuntary movements which 
affected both siblings. This report shows that ADCK3 mutations should be considered a 
potential cause of unexplained complex neurological syndromes even when cerebellar ataxia is 
not the predominant feature. 
 
Unlike previous reports in which the majority of patients had the onset in their childhood or 
infancy (figure 3-13) (Gerards et al. 2010; Horvath et al. 2012; Lagier-Tourenne et al. 2008; 
Mollet et al. 2008), this is the second kindred with a juvenile onset providing further evidence 
that ADCK3 mutations can cause complex cerebellar ataxia with a variable age of onset. 
 
In our patient, the diagnosis of CoQ10 deficiency was confirmed biochemically by CoQ10 
levels measured in fibroblasts. Significantly reduced activities of MRC enzymes were also 
observed in fibroblasts. CoQ10 measurement in muscle is the gold standard for diagnosis of 
CoQ10 deficiency as plasma concentrations of CoQ10 are not reliable and may be influenced by 
dietary factors.(Duberley et al. 2013) However, the measurement in muscle may be normal 
particularly when the deficiency is mild.(Emmanuele et al. 2013) Assessing CoQ10 levels in 
fibroblasts has been documented to be a reliable method to diagnose CoQ10 
deficiency.(Duberley et al. 2013; Duncan et al. 2009; Hargreaves et al. 1999; Rahman et al. 
2001) Therefore measuring CoQ10 levels in fibroblasts can be an alternative to muscle 
measurement. 
 
CoQ10 replacement therapy resulted in subjective and objective improvement in patient 
symptoms and function. The most marked improvements were the  reduction of myoclonus and 
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speech improvement although there were also improvements in ataxic symptoms as measured 
by the SARA scale. CoQ10 deficiency is one of the few treatable causes of ataxia and symptom 
improvement following replacement has been observed in a number of patients, although 
treatment protocols are yet to be standardized.(Emmanuele et al. 2013; Horvath 2012) There are 
few long-term studies however and it is not clear for how long these benefits might be sustained 
or if they alter the overall disease course. 
 
ADCK3 mutations are very rare and the number of patients reported is still low. This is partly 
due to the nonspecific genotype-phenotype correlations of CoQ10-associated genes and the 
difficulty in screening all potentials genes in suspicious cases. CoQ10 deficiency is associated 
with clinically heterogeneous diseases, including cerebellar ataxia, encephalomyopathy, severe 
infantile multisystemic disease, nephropathy, myopathy and multiple-system atrophy, and the 
number of genes involved in the biosynthetic pathway for CoQ10 is increasing.(Emmanuele et 
al. 2013) In this study  WES has been demonstrated to be a powerful tool to detect mutations in 
rare known genes, particularly in unexplained complex syndromes with high genetic 
heterogeneity. It is likely that the application of WES and other NGS technology will allow the 
identification of more patients with CoQ10 deficiency. The novel mutation identified in this 
study also provides new insights into the pathogenesis of ADCK3 mutations. This is the first 
ADCK3 mutation which results in the loss of the stop codon and translation into the UTR. 
CoQ10 deficiency and reduced respiratory enzymes activities in the patient’s fibroblast 
confirmed the pathogenicity of this mutation. It is not yet clear through what mechanism the 
function of the protein is impaired by the extended C-terminal sequence. The elongated mutant 
protein may bear less structure stability and thus be incompetent to carry out its function in 
mitochondria and CoQ10 biosynthesis. However, given the relatively mild disease course, it is 
likely that some residual function remains. 
 
In summary, this study extends the phenotypic spectrum of ADCK3 mutations associated with 
ARCA. Mutations are not only restricted to childhood-onset ataxias, and other neurological 
features such as myoclonus may be prominent. This study also increases the understanding of 
genetic and functional effects of ADCK3 mutations. The loss of a stop codon mutation identified 
in this gene suggests that the terminal segment of ADCK3 may play an unknown but essential 
role in its normal function. The good response to treatment highlights the importance of 
identifying a potentially treatable cause, CoQ10 deficiency, in unexplained recessive cerebellar 
ataxia or ataxia-associated complex syndromes. 
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Chapter 4 
 
Results: Genetic studies in rare known genes of 
inherited neuropathies and other inherited 
disorders 
 
Some causative genes for inherited neuropathies have not been studied thoroughly because their 
mutations are rarely identified. The screening of these genes in specific cohorts is helpful to 
further understand their phenotypic spectrum and to establish the genetic epidemiological 
profiles. In this chapter, genetic studies of NEFL and the promoter region of PMP22 in CMT 
patients are described. Some genes causing other neurological disorders were also investigated 
due to the overlap with inherited neuropathies. For example, KIF5A, the causative gene for 
SPG10, was screened in both CMT2 patients and HSP cases to investigate the phenotypic 
spectrum of its mutations. Also, three genes recently identified for SCAs were sequenced in 
patients with cerebellar ataxia: PDYN for SCA23, AFG3L2 for SCA28 and KCND3 for 
SCA22/SCA19.   
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4.1 Extended phenotypic spectrum of KIF5A mutations: from spastic paraplegia to axonal 
neuropathy 
 
4.1.1 Introduction 
Spastic paraplegia type 10 (SPG10) is a rare form of autosomal dominant HSP caused by 
mutations of the kinesin family member 5A (KIF5A) gene (MIM: 602821).(Reid et al. 2002) 
Axonal neuropathy is frequently associated with SPG10 and has been documented by 
neurophysiological studies in two-thirds of patients.(Goizet et al. 2009; Musumeci et al. 2010; 
Schule et al. 2008; Tessa et al. 2008) Interestingly, two mutations in KIF5A have been identified 
in patients with a typical CMT type 2 phenotype but no pyramidal signs. One mutation 
(p.Glu251Lys, E251K) was carried by the father of a SPG10 patient,(Goizet et al. 2009) and the 
other (p.Gly235Glu, G235E) was detected in a sporadic case.(Crimella et al. 2012) These 
findings have raised the hypothesis that KIF5A mutations have a broad phenotypic spectrum and 
SPG10 and CMT2 may be allelic disorders. However, there is still a lack of large-scale studies 
to address the question. The aim of this study was to establish whether KIF5A mutations can be 
responsible for both HSP associated with neuropathy and for CMT2. 
 
4.1.2 Patients and methods 
(1) Patients 
The diagnosis of HSP or CMT was based on clinical features, imaging and neurophysiology. 
Acquired causes of spasticity and neuropathy were excluded. As part of the diagnostic workup 
patients carrying KIF5A mutations had neurological examination and neurophysiological 
assessment and one patient had a sural nerve biopsy. In patients with an identified KIF5A 
mutation, DNA from affected family members was also tested for segregation where available. 
 
(2) Sanger sequencing 
The vast majority of KIF5A mutations have been identified mainly in the motor domain,(Blair et 
al. 2006; Crimella et al. 2012; Fichera et al. 2004; Goizet et al. 2009; Lo Giudice et al. 2006; 
Musumeci et al. 2010; Reid et al. 2002; Schule et al. 2008; Tessa et al. 2008) therefore, this 
domain was screened in two series of patients by Sanger sequencing (details of methods are 
described in Section 2.3). The first series included 186 patients with a clinical diagnosis of HSP 
with or without neuropathy (HSP series) and the second included 215 patients with axonal 
neuropathy consistent with CMT2 (CMT2 series). Patients in the HSP series were negative for 
mutations in SPAST, REEP1, NIPA1, ATL1 and BSCL2 and patients in the CMT2 series were 
usually negative for mutations in GJB1, MFN2, MPZ, GDAP1, BSCL2, TRPV4, NEFL, HSPB1 
and HSPB8.  
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(3) Targeted resequencing 
A high-throughput targeted resequencing panel covering all coding exons of KIF5A was 
developed to screen an additional 66 patients with HSP or CMT2 with pyramidal signs. Most of 
these patients were negative for ATL1 and SPAST mutations. The probe library was designed and 
enriched by the use of the HaloPlex system (Agilent). Targeted sequencing was performed in the 
Miseq platform.(Illumina) Details of the methods and variant filtering are described in Section 
2.6 and Section 6.2. All mutations identified by the panel were validated by Sanger sequencing.  
 
(3) WES 
One patient was analysed by WES. Enrichment of coding exons and flanking intronic regions 
was performed using the SureSelect Human All Exon 50 Mb kit (Agilent) following the 
manufacturer’s standard protocol. Enriched DNA was subjected to standard sample preparation 
for the Hiseq2000 instrument (Illumina). BWA and GATK software packages were used to align 
sequence reads to the NCBI hg19 reference and to call variant positions. All data were then 
annotated and imported into GEnomes Management Application (GEM.app) for data 
analysis.(Gonzalez et al. 2013) Variants were filtered as described in Section 2.6.   
 
(4) Pathogenicity evaluation of novel mutations.  
For identified novel mutations, in silico prediction of the functional impact of the mutation was 
performed using Polyphen and SIFT. A search of these mutations was performed in exome 
sequences from 221 healthy controls, the EVS database, and the Genome Variant Database for 
Neuromuscular Diseases (NMD database, http://hihg.med.miami.edu/gvd-nmd/). 
 
4.1.3 Results 
(1) Genetic results 
 Five different heterozygous missense KIF5A mutations were identified in six unrelated patients. 
Mutations in two patients were revealed by the panel, three were detected by Sanger sequencing 
and in one patient, the mutation was identified by WES. Pedigree and the nucleotide changes of 
these patients are illustrated in figure 4-1, A (p121). R204Q (c.G891A; p.Arg204Gln), R280H 
(c.G839A; p.Arg280His) and R280C (c.C838T; p.Arg280Cys) have been previously reported in 
patients with SPG10 (Crimella et al. 2012; Fichera et al. 2004; Goizet et al. 2009) whereas 
R204W (c.C890T; p.Arg204Trp) and D232N (c.G694A; p.Asp232Asn) were novel mutations. 
Both novel mutations were not identified in 221 exomes from healthy controls and not reported 
in either the EVS database or NMD database. Furthermore, they were predicted to be probably 
damaging and not tolerated by Polyphen and SIFT and each mutation changed a highly 
conserved amino acid residue (figure 4-1, B). The above evidence supported the pathogenicity 
of these novel mutations.  
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Figure 4-1. KIF5A mutations  
(A) Chromatographs of the identified mutations and pedigree of the six patients in this study. 
The phenotypes illustrated in different colors refer to (1) Classical CMT2: classical CMT2 
phenotype without pyramidal sign, (2) CMT2 + pyramidal signs: CMT2 is the main 
manifestation but there are associated pyramidal signs, (3) HSP + neuropathy: complex spastic 
paraplegia associated with peripheral neuropathy, (4) HSP, no neuropathy: spastic paraplegia 
without peripheral neuropathy. Parents of K-2 and K-3 were clinically unaffected at least until 
their sixth decades though they were unavailable for genetic testing. Parents of K-5 died early 
due to non-neurological diseases.  
(B) The amino acid residues where two novel missense mutations (R204W and D232N) 
occurred were highlighted on kinesin orthologues in various species. The alignment showed 
their strict conservation during evolution from zebrafish to human beings. 
(The figure is cited from Liu et al, 2014) 
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(2) Clinical and pathological findings  
Patients with KIF5A mutations presented with a variable phenotype and age of onset. The 
clinical features of the patients with KIF5A mutations are summarized in table 4-1 (p123). 
Among the three patients who had CMT2 as the predominant phenotype, only K-1 initially 
presented with a classical CMT2 phenotype whereas the remaining two (K-2, K-3) had some 
involvement of the pyramidal tracts. The other three patients had spastic paraplegia as the main 
manifestation and two of them (K-4, K-6) also had peripheral neuropathy. Moreover, some 
patients had additional features: K-3, K-6 and other affected family members of K-6 had 
cognitive dysfunction and learning difficulties since their childhood; K-5 and her sister had 
marked cerebellar ataxia complicating the spasticity. 
 
R280C mutation was identified in two unrelated patients with different phenotypes: K-3 was of 
British origin and had the clinical diagnosis of CMT2 with mild pyramidal signs whereas K-6 
who had lived in Austria for several generations presented with severe spastic paraplegia and 
mild peripheral neuropathy (figure 4-1, A, K-3, K-6). Variable phenotypes in individuals within 
the same family were also observed. K-2 who had D232N mutation presented with complex 
CMT2 associated with spasticity, whereas his brother was affected by pure HSP (figure 4-1, A, 
K-2). 
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 Table 4-1. Clinical features of the patients with KIF5A mutations 
Patient K-1 K-2 K-3 K-4 K-5 K-6 
Mutation R280H D232N R280C R204Q R204W R280C 
Gender F M M M F F 
AO/AE (yr) 42/62 40/50 8/39 <20/38 ~30/56 28/32 
Predominant 
phenotype 
CMT2 CMT2 CMT2 HSP HSP HSP 
Additional 
symptoms 
None Spasticity 
Spasticity, 
Cognitive 
dysfunction 
Peripheral 
neuropathy 
Cerebellar 
ataxia 
Peripheral 
neuropathy, 
cognitive 
dysfunction,  
Lumbar pain 
Presenting 
symptom 
Difficulty in 
walking 
Cramps and 
pain in LL 
Reduced 
sensation in 
LL 
Stiffness in LL 
and difficulty 
in walking 
Difficulty in 
walking 
Difficulty in 
walking 
Pyramidal 
signs 
None 
Hyperreflexia
Hypertonia 
Spastic gait 
Hyperreflexia
Hypertonia 
Extensor 
plantars 
Hyperreflexia 
except absent 
ankle jerks 
Spastic gait 
Hyperreflexia 
with ankle 
clonus 
Hypertonia 
Hyperreflexia 
with ankle 
clonus 
Spastic gait 
Bladder 
dysfunction 
None Mild urgency None 
Significant 
urgency 
Significant 
urgency 
Significant 
urgency* 
Weakness 
      
UL Mild Mild Mild No No No 
LL Moderate Mild Severe No Mild No 
Pinprick 
      
UL 
Moderately 
abnormal 
Mildly 
abnormal 
Normal 
Moderately 
abnormal 
Normal Normal 
LL 
Moderately 
abnormal 
Mildly 
abnormal 
Normal 
Moderately 
abnormal 
Normal Normal 
Vibration 
      
UL Normal 
Mildly 
abnormal 
Mildly 
abnormal 
Moderately 
abnormal 
Severely 
abnormal 
Normal 
LL 
Mildly 
abnormal 
Severely 
abnormal 
Mildly 
abnormal 
Moderately 
abnormal 
Severely 
abnormal 
Normal 
Aid for 
walking 
Crutch AFO Wheelchair Crutch Wheelchair No 
AD= autosomal dominant; AE= age of examination; AFO= ankle foot orthosis; AO= age of 
onset; CMT2= Charcot-Marie-Tooth disease type 2; F= female; HSP= hereditary spastic 
paraplegia; M= male; UL= upper limbs; LL= lower limbs; Weakness: mild= MRC ≥4 in distal 
muscles, moderate= MRC ≤4 in distal muscles, severe= proximal weakness (knee flexion and 
extension, elbow flexion and extension or above); Pinprick and vibration sense: mildly 
abnormal= reduced below wrist/ankle, Moderately abnormal= reduced below elbow/knee, 
Severely abnormal= reduced at or above elbow/knee. * Only reported in some family members 
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Features demonstrating the simultaneous involvement of the peripheral and central nervous 
systems in our patients are shown in figure 4-2. A sural nerve biopsy from K-3 revealed 
markedly reduced numbers of large myelinated fibers, compatible with axonal degeneration 
(figure 4-2, A, B). Meanwhile, spasticity with hyperreflexia was observed on examination. K-2 
had wasting of intrinsic foot muscles and pes cavus while the worn-out areas of the shoes 
indicated a longstanding spastic gait (figure 4-2, E, F).  
 
Figure 4-2. Pathological and clinical evidence of peripheral neuropathy in patients with 
KIF5A mutations 
Sural nerve biopsy of patient K-3:  
A and B. Semi-thin resin section stained with methylene blue azure – basic fuchsin (MBA-BF) 
showed markedly reduced numbers of large myelinated fibres in patient K-3 (A) as compared 
with a healthy age-matched control (B). C and D. Ultrastructural assessment for patient K-3 
revealed numerous regeneration clusters of unmyelinated axons (arrows in A and C) which was 
not observed in a health age-matched control (D). Scale bar: 45μm (A, B), 5μm (C, D). Patient 
K-2:  
E. Pes cavus. F. The worn-out areas of the patient’s shoes are suggestive of the longstanding 
spastic gait.  
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(2) Neurophysiolgical findings  
NCS of the five patients who had a clinically recognisable peripheral neuropathy are presented 
in table 4-2. Neurophysiology showed symmetrically absent or reduced MAPs and SAPs with 
relatively preserved NCVs in upper and lower limbs, consistent with sensorimotor axonal 
polyneuropathy. 
 
Table 4-2. Nerve conduction studies of the patients with KIF5A mutations 
Patient K-1 K-2 K-3 K-4 K-6 
Mutation R280H D232N R280C R204Q R280C 
AE (yr) 53 50 32 40 32 
Median n.      
 Motor DML (ms) 3.5 3.9 6.1 5.5 5.8 
 CMAP (mV) 6 7.2 4.7 7.8 2.2 
 MNCV (m/s) 52 44 44 52 36 
 F-latency (ms) 28 33.2 NR 32.4 NR 
 SAP (uV) 7 Abs Abs 2 6.5 
 SNCV (m/s) 55 Abs Abs 42 37 
Ulnar n.      
 Motor DML (ms) NR 3.2 4.7 3.8 3.4 
 CMAP (mV) NR 5.7 6.4 6.5 11.5 
 MNCV (m/s) NR 53 50 46 42 
 SAP (uV) 5 Abs Abs 4 8.3 
 SNCV (m/s) 54 Abs Abs 48 39 
Radial n.      
 Motor DML (ms) NR NR NR NR NR 
 CMAP (mV) NR NR NR NR NR 
 MNCV (m/s) NR NR NR NR NR 
 SAP (uV) 8 Abs Abs 9 NR 
 SNCV (m/s) 54 Abs Abs 55 NR 
Common peroneal n.      
 Motor DML (ms) Abs Abs Abs Abs 7.2 
 CMAP (mV) Abs Abs Abs Abs 1.1 
 MNCV (m/s) Abs Abs Abs Abs 33 
Tibial n.      
 Motor DML (ms) NR Abs Abs Abs 5 
 CMAP (mV) NR Abs Abs Abs 4.4 
 MNCV (m/s) NR Abs Abs Abs 33 
Sural n.      
 SAP (uV) Abs Abs Abs Abs Abs 
AE= age at examination; Abs=absent; CMAP= compound motor action potential (mV); 
DML=distal motor latency; MNCV= motor nerve conduction velocity (m/s); NR= not recorded; 
n.= nerve; SAP= sensory action potential (uV); SNCV= sensory nerve conduction velocity (m/s) 
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4.1.4 Discussion 
This study reports the largest series of HSP and CMT2 patients screened for KIF5A mutations. 
The identification of five different mutations confirms that KIF5A is associated with both HSP 
and CMT2 phenotypes. In this study the first family with a KIF5A mutation and associated 
cerebellar ataxia is reporting broadening the phenotypic spectrum of KIF5A mutations. 
 
The identified KIF5A mutations and their associated phenotypes are presented in figure 4-3 
(p127). HSP and CMT2 represent two different ends of the spectrum of KIF5A-related disorders: 
classical or complex CMT2 is relatively rare while HSP with axonal neuropathy is the 
commonest phenotype associated with KIF5A mutations. However, a specific phenotype-
genotype correlation for KIF5A mutations could not be defined as some mutations (R280C, 
R280H and D232N) have been associated with more than one phenotype. The intra-familial 
phenotypic variability within families with the D232N mutation provides evidence of the allelic 
relationship of HSP and CMT2. 
 
KIF5A encodes the neuronal kinesis heavy chain (KHC) subunit of kinesin-1, a motor protein 
which plays a role in axonal transport. Kinesin-1 relies on the highly conserved motor domain 
of KHC to bind to the microtubules and converts the chemical energy of adenosine-5'-
triphosphate (ATP) into mechanical energy required for intracellular trafficking.(Barry et al. 
2007; Ebbing et al. 2008; Gunawardena et al.2004; Hirokawa et al. 2009; Xia et al. 1998; Xia et 
al. 2003)  In both CMT2 and SPG10 phenotypes, the majority of the mutations are localized in 
the motor domain  and are clustered around the two switch regions (SWI and SWII in figure 4-3) 
which carry γ-phosphate-sensing activity and are particularly important in the interaction with 
microtubules (figure 4-3, p122). Half of the families in this study have mutations at codon R280 
and 25% (7/28) of all reported families with a KIF5A mutation have an amino acid substitution 
at this position. Although these families are from different parts of the world, it would be 
interesting to carry out a haplotype study to investigate a founder effect. The CpG dinucleotide 
of codon 280 had been proposed as a possible hot spot for KIF5A mutations(Goizet et al. 2009) 
and the  findings support the critical role of this codon in the function of KIF5A.  
 
A small number of SPG10-associated KIF5A mutations (K253N, N256S, R280C and A361V) 
have been investigated using in-vitro and Drosophila models. The results support a loss of 
endogenous kinesin-1 function due to a selective dominant-negative mechanism on the kinesin 
complexes, rather than a toxic gain of function.(Ebbing  et al. 2008; Füger et al. 2012) Only 
mutations localized in the motor domain changed the kinesin gliding properties but not  the 
mutation in the neck (A361V). This suggests that mutations outside of the motor domain may 
have a different disease mechanism.(Ebbing  et al. 2008) 
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Figure 4-3. Phenotypic spectrum of KIF5A mutations 
Top. Genomic organization of the human KIF5A gene and its mutations. Most of the KIF5A 
mutations are localized in exon 8~10 and many are clustered within or around the switch I 
regions (SWI) and the switch II region (SWII) which carry γ-phosphate-sensing activity to 
convert ATP into required energy. KIF5A mutations were labelled with the corresponding 
phenotypes: classical CMT2, CMT2 + pyramidal signs, HSP + neuropathy and HSP, no 
neuropathy (definitions of the phenotypes have been described in figure 1). The mutations 
identified in this study were flanked with the two novel mutations in pink.  
Bottom left. A Venn diagram representing the overlap and distinct phenotypes of KIF5A 
mutations. The majority of these mutations presented by both spastic paraplegia and neuropathy. 
 
CMT2 and HSP have different target cells: the first primarily affects the peripheral nerves, and 
the latter principally affects the corticospinal tract. Both the peripheral nerve axons and the long 
corticospinal tract rely heavily on axonal transport of appropriate cargoes to maintain their 
normal functions. KIF5A is another example of a gene in which mutations can cause axonal 
neuropathy in association with pyramidal signs and is involved in axonal transport similar to 
BSCL2, REEP1, ATL1, SPAST, NIPA1 genes.(Barry et al. 2007; Gunawardena et al. 2004; 
Timmerman et al. 2012; Xia et al. 2003) Likewise CCT5, KIF1A, and DYNC1H1 are other 
genes encoding motor proteins which have an important role in axonal transport and their 
mutations have been identified in patients with complex syndromes involving both the 
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peripheral and central nervous systems.(Bouhouche et al. 2006; Klebe et al. 2012; Riviere et al. 
2011; Weedon et al. 2011; Willemsen et al. 2012) Thus axonal transport represents a potential 
common pathway in the pathogenesis of both axonal neuropathy and spastic paraplegia. 
(Timmerman et al. 2012) Mutant motor proteins affecting axonal transport may lead to a 
neurodegenerative process. However, the mechanism by which mutations of the same gene can 
either selectively or simultaneously affect the upper motor neurons and the peripheral axons is 
still not well understood. Other genetic or environmental factors may influence the phenotype. 
Further studies are needed to understand the function of KIF5A and its roles in the peripheral 
and central nervous systems. 
 
The reported frequency of KIF5A mutations may be underestimated as this is not a genetic 
testing usually included in most of the diagnostic services. The application of targeted 
resequencing for screening KIF5A provides a more comprehensive and cost-effective method. 
In addition, next-generation targeted sequencing and whole exome sequencing are powerful 
tools for identifying mutations in patients with atypical complex symptoms. These approaches 
have effectively facilitated the detection of KIF5A mutations and helped broaden the phenotypic 
spectrum of this gene. 
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4.2 NEFL mutations cause variable CMT phenotypes  
 
4.2.1 Introduction 
Neurofilaments are the main cytoskeleton component of vertebrate axons which determine the 
axonal caliber. Neurofilaments are heteropolymers composed of light, medium, and heavy 
chains and the neurofilament, light polypeptide (NEFL) gene encodes the light chain 
neurofilament protein (NFL).(Friede et el. 1970;  Muma et al. 1993) Mutations in NEFL were 
initially described as a cause of axonal CMT (CMT2E) (De Jonghe et al. 2001; Lupski 2000; 
Mersiyanova et al. 2000) but subsequently were identified in patients with demyelinating CMT 
(CMT1F).(Zuchner et al. 2004) In most affected individuals, age of onset is within the first 
decade of life, the phenotype is usually severe and NCVs are reduced. However, further studies 
have confirmed that NEFL mutations can cause a wide clinical spectrum without an obvious 
genotype-phenotype correlation.(Miltenberger-Miltenyi et al. 2007; Reilly 2009; Zuchner et al. 
2004) NEFL mutations are usually transmitted in a dominant fashion; however, de novo 
dominant mutations and recessive inheritance have been also reported.(Yum et al. 2009) Thus, 
mutation analysis of NEFL should not be restricted to axonal or demyelinating neuropathies, 
and various inheritance patterns should be taken into consideration. The aim of this study was to 
screen NEFL in a cohort of CMT patients to determine the mutation frequency in a UK 
population.  
 
4.2.2 Patients and methods 
NEFL gene (NM_006158) was sequenced by Sanger sequencing in a cohort of 188 CMT 
patients in which mutations in PMP22, MPZ, GJB1, MFN2 or SH3TC2 genes had been 
previously excluded. The cohort included patients with variable inheritance and different 
neurophysiological presentations, including demyelinating, axonal, and intermediate subtypes. 
The study was part of a large-cohort based genetic study which included 1607 patients with 
CMT (425 patients attending an inherited neuropathy clinic and 1182 patients whose DNA was 
sent to the NHNN genetic laboratory for genetic testing) to determine the proportion of different 
subtypes in a UK population.(Murphy et al. 2012) 
  
4.2.3 Result  
(1) Genetic analysis 
Two heterozygous mutations were detected in two unrelated patients: p.Leu311Pro (L311P) was 
a novel mutations while p.Pro8Leu (P8L) had been previously reported.(Jordanova et al. 2003) 
The mutations and pedigree of patients are described in figure 4-4 (p130).   
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Figure 4-4. Nucleotide sequences and the pedigrees of the patients with NEFL mutations 
/= affected members, /= unaffected members. The index patients are labeled with N-I, 
and N-II. 
 
Each NFL subunit comprises a centralα-helical coil domain flanked by a globular head domain 
and non-α-helical tail domains. The two mutations were identified in different domains: P8R in 
the head domain and L311P in the coil domain (figure 4-5, p131). The pathogenicity  of the 
novel mutations was supported by the following evidences: (1) the  mutation was absent in  216 
control chromosomes; (2) functional prediction using PolyPhen2 and SIFT programs suggested 
that L311P was probable damaging and intolerable; (3) multispecies alignment of the sequences 
showed that amino acid codon Leu311 was highly conserved in evolution (figure 4-5).  
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Figure 4-5. NEFL mutations and the corresponding protein domains 
Genomic organization of the human NEFL gene is shown on the top and the functional domains 
of the coding protein NFL is illustrated on the bottom. The two NEFL mutations identified in this 
study are highlighted. Multispecies alignment of the peptide sequences demonstrated the strict 
conservation of the amino acid L311 where the novel mutation is localized. Pink star: novel 
mutation 
 
(2) Clinical features 
Clinical features of the patients with NEFL mutations are summarised in table 4-3. The two 
patients presented with distinct phenotypes. N-I who carried P8L mutation had a classical CMT 
phenotype with onset in the second decade of his life. His father had similar symptoms and signs. 
NCS revealed a demyelinating neuropathy compatible with CMT1 and the sural nerve biopsy 
showed features of demyelination and remyelination with onion bulbs. N-II who harboured the 
L311P mutation had a late-onset sensorimotor neuropathy with walking difficulty as the 
presenting symptom in the fifth decade. His mother and sister were also affected by peripheral 
neuropathy. Neurophysiology was compatible with demyelinating neuropathy with secondary 
axonal loss.  
Table 4-3. Clinical features of patients with NEFL mutations 
Patient N-I N-II 
DNA No. 38295 49358 
Mutation P8R L311P* 
Gender M M 
Inheritance AD AD 
Age of onset <20y/o >50y/o 
Neurophysiology CMT1 CMT1 
* Novel mutation; M= male; F= female; AD= autosomal dominant; AR= autosomal recessive 
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4.2.4 Discussion 
Two NEFL mutations were identified in two unrelated patients, accounting for an approximate 
1% hit rate in the selected cohort. In the overall population included in the above mentioned 
CMT genetic epidemiological study, mutations in NEFL were identified in 0.5% of CMT 
patients who attended the inherited neuropathy clinic at NHNN and in 0.2% of external patients 
whose DNA samples were sent to our laboratory.(Murphy et al. 2012) These findings suggest 
that mutations in the NEFL gene are a rare cause of CMT in the UK population. 
 
The two patients had variable ages of onset. Our findings suggested that NEFL mutation should 
be considered in CMT patients with variable age of onset when mutations in common genes 
have been already excluded. 
 
This study identified mutations in two distinct domains of NFL, indicating the significance of 
their functions. Each domain of NFL has been documented to play an important role in 
neurofilament formation and transport. In vitro studies have shown that mutations in the head 
domain caused disruption of neuroﬁlament assembly and transport and affected intracellular 
localization of mitochondria.(Brownlees et al. 2002; Yates et al. 2009) The coil/rod domain 
determines neurofilament architecture and NEFL mutations in the fragment would cause 
reduction in self-assembly of NFL .(Lee et al. 2008)  
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4.3 Mutation analysis of the upstream untranslated region of PMP22 in CMT1 
 
4.3.1 Introduction 
CMT1A, the commonest form of CMT, is caused by a duplication of a 1.4 Mb fragment on 
chromosome 17 where the PMP22 gene is localized or by point mutations in the PMP22 gene. 
Hereditary neuropathy with liability to pressure palsies (HNPP) is characterised by recurrent 
nerve palsies at points vulnerable to pressure and is caused by either deletion of the same 
fragment on chromosome 17 or more rarely by PMP22 mutations.(Nelis et al. 1998) The 
identification of the two allelic disorders suggested adose-dependent mechanism of PMP22-
related diseases.(Braathen 2012; Li et al. 2013)  A wide range of age of onset and variable motor 
or sensory involvement have been observed in patients with PMP22-related diseases, both 
within and among families.(Boerkoel et al. 2002; Li et al. 2013) Additional modifying genetic 
factors are believed to contribute to the phenotypic heterogeneity. 
 
PMP22 gene encodes peripheral myelin protein 22 (PMP 22) which is mainly expressed in 
myelinating Schwann cells.(Snipes et al. 1992) In vivo, expression of PMP22 is regulated by 
two alternate promoters:  promoter 1 (P1) containing exon 1A and promoter 2 (P2) containing 
exon 1B (figure 4-6). High levels of the transcripts expressed by P1 occur in the neural tissue 
and during myelin formation. Transcripts expressed by P2 are ubiquitously found in non-neural 
tissues such as lung, intestine, heart, and skeletal muscle.(Manfioletti et al. 1990; Nelis et al. 
1998; Suter et al. 1994)  
 
 
Figure 4-6. Two sets of promoters regulate the transcription of PMP22 
Exons are identified by numbers above filled boxes. Exon-1a (Ex1a) containing transcripts are 
predominantly expressed  in myelinating schwann cells. Exon-1b (Ex 1b) containing transcripts 
are expressed in non-neuronal cells. Ex1a and 1b are the transcripts of exon 1 produced by the 
regulation of promoter 1 (P1) and promoter 2 (P2). (modified from Li 2012)  
 
In addition to the two tissue-specific promoters, there are many other transcriptional regulatory 
regions in the 5’UTR of PMP22. It has been documented that an essential element required for 
Schwann cell specific expression is contained at 300bp upstream of the start point for 
transcription.(Suter et al. 1994) Two distinct transcriptional regulatory regions at  −1,600 and 
−2,100 bp of PMP22 were subsequently identified.(Saberan-Djoneidi et al. 2000) These regions 
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can regulate PMP22 expression by interacting with the silencer of the PMP22 promoter CREB 
(cAMP response element binding protein) or the enhancer of PMP22 transcription SREB (sterol 
regulatory element binding protein).(Desarnaud et al. 2000; transcription SREB (sterol 
regulatory element binding protein).(Desarnaud et al. 2000; Desarnaud et al. 1998; Li et al. 
2013; Saberan-Djoneidi et al. 2000) In another further upstream region (-4000bp of PMP22), 
there are also several microdomains which are potential binding sites for other transcription 
factors.(Maier et al. 2003; Sinkiewicz-Darol et al. 2010) (figure 4-7). 
 
 
Figure 4-7. The upstream regulatory elements of the human PMP22 gene. 
Potential binding sites for transcription factors Oct6, PRAR, HMGI, Egr-1, Egr-2, Brn-2, PRBS, 
SREB, CREB in the upstream of human PMP 22 gene and the two promoters were 
marked.(modified from Sinkiewica-Darol et al., 2010) 
 
Previous studies showed that mutations in the nerve specific PMP22 promoter and 5' 
untranslated exon were not a common genetic cause of CMT1A. This study was therefore 
conducted to determine the frequency of mutation/variations in the PMP22 promoter region in 
CMT1.  
 
4.3.2 Patients and methods 
800bp upstream of the transcription start of PMP22 including the nerve specific promoter was 
directly sequenced in 520 patients with clinical diagnosis of CMT1 but negative for PMP22 
duplication or point  mutations and mutations in the MPZ, GBJ1, LITAF and GDAP1 genes. 
Patients included in this cohort belonged to autosomal dominant families or were sporadic. 
 
4.3.3 Result  
No nucleotide variation in the PMP22 promoter region was identified in any of the patients.  
 
4.3.4 Discussion 
It has been speculated that variants in the upstream region of PMP22 can alter the expression of 
the gene and may be either a cause or genetic modifier of CMT. Nelis et al. first screened a 
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500bp long 5' regulatory sequence of PMP22 in a small group of CMT1A patients using single 
strand conformation polymorphism (SSCP).  Only one –141C>G single nucleotide 
polymorphism (SNP) variant was found in a single CMT patient..(Nelis et al. 1998)  To improve 
the low mutation detection ratio of SSCP, Sinkiewicz-Darol et al. then screened the upstream 
regulatory regions of PMP22 by direct sequencing and the investigated region was further 
extended to -3600 bp encompassing numerous binding sites for transcription factors and 
regulatory motifs which were recognized after the Nelis study.(Maier et al. 2003; Sinkiewicz-
Darol et al. 2010) Nevertheless, the intensive analysis only detected five SNP variants with 
undetermined significance and indicated that mutations in the promoter are not common in 
CMT1. Our results supports previous observation that the nerve-specific PMP22 promoter 
region and it upstream region are highly conserved in evolution and rarely mutated.  
 
In conclusion this study confirmed that mutations in the upstream untranslated region of PMP22 
are not a common cause of CMT1. The structure of the region containing the nerve specific 
promoter is highly conserved, supporting the biological significance of the observed 
arrangement of regulatory regions.    
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4.4 Mutation analysis of PDYN, KCND3 and AFG3L2  in patients with cerebellar ataxias 
 
4.4.1 Introduction 
SCAs can be caused by polyglutamine expansions, non-coding expansions and rare 
conventional mutations in different genes. In the UK, more than 60 % of the SCA families are 
caused by  the common polyglutamine expansions SCAs (SCA1, 2, 3, 6, 7, 12, 17, and 
DRPLA).(Marelli et al. 2011) The population of patients with conventional mutations is much 
smaller than those due to polyglutamine expansions. However, the list of SCA genes leading to 
diseases through conventional mutations is rapidly increasing.(Durr 2010; Sailer et al. 2012)  
Point mutations in three genes were recently identified causing SCAs: PDYN for SCA23, 
KCND3 for SCA22/SCA19 and AFG3L2 for SCA28. Identification of these genes and their 
biological functions revealed new insights in the pathomechanisms of cerebellar degeneration 
and potential targets to modulate the disease process. 
 
The locus of SCA23 (MIM_610245) was first mapped to a 6 Mb region on chromosome 
20p12.3–p13 in a large autosomal dominant Dutch ataxia family with pure progressive ataxia 
(Verbeek et al. 2004) and subsequently mutations in the prodynorphin (PDYN) gene 
(MIM_131340) were identiﬁed in further families with progressive gait and limb 
ataxia.(Bakalkin et al. 2010) PDYN is the precursor protein for the opioid neuropeptides, α-
neoendorphin (α-NE),  dynorphins A and B (Dyn A and B). Dynorphins regulate pain processing 
and modulate the rewarding effects of addictive substances.  
 
The SCA22 locus (MIM_607346) was initially mapped to chromosome 1p21-q23 in a four-
generation Chinese family with ADCA.(Chung et al. 2003) Subsequently, the disease loci in a 
French family and an Ashkenazi Jewish American family were also mapped to this region, 
overlapping with the locus of SCA19.(Schelhaas et al. 2004; Verbeek et al. 2002) Recently, 
missense mutations and chromosomal rearrangements in the voltage-gated potassium channel 
Kv4.3-encoding (KCND3) gene were identified  in  affected families with both SCA22 and 
SCA19.(Duarri et al. 2012; Lee et al. 2012) Most of the affected individual presented with 
slowly progressive pure cerebellar ataxia, but a few patients had additional features, such as 
ophthalmoplegia, sensory neuropathy, hyperreflexia, cogwheel rigidity, or urinary 
urgency/incontinence in the absence of pyramidal involvement.(Lee et al. 2012) The encoding 
protein of KCND3, Kv4.3, is an alpha subunit of the Shal family of the A-type voltage-gated K+ 
channels which is highly expressed in the brain, particularly in the cerebellum.(Tsaur et al. 1997) 
Kv4.3 is important in membrane repolarization of excitable cells and may play a significant role 
in the development of the cerebellum.(Hsu et al. 2003; Oberdick et al. 1998; Tsaur et al. 1997) 
The identification of pathogenic KCND3 mutations in SCAs emphasizes the important role of 
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ion channels as key regulators of neuronal excitability in the pathogenesis of cerebellar 
degeneration. 
 
SCA28 (MIM_610246) is a form of SCA characterized by slowly progressive cerebellar ataxia 
with hyperreflexia in lower limbs, ophthalmoparesis and ptosis. The onset is usually in in early 
adulthood.(Cagnoli et al. 2006) but childhood onset has been described in some.(Edener et al. 
2010) AFG3L2, the causative gene for SCA28, encodes for a subunit of the m-AAA protease 
(ATPases associated with various cellular activities), a component of the mitochondrial ATP-
dependent metalloprotease located on the inner mitochondrial membrane. The m-AAA 
metalloproteases have been shown to play a role in the control of proteolytic quality and 
chaperon-like activities in mitochondria by degrading misfolded proteins and promoting the 
assembly of respiratory chain complexes.(Leonhard et al. 1999) It is also essential for axonal 
development and maintenance.(Edener et al. 2010) The identification of AFG3L2 mutations in 
cerebellar ataxia documented the importance of mitochondrial function in cerebellum and 
related pathways.   
 
So far, the frequency of mutations in the PDYN, KCND3 and AFG3L2 genes in the British 
population are still unknown and screening of these new identified genes would be useful to 
determine the frequency of the different genetic subtypes of SCA in UK. The aim of this study 
was to assess the frequency of mutations in PDYN, KCND3 and AFG3L2 in patients with 
hereditary ataxias. All patients were negative for all common polyglutamine expansion SCAs 
(SCA1, 2, 3, 6, 7, 17 and DRPLA). The phenotypic-genotypic correlations were also 
investigated.  
 
4.4.2 Patients and methods 
Direct sequencing of the PDYN coding exons 3 and 4 (NM_024411) and the flanking introns 
was performed in a total of 852 patients: 176 cases with autosomal dominant inheritance, 356 
sporadic cases and 320 cases with familial cerebellar ataxia (defined as the presence of at least 
two affected individuals but the inheritance is undetermined). Patients were predominantly from 
the UK (734 patients), mainly from the south of England. This study also included a group of 
patients from Greece (83 patients), Egypt (17 patients) and India (18 patients). The predominant 
phenotype was pure cerebellar ataxia (73%), and the other 27 % had additional features, such as 
neuropathy, limb spasticity, cognitive decline, myoclonus or seizures. Additional 190 patients 
with multiple-system atrophy with cerebellar features (MSA-C) were also analysed as this is a 
phenocopy of SCA23.  
 
Direct sequencing of all coding exons (exon 2 to 8) of the KCND3 gene (NM_172198) was 
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performed in 230 unrelated patients with familial cerebellar ataxia defined as above. Since 
mutations have only been identified in exon 2 and exon 3, these two exons were further 
sequenced in 180 sporadic patients with a clinical diagnosis of hereditary cerebellar ataxia.  
 
For AFG3L2 (NM_006796), genetic analyses of all the 17 coding exons and the flanking introns 
were performed in 174 unrelated patients with familial cerebellar ataxia defined as above.  
 
The diagnosis, the number of patients and the range of sequencing for each gene are listed in 
table 4-4. 
 
Table 4-4. Genes and studied cohorts of cerebellar ataxias in the chapter 
Gene Studied cohort 
No. of 
patients 
Range of sequencing 
PDYN 
(SCA23) 
1. ADCAs 176 
The two coding exons (exon 3 and exon 4) 
and the flanking introns 
2. Sporadic ataxia 356 
3. Familial cerebellar 
ataxia 
320 
  AFG3L2  
  (SCA28) 
Familial cerebellar ataxia 174 
Coding regions of all 17 exons and the 
flanking introns 
KCDN3 
(SCA22/ 
SCA19) 
1. Familial cerebellar 
ataxia 
230 
Coding regions of all 6 exons and 
the flanking introns 
2.  Sporadic ataxia 180 
Coding regions of exon 2 and 3 and their 
flanking introns 
Familial cerebellar ataxia: defined as the presence of at least two affected members but the 
inheritance is undetermined. 
 
4.4.4 Results 
(1) PDYN variants 
Three novel heterozygous PDYN variants were identified in three unrelated English patients: 
c.65G>A; p.Cys22Tyr (C22Y), c.74G>A; p.Arg25Gln (R25Q) and c.374G>A; p.Glu159Asp 
(G159D).  C22Y was considered pathogenic because it was not reported in the ESV database or 
other public genome databases; it was absent in 570 chromosomes from matched British 
controls; it was predicted to be damaging to protein function by PolyPhen2 and SIFT (table 4-5, 
p139) and it changed a highly conserved amino acid (figure 4-8, p139). The C22Y mutation was 
identiﬁed in a 55-year-old Caucasian man who developed a slowly progressive cerebellar ataxia 
at the age of 22 years. There was no history of cerebellar ataxia in his family members. On 
examination, he had dysarthria, broken pursuit on eye movements and prominent ataxia in the 
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upper and lower limbs. The reflexes were slightly brisk in the lower limbs. He also had 
infrequent seizures from the age of 15 years old. His brain MRI showed cerebellar atrophy and 
left hippocampal sclerosis. His electromyography (EMG), NCS and the muscle biopsy from the 
quadriceps were normal. The remaining two variants, R25Q and G159D, were present in the 
ESV database and both were predicted to cause benign amino acid changes and therefore they 
were rare neutral polymorphisms.  
 
Table 4-5. The PDYN mutations and rare variants detected in this study                                                                  
 
 
 
 
Figure 4-8. Conservation of mutated amino acids in the PDYN gene 
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Three of four previously reported PDYN mutations are localized in the dynorphin A (Dyn A) 
synthesis domain (figure 4-9). The three variants in this study occurred in different regions of 
the PDYN: C22Y and R25Q were located in the opioid peptides α-NE domain in exon 3, while 
G159D was located in exon 4 and lay within the propeptide region of the gene.  The functions 
of these domains are still unclear.  
 
 
Figure 4-9. Genomic structure and mutations of the PDYN gene 
The encoding protein, PDYN, contains the domains of  the opioid peptides α-neoendorphin (α-
NE), prodynorphin (Prodyn), dynorphin A (Dyn A), dynorphin B (Dyn B), and big dynorphin 
(Big Dyn) encompassing Dyn A and Dyn B. The novel putative pathogenic mutation C22Y (red) 
and the two rare neutral polymorphisms R25Q and G159D (blue) are all localized in the 
propeptide region. The locations of previously reported mutations were also shown (black). 
(modified from Bakalkin et al. 2010) 
 
(2) KCND3 and AFG3L2 variants 
One heterozygous synonymous mutation and two intronic SNPs were identified in the KCND3 
gene in 410 patients. Nevertheless, no mutation causing an amino acid substitution was 
identified in the cohort.   
 
As for AFG3L2, one missense SNP, c.2314C>T;p.L772F (rs117182113), was identified in one 
patient. Two synonymous mutations which were not reported in any population were detected 
from two unrelated patients. An additional eleven non-pathogenic SNPs were identified with 
variable frequencies. However, no presumed pathological mutation was found in the selected 
174 patients.  
 
Details of identified variants in the two genes and their frequencies in patients are listed in table 
4-6 (p141).  
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Table 4-6. KCND3 and AFG3L2 variants identified in patients with cerebellar ataxias 
Position dbSNP ID 
Mutation 
type 
cDNA Change 
Protein 
Change 
MAF in 
studied 
cohort 
(%) 
MAF 
in EVS  
(%) 
KCND3 
1:112329552 unknown intron c.1269+14G>T NA 1.7 0.0077 
1:112525085 rs17221819 synonymous c.264C>T p.(P88=) 3.9 9.5341 
1:112319899 rs72548732 intron c.1462-4G>T NA 0.24 1.3225 
AFG3L2 
18:12351360 . synonymous c.1407C>T p.(F469=) 0.57 NA 
18:12329709 . synonymous c.2379G>A p.(E793=) 0.57 NA 
18:12329644 rs117182113 missense c.2314C>T p.(L772F) 0.57 0.1461 
18:12367018 rs141538541 synonymous c.498C>T p.(S166=) 0.57 0.0308 
18:12367144 rs111696683 intronic c.400-28C>T NA 0.57 NA  
18:12371433 rs72875314 intronic c.214+158T>C NA 1.15 0.004 
18:12337322 rs117096851 intron c.2175+18G>A NA 2.87 1.2071 
18:12359920 rs8097342 intron c.752+6C>T NA 3.16 31.516
2 
18:12348285 rs11553521 synonymous c.1650A>G p.(E550=) 3.62 22.074
4 
18:12337288 rs77671335 intron c.2175+52G>A NA 4.02 3.6275 
18:12358661 rs8091858 intron c.1026+8G>A NA 4.6 2.2451 
18:12371258 rs9303771 intronic c.214+333G>T NA 24.14 0.046 
18:12351342 rs11080572 synonymous c.1389G>A p.(L463=) 33.33 31.385
5 
18:12329536 rs1129115 3’-utr c.*28G>C NA 33.91 27.718 
MAF in ESV= the minor-allele frequency data retrieved from ESV database; NA= not available; 
dbSNP ID= identifier of Database of single nucleotide polymorphisms 
(http://www.ncbi.nlm.nih.gov/snp/)   
 
7.2.4 Discussion 
This study identified one novel missense mutation (C22Y) in the PDYN gene in a patient with 
early-onset cerebellar ataxia with a negative family history. This mutation was predicted to be 
damaging and highly conserved suggesting pathogenicity. Two other PDYN variants (R25Q and 
G159D) were found in late-onset ataxia patients. They might be very rare neutral 
polymorphisms as they were detected in the ESV database; they were not well conserved and 
they were predicted to be benign and tolerated, despite absence of both changes in 570 controls.  
 
Our results provided evidence that SCA23 caused by PDYN mutations is very rare and accounts 
for a very a small proportion of patients with hereditary cerebellar ataxia. The frequency of 
PDYN mutations in our cohort is approximately 0.1 % (1/734), which is less than the 0.4% 
(4/1100) in Dutch patients(Bakalkin et al. 2010) and the 0.8% (1/119) in a US cohort.(Fogel et 
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al. 2012)  Given the rarity of its mutations, PDYN screening should be considered where the 
common ataxia genes have been excluded. 
 
Three of the four previously identiﬁed PDYN mutations (L211S, R212W, R215C) were 
localized within the DynA domain and have been proved to have toxic gain-of-function 
mediated through increased expression of Dyn A peptides and increased leakage of ions through 
the plasma membrane.(Watanabe et al. 2012) R138S was the only PDYN mutation which was 
located in the non-opioid propeptide region reported before our study. This mutation was 
predicted to create an extra serine phosphorylation site, and thus might affect processing or 
trafficking of the mutant protein. However, the association of these effects with the motor and 
coordination dysfunction is still unclear.(Bakalkin et al. 2010) However, the C22Y mutation in 
this study lies within the propeptide region of PDYN, and was not predicted to increase 
phosphorylation in this region (predicted by NetPhos 2.0 server, 
www.cbs.dtu.dk/services/NetPhos/). Further work is needed to explore the influence of the 
novel mutation on PDYN function.   
 
This study also represented the first genetic epidemiological study of KCND3 and AFG3L2 
mutations in the UK. No pathogenic variants were identified in either of these two genes 
although many variants were detected. To date, KCND3 mutations have been identified in 
patients of diverse ethnic origins.(Lee et al. 2012) Also, SCA28 was estimated to account for 
3% of the patients of non-polyglutamine expansion SCAs and for approximately 1.5% of all 
SCAs in a large-scale study with 366 European-origin patients recruited.(Cagnoli et al. 2010) 
The absence of KCND3 or AFG3L2 mutations in our patients suggests that the prevalence of 
SCA22/SCA19 and SCA28 vary in different ethnic origins and both may be very rare in the 
British population. 
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Chapter 5 
 
Results: Whole exome sequencing in patients 
with inherited neuropathies and related disorders 
 
An accurate genetic diagnosis has not been achieved in a significant number of patients affected 
by inherited neurological diseases. For example, the current detection rate of disease-associated 
mutation in HSN is less than 20%.(Davidson et al. 2012). Similarly, only approximately 60% of 
patients with cerebellar ataxia receive a definite genetic diagnosis.(Sailer et al. 2012) The 
difficulty in achieving a genetic diagnosis are likely due to the limitations in genetic technology 
to test all the possible known genes, but also because many disease-associated genes and 
mutation types have not been discovered yet. It is possible that many unknown mutations are 
deep intronic changes, large deletions or insertions or novel repeat expansions. This chapter 
describes the application of WES in genetic diagnosis of complex syndromes which could not 
be diagnosed by conventional approach, including HSN complicated by additional features 
(HSN-plus syndromes), ARCAs and recessive CMT6 (axonal neuropathy with optic atrophy). 
Mutations in DNMT1, ADCK3 and SACS were successfully detected, documenting that WES 
can identify pathogenic mutations efficiently in genes which are associated with different 
phenotypes but too large or rare to be routinely screened. WES was also helpful in detecting 
mutations in novel disease-causing gene, such as the RNF216 gene in a family with ARCA. A 
few potential candidate genes for inherited neuropathies were identified through WES including 
PDXK gene in a case of recessive ARCMT2 with optic atrophy and WFS1 and NAV2 genes in 
HSN-plus syndromes.  
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5.1 Overview 
 
5.1.1 Patients and Methods 
WES was performed in patients affected by the following conditions in an attempt to achieve a 
genetic diagnosis:  
(1) A cohort of 17 affected individuals from 12 families who had HSN associated with variable 
degree of cerebellar ataxia, vestibular failure or sensorineuronal hearing impairment (HSN-
plus syndromes). These patients were previously extensively screened and resulted negative 
for mutations in SPTLC1, RAB7, WNK1/HSN2, FAM134B, NTRK1 (TRKA) and NGFB.  
(2) One patient with axonal neuropathy and optic atrophy (CMT6) belonging to a 
consanguineous family 
 (3) A cohort of 18 affected individuals from 16 families with ARCA associated with variable 
additional symptoms, such as spasticity, neuropathy, dystonia, myoclonus, facial 
dysmorphism, or hypogonadism. Friedreich’s ataxia, AOA1, AOA2, ATM, DYT1, SCA1-3 
and acquired aetiologies of cerebellar ataxia were previously excluded in these patients.  
 
5.1.2 Strategy of WES analysis 
For each sample, three micrograms of gDNA was used for library preparation and enrichment 
according to the manufacturer’s protocol. Exome-enriched library were subjected to massively 
parallel sequencing (100 bp paired-end reads) on Hiseq 1000 (Illumina) or Genome Analyzer 
IIx (illumine). Sequence alignment and variant calling were performed against the reference 
human genome (UCSC hg19). Details of the methods are described in Section 2.5. 
 
After total variants were generated in an excel file, benign variants were filtered out by the 
criteria mentioned in Section 2.6.2. Variants in known genes causing similar or related 
phenotypes were firstly considered. For those patients who did not carry pathogenic variants in 
known genes but had similar phenotypes, two strategies were applied to look for potential 
candidate mutation: (1) any mutated gene shared by more than one family was searched; (2) for 
each family, some variants were selected if there is supportive evidence from their gene 
expression patterns, types of mutation, in-silico prediction of pathogeniticity and functional 
impacts previously observed in animal or cellular models. For potential variants selected 
through the two above strategies, they were validated by the following methods: Sanger 
sequencing, segregation testing if further family members were available and screening of the 
genes in further cohorts of similar phenotypes. Taking HSN as an example, the pipeline of 
variants prioritization is summarised in figure 5-1 (p151). 
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Figure 5-1. Pipeline of exonic variants prioritization 
MAF= minor allelic frequency; SNV= single nucleotide variant 
 
5.1.3 Results 
Probable pathogenic mutations identified in patients with inherited neuropathies and complex 
ARCA syndromes are listed in table 5-1 (p152) and table 5-2 (p152) accordingly. The study on 
the identification of the ADCK3 mutation in a family with ARCA and myoclonus has been 
described in Section 3.4.  
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Table 5-1. Probable pathogenic mutations in inherited neuropathies identified by WES  
Phenotype DNA No.*        Gene Mutation 
Mutation in known HSN-related genes 
HSN with deafness 58800 DNMT1 
missense mutation, 
het 
c.1484A>G: p.Y495C 
Mutation in potential novel HSN genes  
AD-HSN associated with 
ataxia and deafness 
59547* WFS1 
missense mutation, 
het 
c.1067C>A:p.S345Y 
Late-onset HSN with ataxia  
53596* 
49876 
NAV2 
missense mutation, 
het 
1. c.2744C>T:p.S915F 
2. c.875A>C:p.Y292S 
ARCMT2 with optic 
atrophy 
45077 PDXK 
missense mutation, 
hom 
c.682G>A:p.A228T 
AD= autosomal dominant; AR= autosomal recessive; CMT2: Charcot-Marie-Tooth disease type 
2; HSN= hereditary sensory neuropathy; het= heterozygous; hom= homozygous; WES= whole 
exome sequencing; *only index patient is listed 
 
 
Table 5-2. Probable pathogenic mutations in complex ARCA syndromes identified by WES  
Phenotype DNA No.*        Gene Mutation 
Mutation in newly-identified genes 
  
ARCA with congenital 
ectodermal dysplasia 
54273 RNF216 Splice site, hom c.2453-2A>G 
Mutation in known ARCA-related genes 
  
ARCA with myoclonus and 
tremor 
52627 ADCK3 
frameshift insertion, 
hom 
c.1844_1845insG: 
p.S616Lfs 
ARCA with spasticity and 
demyelinating neuropathy 
25921 SACS 
frameshift deletion, 
hom 
c.5557_5561delCTTTT 
Mutation in known HSP genes 
   
ARCA with spasticity and 
axonal neuropathy 
5032 
ZFYVE26 
(SPG15) 
nonsense mutation, 
hom 
c.4312C>T:p.R1438X 
ARCA with spasticity and 
axonal neuropathy 
47681 
PNPLA6 
(SPG39) 
missense mutation, 
hom 
c.3817G>A:p.V1273M 
ARCA= autosomal recessive cerebellar ataxia; HSP= hereditary spastic paraplegia; hom= 
homozygous; WES= whole exome sequencing 
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5.2 HSN with deafness caused by a heterozygous missense DNMT1 mutation 
 
(1) Clinical feature 
WES was performed in a 43-year-old patient who developed sensory loss, ulcerations and 
painless fractures at the age of 30 and progressive hearing loss at the age of 36. He had no 
family history of neurological diseases. Neurological examination at the age of 43 showed 
reduced pinprick appreciation, vibration loss and decreased reflexes in the lower limbs. Muscle 
power was normal. Brain MRI showed mild cerebellar atrophy although there no clinical 
cerebellar signs were detectable at the age of 42. Neurophysiology was consistent with a 
sensory axonal neuropathy (table 5-3). Genetic testing for RAB7, HSN2/WNK1, FAM134B, 
SPTLC and SPTLC1 were negative.  
 
Table 5-3. Neurophysiology of the patient with DNMT1 Y495C mutation 
Sensory conduction R L Motor conduction R L 
Median nerve 
  
Median nerve 
  
 
SNAP (uV) NR Abs 
 
DML (ms) NR 3.5 
 
CV (m/s) NR Abs 
 
CMAP (wrist) (mV) NR 8.2 
Ulnar nerve 
   
CMAP (elbow) (mV) NR 7.5 
 
SNAP (uV) NR Abs 
 
CV (m/s) NR 53 
 
CV (m/s) NR Abs 
 
Minimum F-latency (ms) NR 28.3 
Radial nerve 
  
Ulnar nerve 
  
 
SNAP (uV) NR 4 
 
DML (ms) NR 2.7 
 
CV (m/s) NR 56 
 
CMAP (wrist) (mV) NR 12.6 
Sural nerve (calf-ankle) 
  
CMAP (above elbow) 
(mV) 
NR 11.2 
 
SNAP (uV) Abs NR 
 
Minimum F-latency (ms) NR 28.0 
 
CV (m/s) Abs NR Common peroneal nerve 
 
Superficial Peroneal nerve (calf-ankle) DML (ms) 3.4 NR 
 
SNAP (uV) Abs NR 
 
CMAP (ankle) (mV) 5.3 NR 
 
CV (m/s) Abs NR 
 
CMAP (fib. Neck) (mV) 4.2 NR 
     
CV (fib. Neck-ankle) 
(m/s) 
34 NR 
     
Minimum F-latency (ms) 54.3 NR 
Concentric Needle EMG Posterior Tibial nerve 
 
R Tib Ant No spontaneous activity DML (ms) 4.9 NR 
R FDIO Normal motor units recruiting  CMAP (ankle) (mV) 5.7 NR 
  
normally to a full interference pattern  Minimum F-latency (ms) 55.1 NR 
Age at examination= 42; Abs= absent; CMAP= compound motor nerve action potential (mV); 
CV= conduction velocity (m/s); DML= distal motor latency; EMG= electromyography FDIO= 
first dorsal interosseous; L= left limbs; NR= not recorded; R= right limbs; SNAP= sensory 
nerve action potential (uV); Tib Ant= tibialis anterior. 
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(2) Genetic analysis 
Both heterozygous and homozygous variants were analysed as the patient is the only known 
affected member in the family. There were 285 heterozygous variants after filtering out benigh 
variants. Among them, a heterozygous missense mutation, p.Tyr495Cys (Y495C), in the DNA-
methyltransferase 1 gene (DNMT1) was considered to be the causative mutation as it has been 
previously reported in patients with HSN-IE, is a subtype of HSN-I which typically presented 
by sensory neuropathy and hearing loss as the presenting symptoms between the age of 20 and 
35 and dementia subsequently in the fourth decade.(Klein 2012; Klein et al. 2011, also see table 
1-2) The mutation was subsequently validated by Sanger sequencing. The process of whole 
exome analysis is summarised in figure 5-2. 
 
 
Figure 5-2. Whole exome sequencing of the patient with HSN and deafness 
(A) The process of prioritizing exonic variants. DNMT1 Y495C is revealed as the causative  
      mutation after analysis. 
(B) Heterozygosity and the sequencing depth (73X) of the exonic variant shown by IGV.  
(C) Chromatogram from the patient. This mutation has been validated by Sanger sequencing. 
 
(3) Discussion 
DNMT1 plays a crucial role in maintenance of methylation, gene regulation and chromatin 
stability. DNA mismatch repair, cell cycle regulation in post-mitotic neurons and neurogenesis 
are influenced by DNA methylation.(Klein et al. 2011) Mutations in DNMT1 were first 
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associated with HSN-IE and subsequently documented in cases of autosomal dominant 
cerebellar ataxia, deafness and narcolepsy (ADCA-DN), clinically characterised by late-onset 
(30-40 years) narcolepsy-cataplexy, deafness, cerebellar ataxia and variable 
dementia.(Winkelmann et al. 2012) Both HSN-IE and ADCA-DN have sensory neuropathy and 
cerebellar ataxia as parts of the syndrome but present in different ways. Patients with HSN-IE 
often have sensory neuropathy as the presenting symptoms during early adulthood and the 
cerebellar involvement usually occurs later and to a lesser degree, whereas patients with ADCA-
DN have marked cerebellar dysfunction followed by sensory neuropathy at a later stage of the 
disease during the sixth decade. So far, all reported HSN patients had dementia or cognitive 
impairment though the age of onset was variable. (Klein 2012; Klein et al. 2013; Yuan et al. 
2013) Clinical features of patients with reported DNMT1 mutations are summarised in table 5-4 
(p157).  
 
This study documents how WES can rapidly detect mutations in a rare gene like DNMT1 in 
patients with sensory neuropathy and profound deafness but not developed signs of dementia, 
atypical to previously reported HSN-IE cases. The mutation in our patient occurred at Tyr495, 
which is a highly conserved amino acid residue localized within the critical targeting-sequence 
domain of DNMT1 (figure 5-3) and has been proposed as a hot spot for HSN-IE associated 
DNMT1 mutations.(Klein et al. 2013; Klein et al. 2011; Yuan et al. 2013) Our finding supports 
the hypothesis. 
 
Figure 5-3. Location and conservation of DNMT1 Thy495. 
Top. Functional domains of DNMT1 in the N-terminal region are illustrated: PBD=PCNA-
binding domain; TS= targeting sequence; ZnF= zinc finger; BAH1 & 2= bromo adjacent 
homology domains 1 and 2. Bottom. Alignment of the part of the targeting sequence domain 
shows Y495 (red arrow head) is strictly conserved across different species. (modified from 
(Klein et al. 2011) 
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Our results suggest that DNMT1 mutations can be associated with HSN and deafness without 
cognitive involvement although this may develop later since the patient is only 43.  A 
longitudinal follow-up and neuropsychological evaluation are warranted in this patient. The 
study documented that DNMT1 mutations can be associated with variable phenotypes.  Because 
of the possibility of cognitive impairment in an advanced course, genetic testing for DNMT1 
mutations in patients with a pure sensory neuropathy will require more ethical consideration and 
detailed counselling.(Rossor et al. 2013) 
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5.3 ARCA with congenital ectodermal dysplasia caused by a splicing RNF216 mutation 
 
An autosomal recessive family affected by congenital ectodermal dysplasia and cerebellar 
ataxia was studied. WES was performed in the index patient and his asymptomatic father. The 
patient had congenital ectodermal dysplasia and developed cerebellar ataxia in early-adulthood. 
His parents were consanguineous and of Indian origin (the pedigree is shown in figure 5-4, C, 
p159). Genetic analysis is summarised in figure 5-4, A. After filtering out benigh variants, 15 
homozygous variants were first selected in the index patient as they were shared by the father 
(FV-2) in heterozygous status. Among these 15 variants, a homozygous splicing variant, c.2453-
2A>G, in the ring finger protein 216 gene (RNF216) was considered probable pathogenic 
because that recently homozygous or compound heterozygous mutations in RNF216 were 
identified to cause the syndrome of ataxia, hypogonadotropic hypogonadism and dementia in 
several families.(Margolin et al. 2013; Seminara et al. 2002; Shi et al. 2014) Further evidence 
supported the pathogenic role of this novel splicing mutation includes: (1) both asymptomatic 
parent were documented to carry the heterozygous variant (figure 5-4, C), thus confirming the 
segregation of this mutation; (2) it has so far not reported in any public database; (3) it was 
absent in 220 control exomes; (4) the mutation was predicted to cause loss of a splice site by 
five different soft wares (figure 5-5, p160).  
 
The protein encoded by RNF216 interacts with the receptor-interacting serine/threonine-protein 
kinase 1 (RIPK1), which is involved in the TNF-induced NF-κB activation pathways and 
programmed cell death. The variant was predicted to cause loss of a splice site in the zinc finger 
domain of the encoded protein, which is required for its interaction with RIPK1. The encoded 
protein may also function as an E3 ubiquitin-protein ligase which accepts ubiquitin from E2 
ubiquitin-conjugating enzymes and transfers it to substrates. Knockdown of rnf216 in zebrafish 
embryos induced defects in the eye, optic tectum, and cerebellum, which were rescued by wild 
type human RNF216 mRNA.(Margolin et al. 2013)  
 
RNF216 is a newly-identified gene related to ARCA and its phenotypic spectrum is still not 
understood completely. The study suggests that different types of RNF216 mutations may lead 
to a wide range of phenotypes. Our patient presented differently from other reported patient 
with RNF216 mutations: congenital ectodermal dysplasia was first reported and no sign of 
hypogonadism or cognitive impairment at least until 36 years old. Follow-up is necessary to 
monitor if signs suggesting dementia will occur in the future.  
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Figure 5-4. Whole exome sequencing of the family with ARCA and congenital ectodermal 
dysplasia 
(A) The process of prioritizing exonic variants. A homozygous splicing mutation in RNF216 
is selected after pooling with the exome of the patient (FV-1), the heterozygous carrier (FV-2) 
and another family with ARCA.(Margolin et al. 2013; Seminara et al. 2002) Numbers in flank 
indicate the numbers of exonicvariants pass filtering. 
(B) Homozygosity and the sequencing depth (47X) of the mutation shown by IGV.  
(C)Pedigree of the family.=Index patient.  = affected member, /= unaffected 
members.WES was performed in members with a red arrow. Sanger sequencing validated that 
the mutation is segregated with the phenotype within the family. 
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Figure 5-5. RNF216 mutation c.2453-2A>G is predicted to cause loss of a splice site 
The five soft wares used to predict the effect of a splicing mutation are listed on the left side. 
Exonic sequence is shaded grey, intronic sequence is unshaded. Predicted 5' and 3' splice site 
junctions are highlighted by blue or green arrows. The location of the mutation is highlighted by 
red bars, linked between the two halves of the screen by a blue line. Green bars (3') illustrate the 
consensus scores for the 4 splice-site analysis tools used by the software. The maximum score 
for each program is shown to the left of the bars.(Courtesy of Dr. James Polke from 
Neurogenetics Unit, National Hospital for Neurology and Neurosurgery, London.) 
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5.4 Potential candidate genes for inherited neuropathies 
 
5.4.1 A novel heterozygous WFS1 mutation associated with autosomal dominant sensory 
neuropathy-ataxia-deafness syndrome 
(1) Clinical feature 
WES was performed in a family with AD-HSN complicated with cerebellar ataxia and 
sensorineural hearing loss with the attempt to establish the genetic diagnosis (pedigree shown in 
figure 5-6, A, p160). The 15-year-old index patient (III-1) had experienced unsteadiness since 
her childhood. Simultaneously with the onset of gait imbalance, she had numbness and painful 
sensation in the feet. However, she felt little pain even when she had a fracture of her ankle. 
Scoliosis was noted at the age of three. Sensorineural hearing loss was diagnosed in her second 
decade and slowly progressed over the years. One of her older siblings (III-2), had sensory 
impairment, unsteadiness, scoliosis and hearing loss with the onset in teenage years. Their father 
(II-1) developed hearing loss and scoliosis in his early 20s. He also had mild ataxic gait and 
sensory loss in four limbs. The paternal aunt (II-2) was affected by an asymmetric sensory 
neuropathy with substantial autonomic involvement which was diagnosed as Sjogren’s 
syndrome. The paternal grandmother (I-1) was reported to have scoliosis and gait unsteadiness.   
 
Neurological examination at the age of 14 showed the index patient (III-1) had a wide-based 
ataxic gait. She had overshooting tremor in her hands. Sensory examination showed reduction 
of pinprick appreciation distally in the upper limbs up to the elbows and in the lower limbs 
higher than knees. Vibration and position sense were impaired up to the knees. She was 
areflexic and plantars were down going. Muscle power was normal. Brain MRI performed at 
age 14 revealed an atrophic cerebellum. Neurophysiology showed severely reduced or absent 
SAPs, normal or mildly slowed NCV and normal motor responses in the upper and lower limbs, 
consistent with a sensory axonal neuropathy. NCS in the father (II-1) was also compatible with a 
sensory axonal neuropathy but milder than his daughter. Genetic testing for GJB1, PMP22, 
FRDA, RAB7, HSN2, NGFB, FAM134B, SPTLC1, POLG, and ATL1 were negative. 
 
(2) Genetic analysis 
WES was performed in the patient (III-1), her father (II-1) and her aunt (II-2). Genetic analysis 
is summarised in figure 5-6, B (p162). After filtering out benign variants, 102 heterozygous 
variants were shared by the patient (III-1) and her father (II-1). Variants were then divided into 
two groups: those shared by the aunt (II-2) and those not shared by her. A heterozygous 
missense mutation in SETX was first selected because homozygous or compound heterozygous 
mutations in this gene can cause AOA2. However, the variant was excluded since Sanger 
sequencing showed that the affected sibling (III-2) does not carry this variant.  
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Figure 5-6. Whole exome sequencing of the family with autosomal dominant sensory 
neuropathy-ataxia-deafness syndrome 
(A) Pedigree of the family. The phenotype of each individual is listed in the flank.=Index 
patient.  /= affected members, /= unaffected members,= members who are uncertain 
affected by the same disease.WES was performed in members with a red arrow.  
(B) The process of prioritizing exonic variants. WFS1 S356Y is determined to be the 
causative mutation after analysis and validated by Sanger sequencing. Numbers in flank indicate 
the numbers of exonic variants pass filtering.  
 
? 
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Taking into consideration the tissue expression patterns, the evidence from animal or cellular 
models and interacting protein networks, a total of ten variants, six shared by all three 
individuals and four shared only by the index case and her father, were selected as potential 
candidates and then tested in the affected sibling (III-2) by Sanger sequencing. Three variants 
were also presented in the affected brother. Among them, a novel missense mutation, 
c.C1067A:p.Ser356Tyr (S345Y), in the Wolfram syndrome 1 gene (WFS1) was considered to be 
a probable pathogenic mutation due to its predicted malignant functional impact and the high 
conservation of the amino acid Ser356 (figure 5-6, B; figure 5-7, B). WFS1 mutations have been 
associated previously with sensorineural hearing loss, ataxia and peripheral neuropathy. 
 
The coding product WFS1 protein, also called wolframin is a type II membrane protein with 
nine putative transmembrane segments, which is located primarily in the endoplasmic reticulum 
(ER) and highly expressed in brain, pancreas, heart, and insulinoma beta-cell lines.(Hofmann et 
al. 2003; Takeda et al. 2001) So far, most of the mutations leading to Wolfram syndrome were 
detected in the transmembrane domains, particularly in exon 8 (Hansen et al. 2005; Zmyslowska 
et al. 2011), as well as the S356Y mutation identified in the reported family (figure 5-7, A).   
 
 
Figure 5-7. Location and conservation of WFS1 Ser356  
(A) Primary and secondary structures of the WFS1 protein. Numbers indicate the amino 
acid residues. The cytoplasmatic regions are yellow, the endoplasmic regions are green and the 
transmembrane α-helices are blue. The S356Y mutation is localized in the transmembrane 
domain.(modified from Hansen et al. 2005)  
(B) Alignment of human WFS1 protein with homologs of other species. S356 is a highly 
conserved among mammals. 
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(3) Discussion: 
Homozygous or compound heterozygous WFS1 mutations were first recognised to cause the 
autosomal recessive Wolfram syndrome (WFS), also called Diabetes Insipidus, Diabetes 
Mellitus, Optic Atrophy, and Deafness (DIDMOAD), a progressive neurodegenerative disorder 
characterised by childhood to early adolescence onset diabetes mellitus and optic 
atrophy.(Smith et al. 2004). On the other hand, heretozygous missense mutations in the WFS1 
gene have been appreciated as a frequent cause of autosomal dominant non-syndromic low 
frequency sensorineural hearing loss (LFSNHL), particularly in Asia.(Bespalova et al. 2001; 
Fukuoka et al. 2007; Tsai et al. 2007) LFSNHL is a rare dominant condition which affects only 
2000 Hz and below is an unusual type of hearing loss that worsens over time without 
progressing to profound deafness. The identification of WFS1 as the causative gene 
subsequently proved that LFSNHL is the allelic disorder of autosomal dominant deafness 6 
(DFNA6), another condition characterised by congenital, slowly progressive, low-frequency 
(<2000 Hz) sensorineural hearing loss and more frequently seen than LFSNHL. Further study 
reported affected individuals with LFSNHL in the DFNA6 family.(Bespalova et al. 2001; 
Fukuoka et al. 2007; Tsai et al. 2007) Recently, heterozygous WFS1 mutations were also 
identified in many autosomal dominant pedigree with various symptoms, including optic 
atrophy, hearing loss, psychiatric disorders, ataxia, peripheral neuropathy, dementia and urinary 
tract abnormalities.(Chakrabarti et al. 2009; Hogewind et a;. 2010; Johansson et al. 2013; 
McHugh and Friedman 2006) Although the clinical significance of these heterozygous 
mutations is still undetermined, WFS1 is suggested to have modifier effects in a broad spectrum 
of disorders and produce a phenotypic continuum. WFS1 is ubiquitously expressed and its 
coding protein interacts diffusely with many molecules, such as ATPase, the adenyl cyclase and 
ubiquitin ligase.(Fonseca et al. 2012; Gharanei et al. 2013; Guo et al. 2011) This may explain 
the involvement of multiple neurological and non-neurological systems associated with both 
homozygous and heterozygous WFS1 mutations. 
 
As for manifestations of our family, the late-onset sensorineural hearing loss and cerebellar 
ataxia might be related to a less severe loss-of-function effect brought from a heterozygous 
mutation when comparing with the typical Wolfram syndrome. To consolidate the pathogenic 
role of this mutation, screening of a large cohort of similar phenotype and further functional 
studies are warranted.  
 
 
 
 
 
165 
 
5.4.2 NAV2 mutations associated with late-onset sensory neuropathy and cerebellar ataxia  
 
(1) Genetic analysis 
In the cohort of HSN-plus syndromes, two families with late-onset sensory neuropathy and 
cerebellar ataxia shared a common mutated gene: the neuron navigator 2 gene (NAV2) 
(pedigrees shown in figure 5-8, A). Each family carried a novel heterozygous missense mutation 
in NAV2: c.875A>C;p.Thy292Ser (Y292S) was in FII and c.2744C>T;p.Ser915Phe (S915F) in 
FIII. Both mutations were not reported in any public database,  changed a highly conserved 
amino acid codon (figure 5-8, C) and were predicted to have damaging effects by Polyphen and 
SIFT. 
 
Figure 5-8. NAV2 mutations in families with late-onset sensory neuropathy and cerebellar 
ataxia  
(A) Pedigree of the two families with NAV2 mutations. The three affected patients of the 
family FII carried S915F mutation and patient FIII-1 carried Y292S mutation. /= affected 
members, /= unaffected members,=Index patient.WES was performed in members with a 
red arrow. Numbers in the pedigree refers to the current age or age when deceased. AO= age of 
onset. 
(B) Locations of the two novel NAV2 mutations. Y292S is in exon 6 whereas S915F is 
localized in exon 11. The range of the AAA+ATPase (ATPases associated with various cellular 
activities) domain and the P-loop NTPase domain are also illustrated. 
(C) Alignment of the human NAV2 protein with homologs of multiple species. Both S915F 
and Y292 are conserved among mammals.   
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(2) Clinical features 
The three affected siblings in family FII developed unsteadiness which was worse in the dark in 
their fifth decade. They also had numbness in the distal upper and lower limbs. Neurological 
examination of the three brothers (at the age of 67 for FII-1, 68 for FII-2 and 71 for FII-3) all 
showed had an ataxic gait, positive Romberg sign and sensory impairment of all modalities in 
the distal upper and lower limbs. In addition, they all had nystagmus and dysarthria with a 
variable severity. Their parents were not consanguineous and had no neurological diseases at 
least until the age of 70. Neurophysiology in the three brothers showed absent SAPs and 
preserved motor amplitudes in upper and lower limbs, compatible with a sensory axonal 
neuropathy. Brain MRI of FII-2 performed at the age of 64 was normal.  Before WES, they were 
tested negative for mutations in SPTLC1, MFN2, HSN2, NGFB, RAB7, FRDA, Fragile X, PEO1 
hot spots and POLG. SCAs type 1, 2, 3, 6, 7 and common mitochondrial mutations were also 
excluded. 
 
FIII-1 developed unsteadiness and numbness of the distal limbs at the age of 40. Neurological 
examination at age 57 showed an ataxic gait, dysarthric speech, rotational nystagmus on 
horizontal and upper gaze and brisk reflexes in lower limbs. His parents were not 
consanguineous: his father was diagnosed with Parkinson disease at the age of 55, and the 
mother currently at the age of 90 is quite healthy. NCS of FIII-1 showed absent SAPs in upper 
and lower limbs with normal motor responses, compatible with a sensory axonal neuropathy.  
 
(3) Discussion 
NAV2 encodes a member of the neuron navigator gene family and carries some functionally 
critical domain like the AAA+ATPase domain. Genes carrying the AAA+ATPase domain have 
been known to be involved in variable neurological syndromes, like AFG3L2 mutations in 
cerebellar ataxia and spasticity (SCA28), SPAST and SPG7 mutations in HSP.  
 
NAV2 was first identified as an all-trans retinoic acid (atRA)-responsive gene in human 
neuroblastoma cells (retinoic acid-induced in neuroblastoma 1, RAINB1). NAV2 is essential for 
neurite outgrowth and axonal elongation. Transgene overexpression of NAV2 rescued the axonal 
elongation defect in the Caenorhabditis elegans unc-53 mutant, indicating that Nav2 is an 
ortholog of unc-53 that is required for cell migration and axonal outgrowth.(Muley et al. 2008) 
 
The coding protein of NAV2 is located both in the cell body and along the length of the growing 
neurites of SH-SY5Y cells in a pattern that closely mimics that of neurofilament and 
microtubule proteins. There is evidence suggesting that the NAV2 protein may also act by 
facilitating interactions between microtubules and other proteins such as neurofilaments that are 
167 
 
key players in the formation and stability of growing neurites. Transfection of Nav2 deletion 
constructs in Cos-1 cells revealed a region of the protein (aa 837-1065) that could direct 
localization with the microtubule cytoskeleton.(Muley et al. 2008) The S915F mutation carried 
by one of our patients is exactly localised in the region.  
 
Transgenic mice with Nav2 hypomorphic mutant could develop sensory deficits and impaired 
hearing, mimicking the manifestations of our patients.(Peeters et al. 2004) Abnormal cerebellar 
development were also observed in mice lacking the full-length Nav2 transcript.(McNeill et al. 
2011) The above evidence supports that NAV2 is important in the nervous system and maybe a 
good candidate gene for the HSN-ataxia syndrome. Using a region of NAV2 that independently 
associates with the cytoskeleton as bait in a yeast-two-hybrid screen, NAV2 was recently 
identified to be able to interact with 14-3-3ε via a 200-amino acid internal domain.(Marzinke et 
al. 2013) Knockdown of 14-3-3ε leads to a decrease in atRA-mediated neurite outgrowth, 
similar to the elongation defects observed when NAV2 is depleted or mutated. Likewise, 
microtubule defects in C. elegans fed unc-53 RNAi are similar to those fed ftt-2 (a 14-3-3 
homolog) RNAi. The discovery provides further insight into the mechanism by which NAV2 
participates in neuronal migration and elongation, and makes sense of NAV2 mutation in 
neurodegenerative process. 
 
Considering the late onset of symptoms in our affected individuals and multiple lines of 
evidence from the in-vitro cellular modal and the knock-down animal modal, the two novel 
missense mutations in NAV2 are supposed to cause the disease through haplotype insufficiency 
or loss of function. In order to confirm its pathogenicity, it is necessary to do further studies, 
including validation by Sanger sequencing in affected individuals, familial segregation analysis, 
and screening in larger cohorts of patients with similar phenotype and cellular or animal studies.  
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5.4.3 A homozygous PDXK mutation associated with recessive CMT2 and optic atrophy 
 
(1) Clinical feature 
WES was performed in a patient (II-6 in figure 5-9, B, p169) from a Greek Cypriot-origin 
family who was affected by childhood-onset motor and sensory neuropathy followed by optic 
atrophy during adulthood. The proband (II-6) developed distal wasting and weakness of the 
lower limbs at the age of 7 and upper limbs weakness at the age of 12. The symptoms were 
progressive and at the age of 57 he had difficulty in climbing stairs and weakness of grip.  
Sensation of all modalities in all limbs was reduced. He developed progressive vision 
impairment at the age of 47. Neurological examination at the age of 7 showed distal weakness 
and wasting of the intrinsic muscles of the hands and the distal lower limbs. He had pes cavus, 
areflexia and flexor plantar responses. There was glove and stocking sensory loss to all 
modalities. Romberg's sign was positive. Visual fields were constricted with a central scotoma. 
Fundoscopy showed bilateral optic disc atrophy. NCS at the age of 57 showed absent SAPs in 
the upper and lower limbs, absent motor responses or severely reduced MAPs with preserved 
MNCV, compatible with sensorimotor axonal neuropathy in CMT2. Optic nerve and chiasm CT 
was normal. His sister (II-7) developed wasting and weakness of the lower limbs when aged 9 
years and weakness of the upper limbs when aged 12. At the age of 54, she could not run or 
walk more than 200 yards, and had significant weakness of grip. Impaired vision was noted at 
the age of 50. Examination at age 54 revealed reduced glove and stocking sensory loss of all  
modalities, positive Romberg's sign, pes cavus, wasting of the intrinsic muscles of the hand and 
pronounced weakness of dorsiflexion and plantar flexion of the feet. She was areflexic with 
flexor plantar responses. Her gait was high stepping and there was bilateral optic disc pallor.  
NCS at the same age also showed features suggesting sensorimotor axonal neuropathy: 
unrecordable SAP in all sampling nerves, absent CMAP in lower limbs and reduced CMAP in 
upper limbs with preserved NCV. The third sibling (II-4) was considered affected on the basis of 
history provided by relatives. She developed distal wasting and weakness when aged 10 years 
and had progressive impairment of vision from the age of 50 years. Other siblings did not have 
any neurological or ophthalmological complaints at least until 59 years old (II-5) and 69 years 
old (case II-1). The two children of II-6 were unaffected when examined at aged 30 and 
36.Their parents who were consanguineous and unaffected at the age of 99 and 85 years. 
Mitochondrial DNA analysis did not show pathogenic Leber's hereditary optic neuropathy 
mutation. WES was performed in the proband to identify the disease-causing mutation.   
 
(2) Genetic analysis 
WES was performed in the index case (II-6). The process of prioritizing exonic variants is 
summarised in figure 5-9, A (p169). After filtering benigh variants, 18 homozygous variants 
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were identified. Five variants were kept after filtered out non-framshift indels, false positive 
variants and genes with irrelevant functions like HLA. Sanger sequencing to validate the five 
variants were subsequently performed for the patient (II-6) and his affected sister (II-7). A 
homozygous missense mutation, c.G682A;p.Ala228Thr (A228T) in the pyridoxal kinase gene 
(PDXK) was shared by the two affected individuals (figure 5-9, C). PDXK encodes the enzyme 
catalysing the ATP-dependent phosphorylation reaction of pyridoxine (vitamin B6).(Cao et al. 
2006; Musayev et al. 2007) A228T was absent in the ESV database, 221 exome sequences from 
healthy controls at UCL and 65 in-house exomes from patients with ataxia at ION. Its 
pathogenicity is further supported by the damaging effects predicted by Polyphen and SIFT.  
 
 
Figure 5-9. Whole exome sequencing of the family with recessive axonal neuropathy and 
optic atrophy 
(A) The process of prioritizing exonic variants. PDXK A228T is probably a pathogenic 
mutation after analysis. 
(B) Pedigree of the family. /= affected members, /= unaffected  members,  /= 
diseased  members =Index patient.WES was performed in members with a red arrow.  
(modified from (Chalmers et al. 1997) 
(C) Chromatography from the patient and the affected sibling. The homozygous mutation 
segregates within the family. 
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The Ala228 is a highly conserved amino acid localized in the overlapping region of pyridoxal 
phosphate biosynthesis domain and the phosphomethylpyrimidine kinase domain (figure 5-10). 
Both of the two domains harbor critical functions. The pyridoxal phosphate biosynthesis domain 
is the key region participating in the biosynthesis of pyridoxal-5-phosphate (PLP), the active 
form of vitamin B6 (pyridoxine or pyridoxal). The phosphomethylpyrimidine kinase domain, 
also known as HMP-phosphate kinase, catalyses the phosphorylation of HMP-P to HMP-PP in 
the thiamine pyrophosphate (TPP) synthesis pathway. 
 
 
Figure 5-10. Localisation and conservation of PDXK A228T mutation  
(A) Localisations of the novel PDXK A228T mutations. PyrdxlP_synth_PyrdxlKinase: the 
domain responsible for synthesis of pyridoxal-5-phosphate (PLP), Phosphomethylpyrimidine 
kinase: the domain participating the Thiamine pyrophosphate synthesis pathway. Numbers 
indicate amino acids. 
(B) Alignment of the human PDXK protein with homologs of multiple species. A228 is 
highly conserved among mammals.   
 
(3) Discussion 
Recent advancement of genetics has documented some forms of hereditary neurological 
diseases are treatable as they are vitamin-responsive disorders, like ataxia with vitamin E 
deficiency, CoQ10 deficiency caused by ADCK3 mutations (Section 3.4) and riboflavin-
responsive Brown-Vialetto-Van Laere syndrome caused by C20orf54 mutations.(Green et al. 
2010)  Being one of vitamins, the important role of pyridoxin in the nervous system is well 
recognized as it can involve both CNS and PNS. Deficiency of pyridoxine would lead to 
diffident neurological disorders, encephalopathy to peripheral neuropathy.  
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PDXK has dual important physiological functions: (1) it catalyses the step required for the 
synthesis of PLP, which is the active form of pyridoxine and is an important cofactor for over 
100 enzymes involved in amino acid, sugar and neurotransmitter metabolisms; (2) it is involved 
in the biosynthesis of TPP, another essential cofactor for many enzymes. Recently, PLP-
dependent pathways have been suggested to play a role in the pathogenesis of Huntington's 
disease and epilepsy.(Dolina et al. 2012; Sorolla et al. 2010)  
 
This study suggests that PDXK may be a candidate gene for inherited axonal neuropathy with 
optic atrophy. However, there are still some questions needed to answer in order to confirm the 
hypothesis. Genetically, it is necessary to perform segregating test in other family members and 
to extensively screen more patients with similar phenotype. If more evidence comes out from 
genetic study, in vitro and in vivo models should be developed since there is no available animal 
model and little is known about the molecular mechanisms of PDXK mutations at present. 
172 
 
References 
Bespalova IN, Van Camp G, Bom SJ, Brown DJ, Cryns K, DeWan AT, Erson AE, Flothmann K, Kunst HP, 
Kurnool P et al (2001) Mutations in the Wolfram syndrome 1 gene (WFS1) are a common cause of 
low frequency sensorineural hearing loss. Hum Mol Genet 10(22):2501-08 
Cao P, Gong Y, Tang L, Leung YC, Jiang T (2006) Crystal structure of human pyridoxal kinase. J Struct 
Biol 154: 327-32 
Chakrabarti B, Dudbridge F, Kent L, Wheelwright S, Hill-Cawthorne G, Allison C, Banerjee-Basu S, 
Baron-Cohen S (2009) Genes related to sex steroids, neural growth, and social-emotional behavior are 
associated with autistic traits, empathy, and Asperger syndrome. Autism Res 2: 157-77 
Chalmers RM, Riordan-Eva P, Wood NW (1997) Autosomal recessive inheritance of hereditary motor and 
sensory neuropathy with optic atrophy. J Neurol Neurosurg Psychiatry 62: 385-7 
Davidson GL, Murphy SM, Polke JM, Laura M, Salih MA, Muntoni F, Blake J, Brandner S, Davies N, 
Horvath R, Price S, Donaghy M, Roberts M, Foulds N, Ramdharry G, Soler D, Lunn MP, Manji H, 
Davis MB, Houlden H, Reilly MM (2012) Frequency of mutations in the genes associated with 
hereditary sensory and autonomic neuropathy in a UK cohort. J Neurol 259(8):1673-85 
Dolina S, Margalit D, Malitsky S, Pressman E, Rabinkov A (2012) Epilepsy as a pyridoxine-dependent 
condition: quantified urinary biomarkers for status evaluation and monitoring antiepileptic treatment. 
Med Hypotheses 79: 157-64 
Fonseca SG, Urano F, Weir GC, Gromada J, Burcin M (2012) Wolfram syndrome 1 and adenylyl cyclase 
8 interact at the plasma membrane to regulate insulin production and secretion. Nat Cell Biol 14: 
1105-12 
Fukuoka H, Kanda Y, Ohta S, Usami S (2007) Mutations in the WFS1 gene are a frequent cause of 
autosomal dominant nonsyndromic low-frequency hearing loss in Japanese. J Hum Genet 52(6):510-5 
Gharanei S, Zatyka M, Astuti D, Fenton J, Sik A, Nagy Z, Barrett TG (2013) Vacuolar-type H+-ATPase 
V1A subunit is a molecular partner of Wolfram syndrome 1 (WFS1) protein, which regulates its 
expression and stability. Hum Mol Genet 22: 203-17 
Green P, Wiseman M, Crow YJ, Houlden H, Riphagen S, Lin JP, Raymond FL, Childs AM, Sheridan E, 
Edwards S et al (2010) Brown-Vialetto-Van Laere syndrome, a ponto-bulbar palsy with deafness, is 
caused by mutations in c20orf54. Am J Hum Genet 86(3):485-9 
Guo X, Shen S, Song S, He S, Cui Y, Xing G, Wang J, Yin Y, Fan L, He F, Zhang L (2011) The E3 ligase 
Smurf1 regulates Wolfram syndrome protein stability at the endoplasmic reticulum. J Biol Chem 286: 
18037-47 
Hansen L, Eiberg H, Barrett T, Bek T, Kjaersgaard P, Tranebjaerg L, Rosenberg T (2005) Mutation 
analysis of the WFS1 gene in seven Danish Wolfram syndrome families; four new mutations 
identified. Eur J Hum Genet 13: 1275-84 
Hofmann S, Philbrook C, Gerbitz KD, Bauer MF (2003) Wolfram syndrome: structural and functional 
analyses of mutant and wild-type wolframin, the WFS1 gene product. Hum Mol Genet 12: 2003-12 
Hogewind BF, Pennings RJ, Hol FA, Kunst HP, Hoefsloot EH, Cruysberg JR, Cremers CW (2010) 
Autosomal dominant optic neuropathy and sensorineual hearing loss associated with a novel mutation 
of WFS1. Mol Vis 16: 26-35 
173 
 
Johansson S, Irgens H, Chudasama KK, Molnes J, Aerts J, Roque FS, Jonassen I, Levy S, Lima K, 
Knappskog PM, Bell GI, Molven A, Njolstad PR (2013) Exome sequencing and genetic testing for 
MODY. PLoS One 7: e38050 
Klein CJ (2012) DNMT1-Related Dementia, Deafness, and Sensory Neuropathy. In: Pagon RA, Adam 
MP, Bird TD, Dolan CR, Fong CT, Stephens K, editors. SourceGeneReviews™ [Internet]. Seattle 
(WA): University of Washington, Seattle; 1993-2013. 2012 Feb 16 [updated 2012 May 17]. In: Pagon 
RA, Bird TD, Dolan CR, Stephens K, Adam MP, editors. GeneReviews™ [Internet]. Seattle (WA): 
University of Washington, Seattle; 1993-.2012 Feb 16 [updated 2012 May 17].  
Klein CJ, Bird T, Ertekin-Taner N, Lincoln S, Hjorth R, Wu Y, Kwok J, Mer G, Dyck PJ, Nicholson GA 
(2013) DNMT1 mutation hot spot causes varied phenotypes of HSAN1 with dementia and hearing 
loss. Neurology 80(9):824-8 
Klein CJ, Botuyan MV, Wu Y, Ward CJ, Nicholson GA, Hammans S, Hojo K, Yamanishi H, Karpf AR, 
Wallace DC, Simon M, Lander C, Boardman LA, Cunningham JM, Smith GE, Litchy WJ, Boes B, 
Atkinson EJ, Middha S, PJ BD, Parisi JE, Mer G, Smith DI, Dyck PJ (2011) Mutations in DNMT1 
cause hereditary sensory neuropathy with dementia and hearing loss. Nat Genet 43: 595-600 
Margolin DH, Kousi M, Chan YM, Lim ET, Schmahmann JD, Hadjivassiliou M, Hall JE, Adam I, Dwyer 
A, Plummer L, Aldrin SV, O'Rourke J, Kirby A, Lage K, Milunsky A, Milunsky JM, Chan J, Hedley-
Whyte ET, Daly MJ, Katsanis N, Seminara SB (2013) Ataxia, dementia, and hypogonadotropism 
caused by disordered ubiquitination. N Engl J Med 368: 1992-2003 
Marzinke MA, Mavencamp T, Duratinsky J, Clagett-Dame M (2013) 14-3-3epsilon and NAV2 interact to 
regulate neurite outgrowth and axon elongation. Arch Biochem Biophys 540(1-2):94-100 
McHugh RK, Friedman RA (2006) Genetics of hearing loss: Allelism and modifier genes produce a 
phenotypic continuum. Anat Rec A Discov Mol Cell Evol Biol 288: 370-81 
McNeill EM, Klockner-Bormann M, Roesler EC, Talton LE, Moechars D, Clagett-Dame M (2011) Nav2 
hypomorphic mutant mice are ataxic and exhibit abnormalities in cerebellar development. Dev Biol 
353: 331-43 
Muley PD, McNeill EM, Marzinke MA, Knobel KM, Barr MM, Clagett-Dame M (2008) The atRA-
responsive gene neuron navigator 2 functions in neurite outgrowth and axonal elongation. Dev 
Neurobiol 68: 1441-53 
Musayev FN, di Salvo ML, Ko TP, Gandhi AK, Goswami A, Schirch V, Safo MK (2007) Crystal 
Structure of human pyridoxal kinase: structural basis of M(+) and M(2+) activation. Protein Sci 16: 
2184-94 
Peeters PJ, Baker A, Goris I, Daneels G, Verhasselt P, Luyten WH, Geysen JJ, Kass SU, Moechars DW 
(2004) Sensory deficits in mice hypomorphic for a mammalian homologue of unc-53. Brain Res Dev 
Brain Res 150: 89-101 
Rossor AM, Polke JM, Houlden H, Reilly MM (2013) Clinical implications of genetic advances in 
Charcot-Marie-Tooth disease. Nat Rev Neurol 9(10):562-71 
Sailer A, Houlden H (2012) Recent advances in the genetics of cerebellar ataxias. Curr Neurol Neurosci 
Rep 12: 227-36 
Seminara SB, Acierno JS, Jr., Abdulwahid NA, Crowley WF, Jr., Margolin DH (2002) Hypogonadotropic 
174 
 
hypogonadism and cerebellar ataxia: detailed phenotypic characterization of a large, extended kindred. 
J Clin Endocrinol Metab 87: 1607-12 
Shi CH, Schisler JC, Rubel CE, Tan S, Song B, McDonough H, Xu L, Portbury AL, Mao CY, True C, 
Wang RH, Wang QZ, Sun SL, Seminara SB, Patterson C, Xu YM (2014) Ataxia and hypogonadism 
caused by the loss of ubiquitin ligase activity of the U box protein CHIP. Hum Mol Genet 23(4):1013-
24 
Smith CJ, Crock PA, King BR, Meldrum CJ, Scott RJ (2004) Phenotype-genotype correlations in a series 
of wolfram syndrome families. Diabetes Care 27: 2003-9 
Sorolla MA, Rodriguez-Colman MJ, Tamarit J, Ortega Z, Lucas JJ, Ferrer I, Ros J, Cabiscol E (2010) 
Protein oxidation in Huntington disease affects energy production and vitamin B6 metabolism. Free 
Radic Biol Med 49: 612-21 
Takeda K, Inoue H, Tanizawa Y, Matsuzaki Y, Oba J, Watanabe Y, Shinoda K, Oka Y (2001) WFS1 
(Wolfram syndrome 1) gene product: predominant subcellular localization to endoplasmic reticulum 
in cultured cells and neuronal expression in rat brain. Hum Mol Genet 10: 477-84 
Tsai HT, Wang YP, Chung SF, Lin HC, Ho GM, Shu MT (2007) A novel mutation in the WFS1 gene 
identified in a Taiwanese family with low-frequency hearing impairment. BMC Med Genet 8: 26 
Winkelmann J, Lin L, Schormair B, Kornum BR, Faraco J, Plazzi G, Melberg A, Cornelio F, Urban AE, 
Pizza F, Poli F, Grubert F, Wieland T, Graf E, Hallmayer J, Strom TM, Mignot E (2012) Mutations in 
DNMT1 cause autosomal dominant cerebellar ataxia, deafness and narcolepsy. Hum Mol Genet 21: 
2205-10 
Yuan J, Higuchi Y, Nagado T, Nozuma S, Nakamura T, Matsuura E, Hashiguchi A, Sakiyama Y, 
Yoshimura A, Takashima H (2013) Novel mutation in the replication focus targeting sequence domain 
of DNMT1 causes hereditary sensory and autonomic neuropathy IE. J Peripher Nerv Syst 18: 89-93 
Zmyslowska A, Borowiec M, Antosik K, Szalecki M, Stefanski A, Iwaniszewska B, Jedrzejczyk M, 
Pietrzak I, Mlynarski W (2011) Wolfram syndrome in the Polish population: novel mutations and 
genotype-phenotype correlation. Clin Endocrinol (Oxf) 75: 636-41 
175 
 
Chapter 6 
 
Results: Targeted resequencing in inherited 
neuropathies and related disorders 
 
Targeted resequencing is an NGS technology which allows massively parallel sequencing of 
DNA molecules with a library containing only the exons which are specifically designed and 
relevant to diseases of interest. Using a customised design of specific exons to a gene, and 
developing a library, targeted resequencing can support a wider range of genomic applications in 
a faster and more cost effective way. In this chapter, the applications of targeted resequencing in 
two groups of patients are reported. The first resequencing panel for ARCMT1 was a pilot 
project with the attempt to evaluate if targeted sequencing could be used as a diagnostic tool. 
The second panel was aimed to screen mutations in patients with HSP or axonal neuropathy with 
spasticity thus covering numerous genes for both HSP and neuropathy. The two panels were 
designed and executed through different platforms. The experience gained from the reliability 
and efficiency of their performance would help optimize the use of targeted resequencing in the 
future.  
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6.1 Targeted resequencing as a diagnostic tool in inherited neuropathies: a pilot study on 
ARCMT1 
 
6.1.1 Introduction 
ARCMT1 patients generally have an earlier onset and a more severe phenotype than patients 
with typical ADCMT1. Weakness often progresses to involve proximal muscles and may result 
in early loss of ambulation. At least 16 causative genes have been identified for 
ARCMT1.(Reilly et al. 2011; Rossor et al. 2013) However, the underlying genetic aetiology is 
still unknown in a significant number of patients. The overlaps in phenotypes between different 
genotypes increases the number of genes to test and cause difficulty in diagnosis. Therefore, 
targeted resequencing may be considered as a diagnostic tool for ARCMT1.  
 
This study was aimed to apply a resequencing panel for ARCMT1 to evaluate the efficiency 
and reliability of targeted resequencing in mutation detection and its application in the 
diagnostic process for inherited neuropathies. At the time of panel development, mutations in 
SH3TC2, GDAP1 and FGD4 genes have been identified in the British population. Large-scale 
genetic studies confirmed that SH3TC2 is the commonest mutated gene, accounting for 21.7% 
of the molecular diagnoses of ARCMT1 in a referral population.(Murphy et al. 2012) 
Mutations in GDAP1 were identified in either ARCMT1 or ARCMT2. FGD4 is another gene 
which mutations have been identified in British patients with ARCMT1.(Houlden et al. 2009). 
Samples from these genetic-diagnosed patients could provide positive controls for the panel. 
Therefore, the ARCMT1 panel was designed to target coding regions of these three genes. 
 
6.1.2 Methods 
(1) Patients and clinical evaluation  
The study cohort comprised 91 patients with a clinical diagnosis of ARCMT1. As part of the 
diagnostic workup all patients had neurological examination and neurophysiological 
assessment. The patients were previously tested and resulted negative for chromosome 17 
duplication and PMP22 point mutations. In eight of these patients a single heterozygous non-
polymorphic variant in SH3TC2 was previously by Sanger sequencing.   
 
(2) Design of the custom targeted resequencing panel  
The targeted sequencing panel was designed to amplify coding exons of three genes: SH3TC2, 
GDAP1 and FGD4 (table 6-1, p177). Custom oligonucleotide probes of 67 amplicons were first 
designed to capture 38 targeted exons via the web-based DesignStudio 
(https://icom.illumina.com) (Details of the method were described in Section 2.5) 
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Table 6-1. Targeted resequencing panel for ARCMT1 
Number of targeted exons: 38 
Number of attempted amplicons: 67 
Cumulative target (bp): 7,994 
Gene Targeted region 
Coding 
exon 
Amplicons Ref seq CCDS 
GDAP1 chr8:75,262,647-75,276,652 6 22 NM_018972.2 CCDS34911.1 
FGD4 chr12:32,729,242-32,793,518 15 12 NM_139241.2 CCDS8727.1 
SH3TC2 chr5:148,384,223-148,442633 17 33 NM_024577.3 CCDS 4293.1 
Total   38 67   
Chr: chromosome; Target regions were defined by CCDS of the target genes. Each target region 
was then divided into amplicons of around 250bps in length. Ref seq: reference sequence 
according to UCSC iGenomes (hg19) (Homo sapiens) (http://genome.ucsc.edu). 
 
(3) Experimental procedure and data analysis 
Two hundred and 50 ng gDNA was used for library preparation according to the TruSeq sample 
preparation protocol (Illumina). There were totally 96 samples recruited on the panel: one 
negative control provided by the commercial Kit, four positive controls with known mutations in 
the three genes and samples from 91 ARCMT1 patients. DNA libraries were then hybridized to 
exome-capture probes with the TruSeq Kit (Illumina). Automated cluster generation and 
sequencing were performed on the Miseq system (Illumina). All non-polymorphic rare variations 
reported by the panel were validated by Sanger sequencing. (Details of experimental procedures 
were described in Section 2.5.1~2.5.3) 
 
6.1.3 Results 
(1) Sequencing yields and optimal target base coverage 
A total of 1.5 Gb sequences were generated with 92.1% passing quality filter Q30, which infers a 
base call accuracy higher than 99.9%.  Table 6-2 (p178) lists the coverage of each targeted exon. 
74% (28/38) of the targeted exons had the coverage more than 80%. There were four failed 
exons which had the coverage lower than 50%: exon 2, exon 4, exon 8 and exon 14 in SH3TC2.  
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    Table 6-2. Coverage of targeted exons on the ARCMT1 panel 
Chr Start Stop Exon Coverage 
5 148442534 148442585 SH3TC2_ex1 75.7% 
5 148431705 148431803 SH3TC2_ex2 0.0% 
5 148427425 148427552 SH3TC2_ex3 93.5% 
5 148424096 148424201 SH3TC2_ex4 34.2% 
5 148422257 148422400 SH3TC2_ex5 98.9% 
5 148420979 148421180 SH3TC2_ex6 98.4% 
5 148420167 148420240 SH3TC2_ex7 82.8% 
5 148417858 148418053 SH3TC2_ex8 26.4% 
5 148411117 148411250 SH3TC2_ex9 64.6% 
5 148408240 148408281 SH3TC2_ex10 100.0% 
5 148406423 148408117 SH3TC2_ex11 100.0% 
5 148406135 148406315 SH3TC2_ex12 97.4% 
5 148392147 148392297 SH3TC2_ex13 96.2% 
5 148389833 148389955 SH3TC2_ex14 15.0% 
5 148388414 148388564 SH3TC2_ex15 87.5% 
5 148386444 148386640 SH3TC2_ex16 75.3% 
5 148384274 148384465 SH3TC2_ex17 65.6% 
8 75262697 75262813 GDAP1_ex1 100.0% 
8 75263509 75263701 GDAP1_ex2 99.2% 
8 75272372 75272545 GDAP1_ex3 100.0% 
8 75274119 75274213 GDAP1_ex4 98.7% 
8 75275174 75275288 GDAP1_ex5 91.4% 
8 75276220 75276602 GDAP1_ex6 96.0% 
12 32729292 32729383 FGD4_ex3 76.8% 
12 32734894 32735401 FGD4_ex4 61.1% 
12 32751431 32751520 FGD4_ex5 51.4% 
12 32754212 32754357 FGD4_ex6 93.2% 
12 32755095 32755251 FGD4_ex7 99.8% 
12 32760891 32761029 FGD4_ex8 100.0% 
12 32763710 32763768 FDG4_ex9 94.8% 
12 32764071 32764217 FGD4_ex10 98.6% 
12 32772632 32772804 FGD4_ex11 100.0% 
12 32777356 32777386 FGD4_ex12 100.0% 
12 32777910 32778002 FGD4_ex13 100.0% 
12 32778588 32778713 FGD4_ex14 98.1% 
12 32786483 32786623 FGD4_ex15 100.0% 
12 32791589 32791729 FGD4_ex16 100.0% 
12 32793210 32793467 FGD4_ex17 91.1% 
Panel coverage 83.2% 
Coverage is generated from the BEDtools and defined as the total number of none-overlapping 
bases covered by amplicons divided by the total numbers of bases in CCDS of the targeted 
exon. For each exon, the mean coverage of all samples is listed in the table. Panel coverage is 
defined as the mean coverage of all exons. Chr: chromosome, ex: exon. 
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(2) Sensitivity and specificity  
The sensitivity of the panel is defined as proportion of true positives detected by the panel in 
the positive controls with known mutations. There are totally six mutations in the three genes 
from four positive control samples. Every mutation was reported by the panel with a 
satisfactory sequencing depth and a robust variant frequency (table 6-3). Therefore, the panel 
successfully detected all known mutations in the positive controls and gave 100% sensitivity.  
 
Table 6-3. Mutations of the positive controls successfully detected by the ARCMT1 panel 
DNA No. Gene Mutation POS 
Base 
depth 
REF 
(depth) 
ALT 
(depth) 
Quality 
filter 
44730 SH3TC2 R641C Het 5:148407374 1877 G (978) A (897) PASS 
44730 SH3TC2 R954X Het 5:148406435 4630 G (2238) A (2382) PASS 
14605 SH3TC2 S433L Het 5:148407997 4308 G (2112) A (2190) PASS 
46116 GDAP1 P153L Het 8:75272519 817 C (403) T (414) PASS 
46116 GDAP1 Q163X Het 8:75274121 307 C (168) T (138) PASS 
44338 FGD4 R275X Hom 12:32754344 6 C (0) T (6) Q30 
POS: the position of the mutation, REF: reference allele, ALT: alternated allele, Het: 
heterozygous, Hom: homozygous. 
Quality scores measure the probability that a base is called incorrectly. Each base in a read is 
assigned a quality score by a phred-like algorithm (Ewing et al. 1998a; Ewing et al. 1998b), 
similar to that originally developed for Sanger sequencing experiments. The quality score of a 
given base, Q, is defined by the equation Q = -10log10(e) where e is the estimated probability 
of the base call being wrong. Thus, a higher quality score indicates a smaller probability of 
error. Q30 represents an error rate of 1 in 1000, with a corresponding call accuracy of 99.9%. 
 
Specificity and negative predictive value of the ARCMT1 panel are listed in table 6-4 (p180). 
The specificity is defined as proportion of true positives in the patient cohort detected by the 
resequencing panel, which could be confirmed by Sanger sequencing. After filtering out 
synonymous, silent and non-coding variants, a total of 114 variants were tested by Sanger 
sequencing. All 62 variants passing quality filter Q30 were validated, giving the 100% 
specificity. Among the 52 variants which failed to pass Q30, 49 of them were reconfirmed as 
false, thus a negative predictive value of 94%. 
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Table 6-4. Specificity and negative predictive value of the ARCMT1 panel 
Number of variants Sanger sequencing Compatible rate 
passing Q30 62 
TRUE 62 100% * 
FALSE 0 0% 
not passing 52 
TRUE 3 6% 
FALSE 49 94% # 
* Specificity= the proportion of true positives in the patient cohort detected by the resequencing 
microarray, which could be confirmed by Sanger sequencing. 
# Negative predictive value = the proportion of subjects with a negative test result who are 
correctly diagnosed.  
 
 
(3) Variants detected by the panel 
Among the 91 patients, 48 (52.7%) were identified to have at least one non-synonymous rare 
variants (MAF<0.01) in the coding regions of the three genes. Seven unrelated patients (7.6%) 
were identified to carry reported or novel mutations which were probably pathogenic: four had 
homozygous mutations and three had two heterozygous mutations (table 6-5). Some patients 
have rare variants in more than one gene.   
 
Table 6-5. Rare variants detected by the ARCMT1 panel 
Pathogenic grade 
No. of 
patients 
SH3TC2 GDAP1 FGD4 
  Positive 48 42 3 3 
Reported or probable 
pathogenic mutation 
  Hom 4 2 1 1 
  Double Het 3 1 1 1 
Hom or double Het, with at least 
one none-pathogenic SNP 
12 12 0 0 
Single Het 29 27 1 1 
  Negative 43 / / / 
Rare variants are defined as: non-synomic variants in the coding regions with MAF<0.01. 
No.: number of patients, Hom: homozygous variant, Het: heterozygous variant, Double Het: two 
heterozygous variants in one sample, allele unknown, SNP: single nucleotide polymorphism 
 
Details of mutations in the seven patients are listed in table 6-6 (p181). All mutations were 
confirmed by Sanger sequencing (figure 6-1, p182). Two patients carried FGD4 mutations. One 
with early-onset demyelinating neuropathy carried a homozygous FGD4 R442H mutation and 
co-segregation with the phenotype was confirmed within the family (figure 6-1, A). The other 
patients had two heterozygous FGD4 mutations: G620V is a novel mutation, and R577Q has 
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been reported as a very rare variant with unknown clinical significance (figure 6-1, B). Both 
mutations are predicted to generate damaging effects by Polyphen and SIFT. In two patients 
GDAP1 mutations were identified. One patient carried homozygous GDAP1 M116R mutation, 
an already reported pathogenic mutation (figure 6-1, C). The second case had two heterozygous 
GDAP1 mutations: a known pathogenic mutation L238F and a novel G327D mutation (figure 6-
1, D). In SH3TC2, the hot-spot mutation R954X was identified in three patients. Two had 
homozygous mutations (figure 6-1, E). The third one was previously known to carry a single 
heterozygous R954X mutation and a further novel heterozygous mutation Y290X was identified 
through the panel (figure 6-1, F). For patients harbouring two heterozygous mutations, parental 
samples will be tested to confirm whether the two mutations are compound heterozygous 
mutations.  
 
Table 6-6. Reported or probable pathogenic mutations detected by the ARCMT1 panel 
Gene Mutation Pathogenicity prediction 
FGD4 
[p.R442H ; p.R442H] Reported pathogenic mutation 
[p.R577Q (;) p.G620V] 
R577Q: Vary rare variant without SNP ID, MAF=0.016%, 
highly conserved GERD:5.29, PolyPhen: probably damaging 
G620V: Novel mutation, presumed pathogenic; 
MAF=N/A, PolyPhen: probably damaging 
GDAP1 
[p.M116R ; p.M116R] Reported pathogenic mutation 
[p.G327D (;) p.L239F] 
L239F: Reported pathogenic mutation (rs104894080) 
G327D: : Novel mutation, presumed pathogenic, MAF=N/A, 
GERD:4.99, PolyPhen: probably damaging 
SH3TC2 
[p.R954X ; p.R954X] 
 (n=2) 
Reported pathogenic mutation (rs80338933) 
[p.Y290X ; p.R954X] 
Y290X: Novel mutation, presumed pathogenic, MAF=N/A 
R954X: Reported pathogenic mutation (rs80338933) 
SNP: single-nucleotide polymorphism, MAF: minor allele frequency, N/A: not available 
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Figure 6-1. Mutations detected by the ARCMT1 panel validated by Sanger sequencing 
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A total of 1002 rare non-pathogenic SNPs annotated in dbSNP (build 138) corresponding to 38 
distinct sequence variations were found in the 95 analysed patients: SNP (n) in FGD4=16, in 
GDAP1=6, and in SH3TC2=16. The frequencies of these SNPs in the cohort on the ARCMT1 
panel are much higher than their MAF in 1000 Genomes Project (table 6-7).  
 
Table 6-7. Rare single-nucleotide polymorphisms (SNPs) detected by the ARCMT1 panel 
Chr Position SNP ID Number Frequency in panel  MAF 
chr12 32735236 rs904582 58 0.6105 0.000459 
chr12 32754367 rs41276676 6 0.0632 0.000458 
chr12 32755058 rs4931641 26 0.2737 0.000459 
chr12 32755259 rs12823621 15 0.1579 0.000459 
chr12 32763668 rs1004969 17 0.1789 0.000459 
chr12 32763975 rs76666307 1 0.0105 0.000467 
chr12 32764184 rs10844253 56 0.5895 0.000459 
chr12 32777362 rs11052110 37 0.3895 0.000459 
chr12 32777889 rs17539792 18 0.1895 0.000459 
chr12 32778742 rs17539848 19 0.2000 0.000459 
chr12 32778830 rs79100182 4 0.0421 0.000458 
chr12 32778913 rs1909510 68 0.7158 0.000459 
chr12 32786460 rs76834265 2 0.0211 0.00046 
chr12 32786700 rs59572242 26 0.2737 0.000459 
chr12 32791796 rs4575368 17 0.1789 0.000459 
chr12 32793164 rs74073032 15 0.1579 0.000459 
chr8 75262536 rs4541908 17 0.1789 0.000458 
chr8 75262798 rs7828201 6 0.0632 0 
chr8 75262841 rs4321999 6 0.0632 0.000458 
chr8 75272287 rs3780014 64 0.6737 0.000459 
chr8 75274141 rs11554166 51 0.5368 0.000459 
chr8 75275312 rs4463412 93 0.9789 0 
chr5 148384455 rs146920285    1 0.0105 0.000457 
chr5 148386525 rs6871030 58 0.6105 0.000459 
chr5 148386569 rs142451273 1 0.0105 N/A 
chr5 148388420 rs55853803 4 0.0421 0.000459 
chr5 148392362 rs11954893 36 0.3789 0.000459 
chr5 148406032 rs10075404 30 0.3158 0.000459 
chr5 148406386 rs17722209 33 0.3474 0.000459 
chr5 148407481 rs186864272 1 0.0105 0.00045 
chr5 148407708 rs1432794 95 1.0000 0.000458 
chr5 148407892 rs6874630 2 0.0211 0.000456 
chr5 148407893 rs6875902 37 0.3895 0.000459 
chr5 148407945 rs17722227 4 0.0421 0.000459 
chr5 148408101 rs1432793 69 0.7263 0.000459 
chr5 148420221 rs144963732  1 0.0105 N/A 
chr5 148421065 rs80227512 3 0.0316 0.000456 
chr5 148422274 rs17722293 5 0.0526 0.000459 
Chr: chromosome, Number: number of patients who had the SNP on the panel, MAF: minor 
allele frequency, N/A: not available 
184 
 
6.1.4 Discussion 
This study documented that targeted resequencing could detect single base substitutions with a 
reliable accuracy. The ARCMT1 panel which was developed and performed by Truseq system 
provided an excellent sensitivity, specificity and negative predictive value. Also, by 
simultaneously screening several genes per patient, the panel significantly improved the cost-
efficiency of CMT testing and reduced diagnostic turn-around times. 
 
Our results confirmed that mutation in SH3TC2 is the commonest genetic aetiology in patients 
with ARCMT1. This study also illustrated how a resequencing panel can be a comprehensive 
tool for Sanger sequencing. For example, in one patient who was already known to carry a 
heterozygous R954X mutation in SH3TC2, a second heterozygous mutation R290X was 
detected through the panel. The frequency of GDAP1 mutations may be underestimated 
because many patients with GDAP1 mutations have been diagnosed through conventional 
diagnostic process and were not included on the panel. Alternatively, the frequency of FGD4 
mutations using targeted resequencing may be higher than previously reported since mutation 
analysis of FGD4 was not routinely screened in most diagnostic laboratories. The application 
of target resequencing will probably broaden the phenotypic spectrum of FGD4 mutations and 
may reshape our understanding of genotypes and phenotypes related to CMT in the near future. 
 
In our CMT cohort, the frequency of rare SNPs detected through the panel was much higher 
than their MAF in 1000 Genomes Project. In other studies employing resequencing panels, 
higher occurrence rates of SNPs were also observed.(Dufke et al. 2012) Their clinical 
significance is still unclear.  
 
The results of the pilot panel suggested that a small disease-specific panel  covering  a 
particular phenotype, e.g. ARCMT1, is a more feasible strategy in the design of panels in 
comparison with a more  complete panel that includes  several genes (currently, more than 60 
genes)  causing most CMT phenotypes. A small phenotype-specific panel may be more 
advantageous than a complete CMT panel as it may be more cost-effective and, more 
importantly, the number of non-pathogenic variants likely to be detected may be lower. This is 
particularly important when interpreting the results and thus helps reduce substantially the time 
and the cost of validating results. Furthermore, the frequency with which phenotype-specific 
panels will have to be upgraded will be less than that for a panel including all CMT genes as 
new genes are keeping increasing. Based on the experience learned from the ARCMT1 pilot 
panel, currently four phenotype-specific panels are being developed in the diagnostic genetic 
service at the NHNN: a CMT1- intermediate CMT panel, a CMT2- intermediate CMT panel, a 
distal HMN panel and a HSN panel. The panels have been designed to cover a broad spectrum 
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of CMT phenotypes but at the same time they benefit from known phenotype-genotype 
correlation. They are part of the integrative approach of genetic diagnosis of CMT patients 
which combines NGS and conventional Sanger sequencing (figure 6-2). 
 
 
Figure 6-2. Integrative approach of genetic diagnosis of CMT which combines targeted 
resequencing and Sanger sequencing 
Genetic diagnosis starts with the categorization of patients with CMT1, CMT2 and other 
phenotypes. CMT1Patients will be firstly tested for chromosome17 duplication or GJB1 gene 
mutation as these are the most common causes of CMT. After exclusion of these mutations 
patients will be sequenced by the CMT1 panel which includes known genes for the 
demyelinating and intermediate types of CMT.  In patients with CMT2, HSN and dHMN the 
specific panel will be performed. Some genes are included in more than one panel as they can 
cause several phenotypes. Whole exome sequencing will be performed in selected patients in 
which causative gene mutations are still unknown after targeted resequencing. 
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6.2 Mutation analysis of genes for HSP and axonal neuropathy by targeted resequencing 
 
6.2.1 Introduction 
More than 52 loci and 31 genes have been identified to cause dominant, recessive, and X-
linked forms of HSP.(Fink 2013)  The genetic diagnosis of HSP is becoming challenging due to 
the complicated phenotype-genotype correlations. At least two forms of HSP may manifest as 
both AR and AD disorders: SPG7 was originally described as a recessive disorder due to 
homozygous or compound heterozygous SPG7/paraplegin gene mutations but subsequently  
reports of HSP syndromes due to  heterozygous SPG7 mutation have been published.(Arnoldi 
et al. 2008; Brugman et al. 2008; McDermott et al. 2001) Homozygous or compound 
heterozygosous CYP7B1 mutations were known to cause recessive SPG5, but a heterozygous 
missense change was recently reported in a dominant HSP family.(Schule et al. 2009) This is 
further complicated  by the increasing genetic and clinical overlaps with inherited neuropathies. 
As mentioned previously in Section 1.2.1, many forms of HSP are frequently associated with 
peripheral neuropathy, e.g. ATL1 (SPG3A), SPAST (SPG4), BSCL2 (SPG17) and KIF5A 
(SPG10).(Al-Maawali et al. 2011; Du et al. 2011; Goizet et al. 2009; Guelly et al. 2011; 
Ivanova et al. 2007; Kumar et al. 2012; Musumeci et al. 2010; Scarano et al. 2005; Schule et al. 
2003; Windpassinger et al. 2004) Because of the clinical and genetic heterogeneity of HSP, it 
may be more time and cost effective using targeted resequencing rather than Sanger 
sequencing, particularly when dealing with a large scale of patients. Target resequencing is also 
an ideal tool to screen genes for other diseases which may cause phenotypes overlapping with 
HSP.  
 
This study reported the design and application of a resequencing panel targeting the coding 
regions of 31 genes related to HSP and axonal neuropathy. The purpose was to establish the 
epidemiological profile of a group of patients with HSP or axonal neuropathy with spasticity. 
The efficiency and reliability of high-throughput genotyping technology in screening multiple 
genes were also investigated.  
 
6.2.2 Patient and methods 
(1) Patients  
The study cohort comprised 66 unrelated patients with HSP or axonal neuropathy associated 
with spasticity. Twenty four patients had AD inheritance, 5 belonged to consanguineous family 
with a definite AR inheritance and 37 were sporadic cases. Most patients (58/66) had been 
already screened and resulted negative for mutation in SPAST and ATL1 genes. Sixteen patients 
had neurophysiological-documented sensorimotor axonal neuropathy.  
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(2) Design of the custom targeted resequencing panel  
The targeted sequencing panel was designed to amplify the coding regions of 31 genes: 11 for 
AD-HSP, 16 for AR-HSP, 3 for X-liked HSP and MFN2 (gene for CMT2A) (table 6-8, p188).  
MFN2 was included on the panel as patients carrying its mutations can present by axonal 
neuropathy in association with spasticity, overlapping with the complex HSP phenotype. 
Custom oligonucleotide probes were designed through the web-based Agilent Halo Design 
Wizard (http://www.halogenomics.com/haloplex/custom-reagent-kits).  
 
(3) Experimental procedure and data analysis 
250ng of Genomic DNA was used for library preparation and then hybridized to exome-
capture probes with the HaloPlex system (Agilent). 72 samples were included on the panel: 
five positive controls with known mutations in ATL1, SPAST, REEP1, NIPA1 and BSCL2, 66 
samples from the patient cohort mentioned above and one negative control provided by the 
commercial kit. The total number of samples was sequenced by two runs on the Miseq 
platform in order to investigate the optimized sequencing capacity of the panel. Twelve 
samples were pooled and submitted in Flow cell A for the first run, and the rest 60 samples 
were pooled and submitted in Flow cell B for the second run. Samples with different indexes 
were pooled with equimolar amounts of each sample. The final HaloPlex enrichment pool was 
ready for 150 + 150 bp paired-end sequencing using chemistry on the Illumina MiSeq. Before 
aligning reads to the reference genome, reads were trimmed from HaloPlex adaptor sequences 
with NextGene software (Softgenetics). Sequence alignment and variant calling were then 
performed against the reference human genome (UCSC hg19). An overview of the workflow is 
shown in figure 6-3. (Details of experimental procedures were described in Section 2.5) 
 
Figure 6-3. Workflow of the HaloPlex panel for HSP and axonal neuropathy 
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  Table 6-8. Targeted resequencing panel for HSP and axonal neuropathy 
Number of Targeted exons: 463 
Cumulative Target (bp): 94,164 
Predicted coverage: 99.8% 
AD (12 genes) 
Disease Gene Location Ref seq CCDS 
SPG3 ATL1 chr7:4,815,262-4,834,026 NM_014855 CCDS47528.1 
SPG4 SPAST chr2:32,288,680-32,382,706 NM_014946 CCDS1779.1, CCDS1778.1 
SPG6 NIPA1 chr15:23,048,850-23,086,324 NM_001095784 CCDS45190.1, CCDS10011.1 
SPG8 KIAA0196 chr2:198,351,308-198,364,998 NM_199440 CCDS33357.1 
SPG10 KIF5A chr12:57,943,847-57,978,554 NM_004984 CCDS8945.1 
SPG12 RTN2 chr19:45,988,546-46,000,313 NM_005619 CCDS12665.1, CCDS12666.1 
SPG13 HSPD1 chr17:42,875,816-42,907,607 NM_005497 CCDS1569.1 
SPG17 BSCL2 chr14:51,026,743-51,099,784 NM_015915 CCDS32077.1, CCDS9700.1 
SPG31 REEP1 chr2:86,441,120-86,565,206 NM_001164730 CCDS1989.1 
SPG33 ZFYVE27 chr10:99,496,878-99,520,664 NM_001174122 
CCDS31262.1, CCDS31263.1, 
CCDS31264.1 
SPG42 SLC33A1 chr3:155544301-155572248 NM_004733 CCDS3173.1 
CMT2 MFN2 chr1:12,040,238-12,073,572 NM_014874 CCDS30587.1 
AR (16 genes) 
Disease Gene Location Ref seq CCDS 
SPG5 CYP7B1 chr5:10,250,282-10,266,501 NM_012073 CCDS3877.1 
SPG7 SPG7 chr16:89,574,805-89,624,174 NM_003119 CCDS10977.1, CCDS10978.1 
SPG11 SPG11 chr15:44,854,894-44,955,876 NM_025137 CCDS10112.1 
SPG15 ZFYVE26 chr14:68,213,237-68,283,306 NM_015346 CCDS9788.1 
SPG18 ERLIN2 chr8:65,508,529-65,711,348 NM_004820 CCDS6180.1 
SPG20 SPG20 chr13:36,875,775-36,944,317 NM_001142294 CCDS9356.1 
SPG21 SPG21 chr15:65,255,362-65,282,284 NM_016630 CCDS45279.1, CCDS10198.1 
SPG35 FA2H chr8:37,594,097-37,615,319 NM_007175 CCDS6095.1, CCDS34879.1 
SPG39 PNPLA6 chr19:7,599,038-7,626,653 NM_006702 CCDS32891.1 
SPG44 GJC2 chr16:74,746,856-74,808,729 NM_024306 CCDS10911.1 
SPG47 AP4B1 chr1:114,437,371-114,447,741 NM_006594 CCDS865.1 
SPG48 KIAA0415 chr8:126,036,503-126,104,061 NM_014846 CCDS6355.1 
SPG50 AP4M1 chr7:99,699,130-99,704,803 NM_004722 CCDS5685.1 
SPG51 AP4E1 chr15:51,200,869-51,298,097 NM_007347 CCDS32240.1 
SPG52 AP4S1 chr14:31,494,676-31,555,008 NM_007077 CCDS9642.1, CCDS45093.1 
Spasticity
+ SN 
CCT5 chr11:62,457,734-62,475,179 NM_001122955 CCDS8031.1, CCDS44627.1 
X-linked (3 genes) 
Disease Gene Location Ref seq CCDS 
SPG1 L1CAM chrX:153,126,969-153,141,500 NM_000425 
CCDS14733.1, CCDS14734.1, 
CCDS48192.1 
SPG2 PLP1 chrX:103,031,439-103,047,547 NM_001128834 CCDS14514.1, CCDS14513.1 
SPG22 SLC16A2 chrX:73,641,328-73,753,764 NM_006517 CCDS14426.1 
AD: autosomal dominant; AR: autosomal recessive; chr: chromosome; Ref seq: reference 
sequence according to UCSC iGenomes (hg19) (Homo sapiens) (http://genome.ucsc.edu); Target 
regions were defined by CCDS of the target genes; SN: sensory neuropathy 
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(4) Validation of reported variants by Sanger sequencing: 
Synonymus, silent and non-coding variants were filtered out first from all variants reported by 
the panel. The following strategy was then adopted to validate the rest variants by Sanger 
sequencing: (1) Variants which were compatible with the patient’s inheritance were tested. For 
example, single heterozygous variant in known AD-HSP genes were validated in patients with 
dominant inheritance whereas homozygous or double heterozygous variants in AR-HSP genes 
were selected in patients from a recessive family. (2) For sporadic cases with undetermined 
inheritance, both heterozygous variants in AD genes and homozygous/double heterozygous 
variants in AR- genes were tested. (3) Variants in MFN2, SPG7 and CYP7B1 were considered 
in both AD and AR inheritance as mutations in these genes have been reported in heterozygous 
and homozygous status. (4) Variants on chromosome X were tested only when they presented 
in male patients when there was no male to male transmission. 
 
6.2.3 Results 
(1) Sequencing yields and optimal target base coverage 
A total of 3 Gb sequences were generated by two runs, 1.5 Gb sequences per run. Table 6-9 
lists the distribution of target base coverage of each targeted exon on the panel. The mean 
coverage of all 465 targeted exons in Flow cell A with 12 pooled samples was higher than 80%, 
better than 72% in Flow cell B which pooled 60 samples together. In Flow cell A, more than 
half (55.3%) of the exons had the coverage higher than 80%, but the proportion dropped to 
42.8% in Flow cell B.  
 
Table 6-9. Coverage of the targeted exons on the panel for HSP and axonal neuropathy 
 
Flow cell A (n=12) Flow cell B (n=60) 
Coverage No. of exons % No. of exons % 
X ≧80% 256 55.1 198 42.6 
50% ≦ X <80% 89 19.1 182 39.1 
10% ≦ X <50% 62 13.3 75 16.1 
X <10% 58 12.5 10 2 
Panel coverage 81% 72% 
Coverage per exon is generated from the BEDtools and defined as the total number of none-
overlapping bases covered by amplicons divided by the total numbers of bases in CCDS of the 
targeted exon. X represents the mean coverage of all samples per exon. Panel coverage is 
defined as the mean coverage of all exons.  
 
Nineteen out of the 31 genes (61%) had the coverage above 70%.  Genes were then listed from 
high to low in the order of the average coverage in table 6-10 (p190). Failed exons with the 
coverage less than 50% were listed in the table. In some genes, only one or two failed exons 
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lowered the average coverage of the gene significantly.  
 
Table 6-10. Coverage of the genes on the panel for HSP and axonal neuropathy  
Gene Coverage coding exons Failed exon (coverage<50%)  
FA2H 100.0% 7 
  
SLC33A1 97.6% 6 
  
GJC1 94.5% 1 
  
AP4B1 85.9% 10 AP4B1_ex5 
 
NIPA1 85.5% 5 
  
ZFYVE27 80.9% 13 ZFYVE27_ex1 
 
AP5Z1 80.8% 17 AP5Z1_ex1, AP5Z1_ex11 
 
ATL1 80.7% 14 
  
KIF5A 80.5% 28 KIF5A_ex5 
 
MFN2 79.9% 17 MFN2_ex8 
 
CCT5 79.5% 11 
  
RTN2 78.8% 11 RTN2_ex1 
 
SPG7 77.6% 17 SPG7_ex17 
 
KIAA0196 76.9% 28 KIAA0196_ex25, KIAA0196_ex24 
 
ZFYVE26 75.2% 41 ZFYVE26_ex33, ZFYVE26_ex29,  ZFYVE26_ex16 
 
PLP1 72.1% 7 PLP1_ex7, PLP1_ex8 
 
ERLIN2 71.8% 12 ERLIN2_ex6 
 
SPG20 70.7% 8 SPG20_ex9,SPG20_ex6, SPG20_ex3 
 
BSCL2 70.3% 11 BSCL2_ex10 
 
SPAST 68.6% 17 SPAST_ex5, SPAST_ex6 
AP4E1 66.2% 21 AP4E1_ex8 
PNPLA6 66.2% 33 PNPLA6_ex35, PNPLA6_ex3, PNPLA6_ex18 
SPG11 65.4% 40 SPG11_ex25, SPG11_ex37, SPG11_ex17 
AP4S1 65.0% 6 AP4S1_ex6 
AP4M1 64.4% 15 AP4M1_ex1, AP4M1_ex15 
REEP1 62.0% 7 REEP1_ex1, REEP1_ex5 
L1CAM 60.3% 29 L1CAM_ex26, L1CAM_ex3 
HSPD1 59.0% 11 HSPD1_ex3, HSPD1_ex12, HSPD1_ex8 
CYP7B1 57.2% 6 CYP7B1_ex6, CYP7B1_ex1 
SPG21 63.3% 8 SPG21_ex7, SPG21_ex6 
SLC16A2 52.7% 6 SLC16A2_ex5, SLC16A2_ex4 
 
Coverage listed in the table is the mean of coverage of all exons for each gene. The better 
coverage among two runs is chosen to show the optimal performance of the probes. ex: exon 
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(2) Sensitivity and specificity  
There were in total five mutations in five genes from five positive controls on the panel. Each 
of the five mutations was detected as a robust variant which has a satisfactory sequence depth 
and variant frequency (table 6-11). Therefore, the panel successfully detected all known 
mutations in the positive controls and gave 100% sensitivity.  
 
Table 6-11. Mutations of the positive controls successfully detected by the panel for HSP 
and neuropathy 
DNA No. Gene Mutation POS 
Base 
depth 
REF 
(depth) 
ALT 
(depth) 
Quality 
filter 
49028 BSCL2 N88S Het chr11:62469971 5 T (2) C (3) PASS 
52069 NIPA1 G304V Het chr15:23048908 85 C (35) A (50) PASS 
60379 ATL1 V253I Het chr14:51081124 18 G (7) A (11) PASS 
60483 REEP1 Y35X Het chr2:86509294 24 T (5) A (19) PASS 
65223 SPAST R562X Het Chr2:32370073 18 C (12) T (6) PASS 
POS: the position of the mutation, REF: reference allele, ALT: alternated allele, Het: 
heterozygous 
 
Among all the variants reported by the panel, 446 rare variants (MAF<0.01) were kept after 
filtering synonymus, silent and non-coding variants. Applying the strategy mentioned before, a 
total of 260 variants in 31 genes were tested by Sanger sequencing. Only 17 variants passed the 
validation, suggesting a low specificity of the panel although not all variants reported by the 
panel were tested.  A significant number of false positive variants were caused by the remnants 
of restrict enzyme cutting sites, as illustrated in figure 6-4 (p192). 
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Figure 6-4. Example of a false positive report caused by a restriction enzyme cutting site 
on the HaloPlex panel 
The panel reports the variant on the top sample (pointed by the red arrow). However, the 
variant was not detected by Sanger sequencing and thus a false positive report.  Alignment of 
the sample with the other two samples revealed that the variant is localised in a restriction 
enzyme cutting site. 
 
(3) Probable pathogenic mutations detected by the panel   
Nine unrelated patients were identified to carry reported or novel mutations which are probably 
pathogenic (table 6-12, p193).  All mutations were confirmed by Sanger sequencing (figure 6-5, 
p194).  
 
Two heterozygous MFN2 mutations were identified in two unrelated patients. S231P is a novel 
mutation detected in a sporadic case who had an early-onset sensorimotor axonal neuropathy 
with hyperreflexia (figure 6-5, A). R519C was a very rare variant only reported on ESV with 
an extremely low frequency (MAF<0.007%) (figure 6-5, B). The pathogenic role of this 
variant was supported by the predicted damaging effect and high conservation of the 
substituted codon. The patient with R519C mutation had peripheral neuropathy and additional 
CNS involvement like spastic paraperesis and learning difficulty.  
 
There are other heterozygous mutations in AD-HSP genes. One ATL1 mutation (R239C) was 
identified in a sporadic patient with pure HSP (figure 6-5, C). This is a previously reported 
pathogenic mutation related to HSP. A novel I226T mutation in KIAA0196 was detected in a 
patient with spastic paraplegia and sensory axonal neuropathy which was DOPA responsive 
(figure 6-5, D). She was from a dominant family as her daughter was also affected by spasticity 
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and sensory impairment. Two previously reported pathogenic mutations in SPAST were 
identified in two patients. The patient with the missense mutation S44L had a pure HSP 
phenotype and AD inheritance (figure 6-5, E). The other heterozygous was 1pb deletion at the 
splicing cite (c.1494-2delT) which was carried by a patient with HSP, visual impairment, 
learning difficulties and nystagms (figure 6-5, F).  
 
Mutations in AR-HSP gene were also identified. One patient was identified to carry two 
heterozygous mutations in FA2H: p.R154C is a presumed pathogenic novel mutation and 
p.T207M is a very rare variant with predicted damaging effects (figure 6-5, G). Parents of the 
individual will be tested in the future to confirm if the two mutations are compound 
heterozygous mutations. Two heterozygous missense mutations in KIF5A were detected and 
have been described in Section 4-1.  
 
Table 6-12. Reported or probable pathogenic mutations detected by the panel for HSP and 
axonal neuropathy  
DNA 
No. 
Gene Mutation Significance Inheritance Phenotype 
66679 MFN2 
S231P 
(Het) 
Novel mutation, 
presumed pathogenic 
sporadic 
Sensorimotor axonal 
neuropathy with 
hyperreflexia 
30156 MFN2 
R519C 
(Het) 
Vary rare variant without 
SNP ID; MAF <0.007% 
on ESV, PolyPhen: 
damaging 
sporadic 
cHSP with neuropathy 
and  learning difficulty, 
childhood-onset 
66681 ATL1 
R239C 
(Het) 
Reported pathogenic 
mutation (rs119476046) 
sporadic pHSP, early onset 
62182 KIAA0196 
I226T 
(Het) 
Novel mutation, 
presumed pathogenic 
AD 
cHSP: L-Dopa 
responsive spasticity 
with sensory axonal 
neuropathy, early onset 
45020 SPAST 
S44L 
(Het) 
Reported pathogenic 
mutation (rs121908515) 
AD 
pHSP, two children are 
affected 
23578 SPAST 
c.1494-2delT 
(Het) 
Reported pathogenic 
mutation (CD023280) 
sporadic  
cHSP with visual 
impairment, learning 
difficulties, nystagmus 
51210 FA2H 
[p.R154C (;) 
p.T207M] 
p.R154C: novel 
mutation, presumed 
pathogenic; 
p.T207M: vary rare 
variant without SNP ID 
(MAF=0.01% on ESV, 
PolyPhen: damaging 
sporadic 
Spastic ataxia (cHSP 
with ataxia) 
60113 KIF5A 
R204W 
(Het) 
N vel mutation, 
presumed pathogenic 
AD 
Spastic ataxia (cHSP 
with ataxia), dystonia, 
adult-onset, one affected 
sister 
48092 KIF5A 
R204Q 
(Het) 
Reported pathogenic 
mutation 
AD 
cHSP with sensorimotor 
axonal neuropathy, two 
children affected 
AD: autosomal dominant, AR: autosomal recessive, cHSP: complex HSP, Het: heterozygous 
variant, pHSP: pure HSP, SNP: single nucleotide polymorphism, MAF: minor allele frequency.  
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Figure 6-5. Reported or probable pathogenic mutations detected by the panel for HSP and 
axonal neuropathy were validated by Sanger sequencing 
 
6.2.4 Discussion 
The panel has helped identify reported or probable pathogenic mutations in 9 patients from the 
66 index patients. The overall diagnosis rate was 13.6% and the hit rate was 13.1% (8/61) in 
SPAST-negative cases. Previous studies conducted by Sanger sequencing revealed that SPAST 
is the commonest causative HSP gene, accounting for approximately 50% of AD-HSP 
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cases(Hazan et al. 1999), and ATL1 is the second most common causative gene  explaining 
another 10% of AD-HSP cases.(Hazan et al. 1999) Mutations in most of the AR-HSP genes are 
much rarer and  little information about the prevalence are available.(Dufke et al. 2012) 
Recently, it has been  reported that a genetic diagnosis could be established only in 11% of 
SPAST-negative AD-HSP cases by resequencing technology.(Dufke et al. 2012) The higher 
detection rates in our study provided evidence that targeted resequencing is a competent tool to 
simultaneously screen a large number of genes for diseases of high genetic heterogeneity, like 
HSP.  
 
The panel was aimed to screen mutations in patients with various inheritance modes, not 
limited in AD cases. This was because that a significant number of our patients were sporadic 
thus genes related to different inheritance patterns should all be considered. Our results showed 
five patients were sporadic cases among the nine patients diagnosed though the panel. This 
study suggested that a panel including numerous genes could substantially raise the genetic 
diagnosis rate of HSP patients since it encompassed most subtypes. 
 
Eight missense mutations and one deletion were identified in patients with HSP or axonal 
neuropathy by the resequencing panel, documenting that targeted resequencing could 
successfully detect both single base substitutions and small indels.  
 
Genetic findings in this study have greatly contributed to broaden the phenotypic spectrums of 
many HSP genes. For example, the patient harbouring a novel KIAA0196 I226T mutation 
presented with a L-Dopa responsive spastic paraplegia and sensory neuropathy. This is a new 
phenotype since previous reported patients with KIAA0196 mutations were clinically 
characterised by pure HSP.(Rocco et al. 2000; Valdmanis et al. 2007) Furthermore, the panel 
detected the first KIF5A mutation  associated with cerebellar ataxia (KIF5A R204W in table 6-
12, details of KIF5A mutations were described in Section 4.1). The accumulation of genetic 
data generated by targeted resequencing will increase rapidly our understanding of phenotypic-
genotypic correlations of many rare genes and will improve the process of genetic diagnosis in 
the future.   
 
This was also the first resequencing panel designed for the genetic diagnosis of complex 
syndromes spanning over more than one group of neurological disorders. For the two patients 
with MFN2 mutations, both had axonal neuropathy complicated with pyramidal tract 
involvement, clinically overlapped with cHSP. The findings highlighted MFN2 is a must gene 
to screen in patient affected by spastic paraperesis when there is simultaneous involvement of 
peripheral nerves. The experience from the HSP-axonal neuropathy panel indicates that more 
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CMT2 genes which may cause both LMN and UMN signs can be recruited together when 
studying HSP patients. Conversely, it is reasonable to put some HSP genes which have a high 
association with peripheral neuropathy on the panel for CMT2 genes. This study documented 
that targeted resequencing is flexible and powerful in studying patients whose symptoms 
involve more than one neurological system. 
 
A major challenge in the application of targeting resequencing is how to interpret the data 
when variants in multiple genes were detected simultaneously. Several ways could help to 
determine the clinical significance of a variant, including Sanger sequencing, segregation tests 
in family members, screening in controls or larger cohorts, in silico prediction, conservation of 
the affected base and amino acid in evolution. However, sometimes it was still very difficult in 
distinguishing which mutation was likely to be pathogenic. 
  
Another critical issue is to achieve sufficient read depths and satisfactory sequencing coverage 
for use in clinical practice. If the sequence yields fail to cover the target regions well, the costs 
and time to do Sanger sequencing for the missing regions would be considerably high. This 
study performed sequencing in two conditions by the use of the same library probes, and the 
run which pooled less samples yielded sequences with a better coverage. Our results pointed 
out the importance to get the balance between number of targeted regions and amount of 
testing samples. This would be helpful for the future design of resequencing panels. 
 
Although there are some issues in sequence generation and data processing, targeted 
resequencing still shows its excellent efficiency of screening mutations in a lot of known genes.  
Considering the high cost and huge size of data generated by WES or even whole genome 
sequencing (WGS), it is an efficient way to utilise a custom-designed panel to screen most of the 
related known genes in selective groups of patients first. WES or WGS can be reserved for those 
whose pathogenic mutations are still unknown after targeted resequencing. 
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Chapter 7 
 
General discussion 
 
This chapter provides an overview of the genetic studies in this thesis. Mutations in several 
genes for inherited neuropathies and related disorders have been identified by these studies. 
These genetic findings contribute to both clinical diagnosis and the understanding of molecular 
genetics. Most of these mutations were identified from patients with new and unexpected 
phenotypes, broadening the phenotypic spectrum of these mutated genes. Screening studies in 
large cohorts also defined more accurately the frequency of specific gene mutations. 
Understanding the molecular genetics of these genes can provide a comprehensive perspective 
on the pathogenesis of inherited neuropathies. Many mutations were detected through NGS. The 
challenges faced when applying NGS in genetic diagnosis and how to address these challenges 
in the future will also be discussed.  
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7.1 Contribution of this thesis to clinical diagnosis 
 
Genetic findings in this thesis are summarised in table 7-1 (p202). Knowledge gained from these 
findings is very helpful for decision making of how to approach genetic testing in clinical 
practice. The contributions of this thesis to clinical diagnosis are described below:  
 
(1) Screening studies in large cohorts 
The aim of these studies was to define more accurately the frequency of specific gene mutations 
and their phenotypic spectrum. From this thesis, the mutation frequencies of NEFL 
mutations in CMT, SPTLC2 mutations in HSN-I and PDYN mutations in ADCA in the British 
population was documented. The two NEFL mutations were associated with early-onset CMT1 
and late-onset cases individually, suggesting that mutation analysis of NEFL should be 
considered  in CMT patients with variable age of onset when mutations in common genes have 
been already excluded. It could also be inferred that mutations in the PMP22 promoter, KCND3, 
or AFG3L2 are very rare from the negative screening.  
 
(2) Identification of novel genes for inherited neuropathies: 
Two novel genes for CMT2 identified by WES were described in this thesis: MARS and 
C12orf65. A novel missense mutation in the MARS gene was detected in a family with late-onset 
CMT2. Identification of this mutation highlights the importance to take incomplete penetrance 
into consideration when determining the inheritance of a patient with a late-onset course. The 
C12orf65 mutation is the first mutation documented in patients with a recessive form of axonal 
neuropathy with optic atrophy (CMT6). Although only rare mutations were reported, multiple 
symptoms in PNS, CNS and extra-neurological systems are the features of these patients with 
C12orf65 mutations.  
 
(3) Mutations in known rare gene identified through NGS 
Many mutations in known rare genes were identified through NGS in this thesis. Most of these 
genes are not tested in most of the diagnostic labs routinely because it is not cost effective to 
screen those genes which are very rarely mutated or very large in size. The introduction of NGS 
has made sequencing in these “difficult genes” much easier. In parallel with the identification of 
more mutations, the understanding of mutation frequencies and the phenotypic spectrum of 
these genes is expanding. This is best illustrated by mutation analysis of KIF5A by the 
combination of NGS and Sanger sequencing. Through this study, KIF5A has been confirmed to 
be one of the causative genes for CMT2. The phenotypic spectrum of KIF5A mutations has also 
been broadened showing that cerebellar ataxia can be an associated feature. Another example is 
the DNMT1 mutation identified by WES in this thesis. Although the pathogenic mutation has 
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been reported before, this is the first time that a DNMT1 mutation has been shown to cause a 
sensory neuropathy only with no cognitive impairment. The learning point of this genetic 
finding is to include DNMT1 mutations in the possible aetiologies of patients with HSN and 
sensorineuronal loss, even when cognitive function is not impaired. This thesis also identified 
new phenotypes for RNF216, KIAA0196, SPAST and ADCK3 (see table 7-1). 
 
Most of the patients carrying the mutations described above presented with a complex syndrome 
involving more than one part of the nervous system. Mutations in C12orf65, KIF5A and many 
other HSP genes have affected both the PNS and CNS. WES also detected pathogenic mutations 
in two HSP genes (PNPLA6 and ZFYVE26) in ARCA families. These results suggest a 
significant overlap between cerebellar ataxia and HSP. The clinical and genetic overlap between 
inherited neuropathies and HSP and/or cerebellar ataxia has been further reinforced by these 
genetic findings (illustrated by figure 7-1). Therefore, various associated features should be 
looked for carefully and taken into consideration when evaluating a patient with inherited 
neuropathy of undetermined caused. Screening of genes causing other overlapping diseases may 
be considered for these patients. It is not uncommon for these mutations to be identified in 
sporadic cases. Absence of family history cannot be an exclusion criterion of inherited 
neuropathy.  
 
Figure 7-1. Complex neuropathy syndromes representing the overlap between inherited 
neuropathy, hereditary spastic spastic paraglegia, and cerebellar ataxia 
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Table 7-1. Genetic findings of studies in this thesis 
  Gene Mutation Phenotype 
Screening studies in 
large cohorts by 
Sanger sequencing  
  
  
  
  
  
NEFL P8R, L311P* ADCMT1, early and late onset 
SPTLC2 A182P* AD-HSN (HSN type I) 
PMP22 
promoter 
None   
PDYN C22Y* ADCA 
KCND3 None   
AFG3L2 None   
Novel genes for 
inherited neuropathies 
C12orf65 V116X*  
ARCMT2 with optic atrophy and 
pyramidal signs 
MARS R618C* 
ADCMT2, late-onset and 
incomplete penetrance 
Mutations in known 
rare gene identified 
through NGS 
Genes for inherited neuropathies 
SH3TC2 
[p.R954X ; p.R954X] 
(n=2),  
[p.Y290X (;) 
p.R954X]* 
ARCMT1 
GDPA1 
[ .M116R ; p.M116R], 
[p.G327D (;) p.L239F]* 
ARCMT1 
FGD4 
[p.R442H ; p.R442H], 
[p.R577Q (;) 
p.G620V]* 
ARCMT1 
MFN2 S231P*, R519C 
CMT2 with spasticity, cHSP with 
neuropathy and  learning difficulty 
DNMT1 Y495C HSN with deafness 
Genes for HSP 
KIF5A++ 
R204Q, R204W*, 
D232N*, R280H, 
R280C (n=2) 
CMT2#, CMT2 with spasiticity#, 
pHSP, cHSP with axonal 
neuropathy, cHSP with cerebellar 
ataxia# ATL1 R239C pHSP 
KIAA0196 I226T* 
L-Dopa responsive spasticity with 
sensory axonal neuropathy# 
SPAST S44L, c.1494-2delT 
pHSP, cHSP with visual 
impairment, learning difficulty# 
FA2H [p.R154C (;) p.T207M] cHSP with cerebellar ataxia# 
ZNFVE26 R1438X 
ARCA with spasticity and axonal 
neuropathy 
PNPLA6 V1273M 
ARCA with spasticity and axonal 
neuropathy 
Genes for hereditary cerebellar ataxia  
RNF216 c.2453-2A>G* 
ARCA with congenital ectodermal 
dysplasia 
ADCK3 S616Lfs 
ARCA with tremor, myoclonus and 
dystonia# 
SACS c.5557_5561delCTTTT 
ARCA with spasticity and 
demyelinating neuropathy 
* novel mutation, # novel phenotype for the gene, ++mutations were identified by both large-
cohort screening and NGS 
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(4) Identification for mutations with treatable hereditary disorders 
WES detected a novel ADCK3 mutation causing CoQ10 deficiency in one patient and CoQ10 
supplement helped her improve the clinical symptoms substantially. Introduction of NGS can 
lead to identification of more mutations in some treatable hereditary diseases, and therefore 
benefit more patients. Moreover, the identification of a novel SPTLC2 mutation in HSN-1 has 
highlighted the role of deoxy-sphingolipids as a potential screening biomarker for sensory 
neuropathy which is under investigation currently. The toxic effects of deoxy-sphingolipids 
generated by mutated SPT also represent a potential target for treatment in the future and this is 
currently undergoing further investigations by our group.  
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7.2 Contribution of this thesis to molecular genetics 
 
Mutations identified in this thesis will help understand the roles of these mutated genes in the 
pathogenesis of inherited neuropathy and even provide insights into the underlying mechanisms 
of other neurological disorders. Their proposed pathomechanisms are summarised in figure 7-2.  
 
 
Figure 7-2. Genes causing inherited neuropathies and their biological  functions 
Genes flanked in red are those studied in this thesis.(modified from Rossor et al. 2013 
 
Biological functions of these genes can be categorized into the following pathways: 
 
(1) Intracellular trafficking and mutant protein processing 
Many mutant genes that cause inherited neuropathies are involved in intracellular trafficking and 
related pathways. These diverse processes occur in subcellular organelles such as ER, Golgi 
apparatus, endosomes, lysosome and phagosomes. Below are some examples. SH3TC2 
expression is restricted to Schwann cells. The gene product, SH3TC2, localizes to the 
perinuclear recycling compartment and has been shown to participate in endosomal 
recycling.(Stendel et al. 2010). Atlastin-1, the dynamin-like GTPase responsible for spastic 
paraplegia SPG3A, remodels lipid membranes and may form tubules and vesicles in the 
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ER.(Muriel et al. 2009) As mentioned earlier, SPTLC2 encodes for a subunit of an enzyme 
involved in the pathways of sphingolipid metabolism and mutant protein is believed to cause 
accumulation of atypical sphingolipids that may have a neurotoxic effect.(Rotthier et al. 2012)  
 
Many other genes cause inherited neuropathies through abnormal protein processing and 
trafficking. For example, the aminoacyl-tRNA synthetase (ARS) gene family is composed of 
ubiquitously expressed housekeeping genes which are important for protein synthesis.  
Previously, four genes in this family, GARS, YARS, AARS and KARS have been identified as 
causes of CMT or related inherited neuropathies. The identification of a MARS mutation in a 
CMT2 family in this thesis further supports the hypothesis that genes in the ARS family are 
closely associated with axonal degeneration. This strongly indicates that these genes may 
harbour nerve-specific functions which are currently not completely understood yet. One 
hypothesis is the high metabolic demand of motor neurons and axons make them more 
vulnerable to dysfunction of t-RNA synthetases.(Antonellis et al. 2006; Jordanova et al. 2006) 
 
(2) Axonal transport and cytoskeleton organization 
Many mutant genes identified in peripheral neuropathies encode motor proteins or proteins 
directly interacting with cytoskeletons, e.g KIF5A, NEFL and FGD4. The FGD4 gene encodes a 
protein which contains an actin filament-binding domain and is involved in the regulation of the 
actin cytoskeleton and cell shape.(Delague et al. 2007; Stendel et al. 2007) NEFL encodes NFL, 
the major intermediate filament in neurons and axons and is required for axon calibre and nerve 
conduction. It is involved in cytoskeleton maintenance and indirectly in axonal transport. The 
encoded proteins of KIF5A, KIF5s, are microtubule-directed, ATP-dependent motors that move 
cargo in anterograde axonal transport. In humans, KIF5s are necessary for axonal transport of 
neurofilament subunits and mitochondria.(Ebbing et al. 2008; Hirokawa et al. 2009) KIF5 
proteins also regulate transport of cargoes in dendrites and have roles in a number of membrane 
traffic pathways in the cell body, including in ER-to-Golgi, Golgi-to-ER, Golgi to plasma 
membrane, and recycling endosomes and lysosomes.  
 
The net effect of various mutant protein processing events frequently converges on deficiencies 
in axonal transport. Therefore, many genes participating in mutant protein processing can affect 
axonal transport, like ATL1. Also, some cellular studies showed that mutations in YARS and 
GARS impaired axonal transport and affected synaptic plasticity, suggesting these ARS genes 
are involved in axonal transportation in addition to protein processing.(Rossor et al. 2012;) 
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(3) Mitochondrial dysfunction 
Mitochondria dysfunction can be caused by defects of either mitochondrial DNA or the nuclear 
genome encoding subunits of the mitochondrial respiratory chain. C12orf65 is a newly identified 
gene for recessive axonal neuropathy and optic atrophy and plays a role in mitochondrial 
complex assembly and respiration. Interestingly, mutations in MFN2 can cause a dominant form 
of axonal CMT and optic atrophy also due to mitochondrial dysfunction. MFN2 encodes an 
outer mitochondrial membrane protein. Loss of MFN2 affects mitochondria movements and 
transport along the axon, suggesting that this may be the cause of the length-dependent axonal 
degeneration observed in CMT2A.(Misko et al. 2010) Some other gene mutations have been 
demonstrated  to cause mitochondrial dysfunction in CMT including GDAP1 and NEFL. 
GDAP1 encodes another mitochondrial outer membrane protein. Recessive GDAP1 mutants 
reduce mitochondrial fission activity, whereas dominant ones interfere with the fusion 
process.(Niemann et al. 2009) Mitochondrial dysfunction is thought to contribute to the 
pathogenesis of NEFL mutations as rounding of mitochondria occurred before disruption of the 
neurofilament network in a model of CMT2E.(Tradewell et al. 2009) C12orf65 is a newly 
identified neuropathy-related gene which is implicated in mitochondrial function. Furthermore, 
KIF5A is indirectly associated with the normal function of mitochondria because the KIF5 
motors participate in mitochondrial transport.(Hirokawa et al. 2009) These genetic findings 
provide evidence that mitochondrial dysfunction is a common mechanism underlying axonal 
neuropathy. 
 
(4) Myelin formation 
PMP22 encodes peripheral myelin protein 22, which is mainly expressed in Schwann 
cells.(Snipes et al. 1992) The severity of CMT1A seems to be associated with the number of 
extra PMP22 copies, providing evidence that PMP22 duplications cause the demyelinating 
neuropathy though a gene dosage effect.(Lupski et al. 1992) Multiple studies in transgenic 
PMP22 mice also support the hypothesis that a dosage effect is the major determinant of the 
type and extent of the neuropathy.(Patzko et al.2011; Schenone et al. 2011) 
 
(5) Epigenetic modification and regulation 
DNMT1 plays a crucial role in maintenance of methylation, gene regulation and chromatin 
stability. DNA methylation in important in DNA mismatch repair, cell cycle regulation in post-
mitotic neurons and neurogenesis.(Klein et al. 2011; Winkelmann et al. 2012) Clinically, 
DNMT1 mutations have been associated with sensory neuropathy, deafness, ataxia, dementia 
and psychiatric symptoms, in parallel with the multiple functions of the gene. 
 
Molecular genetic studies have been critical in understanding pathophysiological links between 
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inherited neuropathies and other neurological disorders. Inherited neuropathies, cerebellar 
ataxias, and HSPs are highly genetically heterogeneous disorders caused by mutations in many 
genes. Although the genes responsible for these neurological disorders are different, many of 
them play similar roles in the nervous system or participate in the same cellular pathways (table 
7-2, p208). 
 
Inherited neuropathies caused by mutations in genes associated with mitochondrial function 
have been mentioned earlier. Many other diseases have mitochondrial dysfunction as the main 
pathological process, like ADCK3 mutations in cerebellar ataxia and SPG7 mutations in HSP. 
The strong association between mitochondrial function and various components of the motor 
system may be due to the heavy energy consumption demands of the long axons, the 
corticospinal tract, motor neurons and Purkinje cells.(Blackstone et al. 2010) 
 
Axonal transport represents a potential common pathway in the pathogenesis of both axonal 
neuropathies and spastic paraplegia.(Timmerman et al. 2012) KIF5A mutations provide further 
evidence for this with a wide phenotypic spectrum ranging from CMT2 to HSP. Like axonal 
neuropathies, many forms of HSP have mutants genes which are involved in axonal transport, 
like BSCL2, REEP1, ATL1, SPAST and NIPA1 .(Barry et al. 2007; Gunawardena et al. 2004; 
Timmerman et al. 2012; Xia et al. 2003)  
 
Genes associated with vesicle trafficking and protein processing are another group which 
commonly have a dual pathological effect on both the PNS and CNS. Mutations in these genes 
can cause CMT/dHMN with pyramidal features (FIG4, GARS, TRPV4) or cHSP with axonal 
neuropathy (KIAA0196, ZFYVE26).(Blackstone et al. 2010; Timmerman et al. 2012)  
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Table 7-2. Genes responsible for inherited neuropathies, cerebellar ataxias and hereditary 
spastic paraplegia and their functions 
Functional 
groups 
Mutant genes of different neurological disorders 
CMT HSN dHMN CA HSP 
Intracellular 
processing of 
proteins 
     
 
Protein 
misfolding and 
vesicle 
trafficking 
PMP22, MPZ, 
BSCL2, HSPB8, 
RAB7, LITAF, 
MTMR2,MTMR
1FIG4,SH3TC2, 
FGD4 
RAB7, 
HSN2(WNK1), 
FAM134B, ATL1 
BSCL2, HSPB8, 
DCTN1,ATP7A 
 
ATL1,SPAST, 
NIPA1,KIAA0196
SPG11,RTN2, 
ZFYVE26, 
BSCL2,SPG20, 
SPG21,REEP1, 
KIAA0415 
Protein 
synthesis 
GARS,YARS, 
AARS,KARS, 
MARS 
HSPB1,HSPB8 
 
GARS,HSPB1, 
HSPB8,IGHMBP2 
  
Channel 
function 
TRPV4 SCN9A TRPV4 
CACNA1A, 
KCND3 
 
Phospholipid 
homeostasis 
 
SPTLC1, 
SPTLC2 
 TDP1 PNPLA6 
Axonal 
transport and 
cytoskeleton 
organization 
NEFL,GARS, 
FGD4, 
KIF5A, 
KIF1B,LMNA 
KIF1A,IKBKAP, 
CCT5, NTRK, 
NGFB,DNMT, 
ATL1 
DCTN1,GARS SPTBN2 ATL1, KIF5A 
Mitochondrial 
function 
MFN2, NEFL, 
GDAP1, 
PMP22, 
C12orf65 
  
ATXN2, 
CACNA1A, 
ATXN7, ATN1, 
PPP2R2B, 
AFG3L2, 
PDSS1, 
PDSS2, 
COQ2, 
ADCK3, 
POLG 
SPG7, HSPD1, 
C12orf65 
Toxic 
accumulation of 
aggregates and 
intranuclear 
inclusions 
PMP22   
ATXN1, 
ATXN2, 
ATXN3, 
ATXN7, TBP, 
ATN1, ATXN8, 
ATXN10 
 
RNA regulation 
and epigenetic 
modification 
EGR2, MED25 DNMT1  
ATXN1, 
ATXN2, 
ATXN3, 
ATXN7, 
ATXN8, TBP, 
ATN1, 
BEAN-TK2 
 
Myelination 
PMP22, MPZ, 
GJB1, NEFL, 
GDAP1, EGR2, 
PRX, SOX10 
   
PLP1, FA2H, 
GJC2 
CA: cerebellar ataxia. Genes studied in this thesis are expressed in bold. 
Functional classification for genes are based on Durr et al. 2010, Anheim 2011, Matilla-Duenas 
et al.2010, Timmerman et al. 2012, Blacktson et al. 2011, Tucci et al. 2013 and Liu et al. 2014. 
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7.3 Challenges and future perspectives for next-generation sequencing 
 
Over the past three years, NGS has been demonstrated to be a powerful tool in identifying 
disease-associated variants in several inherited human diseases. The introduction of high-
throughput sequencing technologies has radically changed the approach of clinical geneticists 
towards human diseases and the nature of biomedical research.(Goh et al.2012; Torkamani et al. 
2011) However, the current wide-spread availability of these techniques and the potential to 
generate large amounts of sequence data means that scientists are now faced with the challenges 
associated with the design of large-scale projects and analysis of the vast data generated. This 
poses significant challenges at various stages of the projects including planning, sample 
preparation, run processing and downstream analyses.(Kircher et al. 2011) 
 
(1) Challenges of project design 
Although a few studies have reported small indels which were detected by WES or targeted 
resequencing, the identification of long-fragment gene rearrangements still represents one of the 
major limitations. For targeted resequencing, it is possible to customize the library to target 
specific functional elements not in the coding region, such as introns, promoters, enhancers, 
silencers, microRNA binding sites, conserved regions, etc. However, it may reduce the panel’s 
clinical utility when these non-coding regions are included. Moreover, the need of continually 
updating a panel due to newly discovered genes can markedly increase cost for targeting 
resequencing when applied in genetic diagnosis.  
 
(2) Challenges of data production 
Different commercial platforms provide users with the ability to construct application-specific 
sequencing libraries using a variety of protocols and different sequencing primers. The most 
important requirement for a DNA library to be sequenced on the Illumina platform is the 
presence of specific outer adapter sequences, complementary to the oligonucleotides on the flow 
cell used for cluster generation. Library adapters can be added by a variety of approaches, e.g. 
single strand ligation, double strand blunt-end ligation, double strand overhang ligation, and 
restriction enzyme overhangs in, or by extension from overhanging primers (e.g. multiplex PCR 
or molecular inversion probes). Each of these approaches has a different susceptibility to the 
creation of library adapter dimers, chimeric sequences and other library artifacts. The above 
conditions lead to generation of artifact sequences, which may have a negative impact on the 
image analysis and base-calling by overrepresentation of certain sequence populations and thus 
the generation of a false positive report.(Kircher et al. 2011)  In this thesis, false-positive reports 
were found to increase substantially when the adapters were added by restriction enzyme 
overhangs (details described in Section 6.2).  Sequencing of large numbers of such artifacts is 
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not cost effective and lowers the potential number of informative sequences that can be 
generated per run.  
 
Other problems in data production come from samples. Results in this thesis showed that small 
amounts of input materials caused by a failure of library enrichment generated a higher fraction 
of library artifacts. This may be due to the relative abundance of adapter oligonucleotides 
compared to insert molecules. Sample contamination during library preparation from other DNA 
sources is another important issue. Library preparations starting from low amounts of sample 
DNA and protocols using single strand ligation procedures are more prone to 
contamination.(Kircher et al. 2011) 
 
(3) Challenges of data analysis 
Interpretation of the clinical significance of rare variants can be challenging. This is a 
critical issue when multiple variants in related genes are identified simultaneously from the 
same individual by NGS. To determine the pathogenicity of a variant one needs to consider all 
the following evidence: novelty of a variant, the knowledge that other variants in the same gene 
have been shown to cause the  disease,  the damage a particular variant may cause, the 
association of a variant with the gene expression in tissues of relevance to the disease. A 
documented segregation within the family is strongly supportive, whereas a functionally 
relevant protein interacting network of the mutated gene provides soft evidence. Unfortunately, 
it is common that either not all requirements can be fulfilled perfectly or there are more than one 
variant which can satisfy the criteria. 
 
It is also challenging to analysis data when dealing with cases with limited clinical information 
(especially inheritance pattern) as currently WES has been applied frequently in patients who 
are sporadic or from small families where the inheritance pattern cannot always be determined. 
In WES studies for the cohort of ARCA in this thesis, a clear recessive inheritance greatly 
reduced the number of potential variants as only homozygous or compound heterozygous 
variants were taken into consideration, thus facilitating the process of gene identification. On 
the contrary, for sporadic HSN patients with uncertain inheritance, the lack of other affected 
members made it hard to reduce the number of candidate variants and progress further in the 
analysis.   
 
(4) Future perspectives 
With WES becoming increasingly available and cost effective, a larger number of variants will 
be identified. It is estimated that the total number of disease-associated variants will increase by 
approximately 37% in the next four years.(Cassa et al. 2012) To overcome the challenges of 
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interpreting NGS data, it is important to collect more human genome sequences and through 
collaboration with multiple collaborating groups, the accumulated data will help clarify the 
clinical significance of some rare variants. Development of user-friendly international databases 
and bioinformatic platforms are also vital to facilitate data sharing and statistical analysis. For 
instance, GEnomes Management Application (GEM.app) is a software tool developed to 
annotate, manage, visualize, and analyze large genomic datasets 
(https://genomics.med.miami.edu/). GEM.app currently contains more than 1,600 whole 
exomes from 50 different phenotypes studied by 40 principal investigators from 15 different 
countries.(Gonzalez et al. 2013) In the context of disease risk predictions,  longitudinal and 
clinical  studies  exploring  the  role  of multiple  variants  must  be  pursued.(Torkamani et al. 
2011) 
 
Meanwhile, the establishment of genome database, the accumulation of information about 
biological processes, molecular functions and the cellular components of a gene via diverse 
gene ontology (GO) databases will be helpful in the identification of novel disease-causing 
genes. The proteomic information is particularly useful when analyzing genetic defects in genes 
which involve specific tissues or systems, e.g. inherited peripheral neuropathies, cerebellar 
ataxia or HSP. Taking CMT as the example, genes which are highly expressed or have evidence 
of unique alternative splicing in peripheral nerves or are associated with known pathways 
causing neuropathy are excellent disease causing candidates.  
 
NGS is rapidly revolutionizing genetic testing in hereditary neurological disorders. An 
integrated approach for genetic diagnosis will be established by the combination of NGS and 
conventional Sanger sequencing. With the reduction of costs, it will be possible in the near 
future to employ NGS at an earlier stage in the diagnostic pathway. Customized genetic 
screening panels will be more wildly used in clinical practice, and even WES will be adopted in 
the diagnostic process as routine for patients who have not a genetically confirmed inherited 
disorder in the next few years.(Rossor et al. 2013)  
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